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Thesis Summary  
 
 
Islet transplantation is a developing therapy for type 1 diabetic patients (T1D), which has been 
limited by problems associated with hypoxia, poor revascularisation and allograft rejection. 
Immunosuppressive agents used to prevent rejection are associated with severe side effects 
including islet toxicity, increased susceptibility to the development of cancer, infections and 
cardio-vascular problems. In order for islet transplantation to be used widely as a potentially 
curative treatment for T1D there is a need to develop novel therapies to treat allograft rejection 
without the use of immunosuppressive agents. 
 
In chapter 3, the immunomodulatory effects of IFN-γ on human monocyte-derived DC were 
investigated, using a standard 7-day in vitro DC propagation protocol. IFN-γ was shown to 
exert its immunomodulatory function on monocytes early during DC differentiation (IFNγ-DCD0), 
resulting in an immature DC (iDC) phenotype with reduced expression of maturation markers 
CD83 and RelB. IFNγ-DCD0 induced a state of T-cell hyporesponsiveness in a MLR, whilst IFN-
γ treatment at day 5 (IFNγ-DCD5) did not modulate DC function. The ability of IFN-γ to promote 
the generation of maturation arrested DC, could potentially serve as a cellular therapy for 
transplant rejection. However  DC propagation using the  standard 7-10 day protocol is not 
clinically applicable in the islet transplant setting. 
 
In chapter 4, a „FAST-DC‟ protocol to promote the rapid generation of tolerogenic DC was 
investigated and used to generate IFNγ modulated DC in 48h. These IFNγ-DC featured an iDC 
phenotype similar to that seen in chapter 3.  Maturation arrested IFNγ-DC caused significant T-
cell hyporesponsiveness and promoted a higher frequency of CD4+CD25+ Foxp3HI T-regulatory 
cells. IFNγ-DC primed T-cells were shown to be functionally suppressive in an antigen specific 
manner. It was also confirmed that IFN-γ reduced the phosphorylation of IL-4 activated STAT-  9 
6, which in turn affected the downstream gene expression of Interferon regulatory factor 4 
(IRF4).  IFNγ-DC  were  also  investigated  in  vivo,  where  a  humanised  model  of  islet  allo-
transplantation model was developed. Diabetic NOD-SCID mice were transplanted with human 
islets  and  challenged  with  donor-derived  DC  and  allogeneic  PBMNC.  After  21  days  post 
transplantation, there  was no  significant  change  to  euglycaemic state,  between  the  tested 
groups. 
 
Genetic modification of the allograft is an alternative therapy to protecting the graft from the 
recipient‟s  immune  system.  In  chapter  5,  human  islets  were  genetically  modified  with 
programmed cell death ligand 2 (PD-L2), an inhibitory molecule known inhibit T-cell immune 
responses. Two recombinant adenovirus constructs carrying the PD-L2 gene were generated. 
One construct encoded a soluble isoform, while the other expressed a full transmembrane PD-
L2 molecule. Adenoviral transduction did not affect the viability or insulin producing capacity of 
islets.  Interestingly,  soluble  PD-L2  was  more  efficient  at  inducing  signalling  by  1000  fold, 
compared to the transmembrane isoform.                  
 
In summary, this thesis demonstrated the timing of IFN-γ exposure is crucial in determining the 
function  of  DC  and  their  maturational  state,  where  IFN-γ  exposure  only  during  DC 
differentiation resulted in the inhibition of DC maturation. Secondly, the combination of IFN-γ 
and a FAST-DC protocol, enabled the generation of tolerogenic DC in 48h, making DC therapy 
more clinically applicable. Finally, the induced expression of soluble PD-L2 by human islets 
potently signals through human PD-1, which may provide the basis for the protection of islets 
from allo- and auto T-cell responses.  
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Type 1 diabetes (T1D) is a debilitating autoimmune disease, which is currently treated with 
exogenous insulin administration. This approach however is limited by its inability to achieve 
physiological blood  glucose  levels.  Islet  allograft  transplantation  is an  emerging  potentially 
curative therapy, which is limited by many factors including alloimmunity and reoccurrence of 
autoimmunity. Islet allograft recipients are required to use toxic immunosuppressive agents to 
prevent the destruction of the islet allograft. Unfortunately, immunosuppressant therapy is non-
specific and associated with severe side-effects, which in most cases outweighs the benefits of 
islet transplantation. Consequently, only patients with severe episodes of hypo-unawareness 
have access to allogeneic islet transplantation. In order for islet transplantation to become a 
standard therapy for T1D, there is a need to develop novel therapies that target auto- and allo- 
immune responses concurrently.  
 
This chapter aims to review the current literature and the background for the basis of this 
thesis. In particular it focuses on the function of dendritic cells to act either as an „immunogenic‟ 
or „tolerogenic‟ antigen presenting cell in allograft responses. The review then discusses the 
application of gene therapy of the graft as an approach to achieve transplant tolerance. Finally 
the negative regulatory pathway of Programmed death 1 and its ligands is extensively reviewed 
for its involvement in peripheral tolerance and its potential to target both allo- and auto immune 
responses.  
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1.2 Type 1 Diabetes  
 
Type 1 diabetes mellitus (T1D) is an autoimmune disease, where self reactive T-cells mediate 
the destruction of the insulin producing beta-cells of the pancreas [1-3]. The destruction of 
beta-cells affects the normal control of blood glucose levels, resulting in hyperglycaemia. This 
condition is commonly diagnosed in childhood, but can develop at any age including later in 
life. T1D affects over 120,000 people in Australia, with an expected 3% increase globally each 
year.  (International diabetes federation, Diabetes Atlas 3rd edition IDF 2007). Figure 1.2.1 
depicts the progression and development of the disease in association with beta-cell mass. 
Usually at the time of diagnosis more than 80% of islets have been destroyed [4], with minimal 
to no secretion of insulin. The current gold standard treatment for T1D is life-long use of 
exogenous insulin replacement therapy, which is limited by its inability to promote physiological 
glucose levels. Poor glucose control can result in ketoacidosis and hypoglycaemia, both of 
which are life threatening conditions. The Diabetes Control and Complications Trial (DCCT) 
and the Epidemiology of Diabetes Interventions and Complications studies have demonstrated 
that poor glucose control in T1D patients is associated with the onset and progression of micro-
vascular  (retinopathy,  nephropathy  and  neuropathy)  and  macrovascular  (cardiovascular, 
cerebro-vascular and peripheral vascular disease) complications [5-10].  The development of 




















Figure 1.2.1 Developmental stages of Type 1 Diabetes. Most patients that develop 
Type 1 diabetes have a genetic disposition which is primarily associated with HLADR3, 
HLADR4 and HLADQ. An environmental trigger is believed to precipitate the initiation 
of  autoimmune  responses  that  results  in  beta  mass  loss.  Initially  the  disease  is 
asymptomatic  with  normal  insulin  release  and  glucose  control.  Over  time  with 
progressive loss of insulin, the disease manifests itself promoting hyperglycaemia with 
over  80%  of  the  beta  cell  mass  being  destroyed.  A  modified  adaptation  from 
Eisenbarth GS, Jeffrey J. The natural history of type 1A diabetes. Arquivos Brasilerios 
de Endocrinologia Metabologia 2008; volume 52: page 146-155. 
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The  major  genetic  determinants  of  T1D  are  the  genes  within  the  major  histocompatibility 
complex (otherwise known as human leukocyte antigen in humans) class II. Most T1D patients 
express HLA-DR3 or HLA-DR4 class II alleles, while 30-40% are heterozygous and carry the 
high risk genotype of HLA-DR3/DR4 [11]. However the strongest association  with disease 
susceptibility is HLA-DQ [12]. HLA-DQ a heterodimer (ʱ and β chains), which controls immune 
recognition and antigen presentation to CD4+ T cells.  The HLA-DQ may therefore influence 
the development T1D by determining immune responses that lead to beta-cell destruction.  
 
1.2.1 Islets of langerhans  
 
The  pancreas  consists  of exocrine  and  endocrine  tissue  that  play  a  crucial role  in  aiding 
digestion and regulating blood glucose levels. The exocrine tissue is involved in the secretion 
of digestive enzymes, whilst the endocrine tissue produces hormones like insulin to control 
blood glucose levels. The endocrine cells of the pancreas are structured into cell clusters 
known as islets of langerhans that are scattered throughout the exocrine tissue. Islets take up 
only 1-2% of the total pancreas mass [13]. The size of islets can vary in size from 20 to 250 µm 
in diameter. Islets of langerhans cell clusters consist of insulin producing β-cells and ʱ-cells 
that produce glucagon that stimulates the release of glucose from the liver. ʴ-cells are also 
present and are involved in secreting somatostatin and pancreatic polypeptide [14]. To a lesser 
extent other cell types are also found in islet clusters, such as stromal cells, blood vessels, 
neurons and immune cells such as dendritic cells [15]. In order to produce insulin, β-cells 
consume large amounts oxygen to produce ATP, accordingly to maintain an adequate supply 
of oxygen islets are inherently highly vascularised, making them highly sensitive to hypoxic 
conditions  [16].  Proinsulin  is  an  insulin  precursor  that  is  made  up  by  an  A  and  B  chain   20 
connected by a connecting peptide (c-peptide). Subsequently, c-peptide is a diagnostic marker 
for insulin secretion [17].  
 
1.2.2 Islet transplantation – a potentially curative therapy for type 1 diabetes  
 
Whole pancreas transplantation is an attractive therapy for T1D patients, which re-establishes 
normal glucose metabolism and is associated with complete and sustained normalization of 
glycosylated  HbA1c  [18].  However  pancreatic  transplantation  involves  a  large  surgical 
procedure which is associated with a high degree of morbidity. Islet transplantation provides a 
less invasive alternative surgical procedure, which involves the infusion of isolated islets into 
the portal vein of the liver as demonstrated by figure 1.2.2. Islet transplantation is considered to 
be a relatively safe procedure in comparison to whole pancreas transplantation [19].  
 
The isolation of islets was developed over 30 years ago and since has provided the basis for 
developing islet transplantation as a potentially curative therapy for T1D patients [13]. In 1990 
the first islet transplanted patient reached insulin independence for 22 days prior to graft failure 
[20]. Despite improvements in protocols, less than 12% of patients were insulin independent 
one year post transplant, between the year 1990-2000 [21]. In 2000 Shapiro and colleagues 
reported the successful islet transplantation of 7 patients whom became insulin independent 
[22]. Their success was primarily due to the development of the Edmonton protocol, which now 
has been standardised worldwide [23]. The success of the Edmonton protocol was associated 
with an optimised immune therapy regime that consists of a combination of anti-Il2 antibody, 
Sirolimus  and  low  dose  tacrolimus.  Despite  these  promising  advances,  only  10%  of  islet 
transplant recipients are insulin independent 5 years post-transplantation. However 80% of 
recipients  remain  C-peptide  positive  [22,  24].  Partial  graft  function  has  been  shown  to   21 
remarkably  improve  the  quality  of  life  of  T1D,  by  reducing  the  episodes  and  severity  of 
hyperawareness[25].  
 
1.2.3 Immunosuppression – a barrier to the success of islet transplantation 
 
Cell  and  organ  transplant  recipients  in  a  majority  of  cases  require  life-long  use  of 
immunosuppressive regimes in order to prevent acute allograft rejection. Immunosuppressive 
reagents are highly non-specific and are associated with a variety of side effects. In particular 
agents that target T-cell proliferation and cytokine production like, cyclosporine, azathioprine, 
mycophenolate  mofetil and  rapamycin,  anti-CD3  and  anti-IL-2 antibodies [26]  increase  the 
susceptibility of recipients to develop infections and malignancies [27]. The organo-toxicity of 
these drugs have also been associated with the development of cardiovascular complications 
giving rise to a high prevalence of hypertension, hyperlipidemia and to a lesser extent the onset 
of diabetes with long-term use [28]. Some immunosuppressive agents are significantly toxic 
and contribute to loss of islet cell mass post-transplantation [29-31]. The development of the 
Edmonton protocol, consisting of a corticosteroid free regime, with the use of sirolimus, low 
dose  tacrolimus  and  induction  therapy  with  anti-Interleukin  2  (IL-2)  receptor  antibody,  has 
greatly improved the outcomes of islet transplantation. However, recipients are still susceptible 
to  the  non-specific  side  effects  of  long  term  immunosuppression.  Subsequently  islet 
transplantation is currently only available to adults that suffer from severe episodes of hypo-
unawareness. In order for islet transplantation to be widely used including in children, novel 
therapies that target both the allo and autoimmune reactions need to be developed, which 
promote tolerance without the use of immunosuppression. 
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Figure 1.2.2: Islet Transplantation. The donor pancreas is inflated with digestive enzymes 
prior to the transfer into a Ricordi chamber which mechanically breaks down the tissue with 
metal  marble  bearings.  Islets  are  then  purified  by  density  gradient  centrifugation.  Purified 
isolated islets of high quality that are then infused into the portal vein of the recipient‟s liver.    23 
 
1.3 Transplantation immunology  
 
1.3.1 Allogeneic T-cell Activation and priming  
 
Allograft rejection involves co-ordinated immune responses, which recognise the allograft as 
foreign  and  subsequently  cause  allograft  failure.  Antigen  presenting  cells  (APC)  and  in 
particular dendritic cells (DC) play a key role in presenting donor antigens to T-cells, which 
initiates the allo-immune response. At the molecular level, T-cells require multiple signals of 
activation to initiate cellular-mediated allograft rejection, however there are three major signals 
that are essential for T-cell activation. As depicted in figure 1.3.1A signal one of activation is 
delivered by the T-cell Receptor (TCR) that binds to the DC Major Histocompatibility (MHC) or 
otherwise known as the Human Leukocyte Antigen (HLA) in human, peptide complex. This 
mediates the recognition of specific epitopes of the antigen presented in combination with the 
presented MHC molecule [32]. However, this signal alone is unable to initiate sustained T-cell 
proliferation, resulting in T-cell apoptosis, or T-cell anergy [33] (an unresponsive T-cell state - to 
be later discussed in section 1.2.3).  Full T-cell activation requires signalling from DC co-
stimulatory molecules that provide signal 2 of activation [34]. There are a growing number of 
characterised positive and negative co-stimulatory molecules [35], some of which have been 
summarised in figure 1.3.1B.  In addition to co-stimulation, T-cells require cytokine production 
(signal 3) to drive their clonal expansion, DC for example produce IL-12 and T-cells secrete IL-




















Figure 1.3.1: T-cell Activation. The activation of T-cells requires multiple signals of activation. 
The binding of MHC-peptide complex presented by DC to the TCR, this interaction initiates 
signal 1. Signal 2 is produced by the association of co-stimulatory signals CD80/CD86 with 
CD28 expressed on T-cells. Signal 2 amplifies MHC and TCR interaction to produce, IL-12 and 
IL-2 (signal 3). 
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Figure 1.3.1B: This table illustrates the many positive and negative co-stimulatory pathways 
involved in T-cell activation. Those interactions highlighted in green promote positive signalling 










Signal  Co-stimulatory molecule  Ligand 
 
Positive  CD28  CD80/86 (B7-1/2) 
 
Positive  CD27  CD70 
 
Positive  HVEM  LIGHT, BTLA 
 
Positive  ICOS  ICOS-L 
 
Positive  OX40 (CD134)  OX40L 
 
Positive  4-1BB (CD137)  4-1BBL 
 
Positive   CD30  CD30L (CD153) 
 
Positive  SLAM (CD150)  SLAM 
 
Negative  BTLA  HVEM 
 
Negative  CTLA-4  CD80/86 (B7-1/2) 
 
Negative  PD-1  PD-L1 / PD-L2 
 
Negative  Unknown  B7-H4 
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1.3.2 Allorecognition  
 
The allorecognition of allograft MHC complex antigens by recipient T-cells is the primary event 
which promotes allograft rejection. The term allorecognition refers to the T-cell recognition of 
MHC glycoprotein genetic polymorphisms, which are highly variable between individuals [38]. 
There are two classes of MHC molecules, class I and II.  MHC class I molecules otherwise 
known as human leukocyte antigens (HLA) A, B and C is constitutively expressed on a variety 
of nucleated cells. MHC class II (HLA-DR, DP and DQ) on the other hand is restricted to bone 
marrow derived APC, such as DC, macrophage, B lymphocytes and thymic epithelial cells [39]. 
Crystal structures have demonstrated that MHC molecules carry peptides on a „Groove‟ which 
allows the peptides to bind and thus be presented to the TCR [40]. CD8+ T-cells are known to 
recognize  peptides  presented  by  MHC  class  I,  which  carry  peptides  that  originate  from 
intracellular  proteins.  CD4+  T-cells  on  the  other  hand  recognise  MHC  class  II  peptide 
complexes, that present extracellular protein derived peptides [39]. Recipient DC capture and 
process  donor  antigens  to  elicit  an  immune  response,  known  as  the  indirect  pathway  of 
allorecognition. Passenger leukocytes also promote an immune response by activating T-cells 
with their polymorphic MHC molecules named the direct pathway of allorecognition. Recipient 
DC can also take-up donor antigen and MHC, via a semi-direct pathway of allorecognition, 
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Direct allorecognition 
The  direct  pathway  of  allorecognition  as  shown  in  figure  1.3.2  involves  donor  derived 
passenger leukocytes resident in the transplanted tissue. These tissue resident immature DC 
subsequently mature and migrate in response to proinflammatory signals produced by tissue 
injury during surgery [41-43]. Maturing DC migrate to secondary lymphoid tissue to encounter 
and present foreign MHC to recipient T-cells [44, 45].  DC are predominantly responsible for 
the activation of recipient T-cells [46], where 1 - 7% of the recipient T-cell repertoire respond to 
foreign MHC via the direct pathway of allorecognition [47]. Donor-derived DC die within a few 
weeks  after  transplantation,  resulting  in  the  decrease  of  direct  allorecognition  and  thus  a 
decline of donor-antigen specific T-cells over time [48-50]. 
 
Indirect allorecognition 
The  indirect  pathway  of  allorecognition  involves  recipient  DC  that  migrate  to  the  site  of 
transplantation. Recipient iDC capture and process donor antigens after shedding from the 
allograft. They mature and migrate to secondary lymphoid tissue, causing T-cell activation with 
allo-peptides derived from polymorphic sequences of allogeneic MHC molecules bound to self-
MHC  molecules[46,  51,  52]  [53].The  indirect  pathway  plays  an  important  role  in  the 
development of chronic allograft rejection. This is evidenced by the elevated frequencies of T-
cells with indirect anti-donor specificity seen in patients with chronic heart, kidney and lung 
transplant rejection [54-61]. Thus the indirect pathway is believed to take precedence, when the 
direct  pathway  becomes  exhausted.  However  animal  studies  have  demonstrated  that  the 
indirect pathway is able to promote acute rejection in the absence of the direct pathway of 
allorecognition [62]. 
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Semi-direct allorecognition 
The semi-direct pathway, involves the transfer of lipid rafts from the cell membrane of donor 
DC to recipient DC. Accordingly, intact surface molecules including allogeneic MHC molecules 
can be transferred from donor to recipient DC and vica-verse, by direct cell to cell contact [63, 
64]. The release and uptake of exosomes have also been proposed as a mechanism for DC in 
acquiring and sharing foreign cell molecules [65]. As a result recipient DC can acquire donor 
MHC molecules promoting T-cell activation via the direct pathway of allorecognition. Recipient 
DC  can  also  take  up  other  donor  DC  cell  surface  molecules  in  this  manner,  which  are 
processed and then loaded onto self-MHC molecules, resulting in the presentation of allo-

































Figure 1.3.2: The direct pathway of allorecognition. Immature „passenger‟ DC migrate out of 
the islet graft in response to the proinflammatory environment. DC subsequently mature and 
migrated to secondary lymphoid tissue, where they activate recipient T-cells causing the clonal 
expansion of alloreactive T-cells, which leads to allograft tissue destruction. 
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1.3.3 T-cell subtypes 
 
T-cell subtype differentiation is defined by their expression of cytokines and signalling pathways 
from which their differentiation was mediated. Currently there are three main sub-types that 
have been commonly described and characterised. These subsets include T helper type 1 
(Th1), Th2 and Th17, which are described below and summarised in figure 1.3.3. 
 
Th1 
Th1  subtype  of  effecter  cells  are  characterised  by  their  production  of  pro-inflammatory 
cytokines IL-2, IFN-γ and TNF-ʱ. This cell type is known by its unique ability to express the 
transcription factor T-bet, which signals through STAT1 and STAT4 [66]. The binding of IFN-γ 
promotes the expression of T-bet, which upregulates the beta-2 chain of the IL-12R which in 
turn potentiates the expression of IFN-γ [67] [68] [69]. This forms a positive feed-back loop, 
where increased IFN-γ production reinforces Th1 differentiation, as DC secreted IL-12 binds to 
the IL12R and in combination with TCR signalling increases the transcription of IFN-γ and T-bet 




The differentiation of T helper 2 subtype (Th2) T-cell sub-set is characterised by the production 
of IL-4, IL-15 and IL-13 and the expression of GATA-3 and STAT-6 [71], which is  primarily 
involved in humoral immunity, by providing B-cell help. Th2 T-cell responses are antagonistic to 
the development of the Th1 population [72] [73], thus historically Th2 responses were thought 
to protect foreign tissue. However this is no longer strictly considered to be the case, as Th2 T-  31 
cells have been shown to mediate the rejection of MHC-mismatched allografts [74] and is 
believed a primary role in chronic allograft rejection. 
 
Th17 
The Th17 subtype is defined by its ability to produce proinflammatory cytokine IL-17A [75, 76], 
which forms part of a IL-17 family of cytokines (A-F)[77-81].  IL17A predominately is secreted 
by  activated  CD4+  T-cells,  however  other  studies  have  also  demonstrated  that  IL17A  is 
expressed by γʴ T-cells, CD8+ memory T-cells, eosinophils, neutrophils and monocytes [82-
88]. This cytokine plays an important role in the activation and recruitment of neutrophils and 
monocytes  to  sites  of  inflammation  [89-92],  whilst  also  enhancing  granulocyte-colony 
stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) 
promoting the growth and maturation of myeloid cells. Th17 cells have been implicated in 
pathogenesis of autoimmune diseases and allograft rejection. Elevated expression of IL17 
mRNA and protein have been found in graft infiltrating mononuclear cells in acute renal graft 
rejection both in rat models and in humans[93]. Other studies in lung and cardiac rejection have 
also supported the role of IL17 in acute rather than chronic allograft rejection [94-96]. Th17 
differentiation  is  characterized  by  its  unique  signalling  pathways  involving  receptor-related 
orphan receptor (ROR C2 or RAR-alpha) and STAT3 (as summarised in figure 1.5) [97, 98]. In 
humans IL1-β is important in promoting Th17 differentiation alone and in combination with IL-
23, which enhances the conversion of human Tregs to Th17 T cells. PGE2, a key mediator of 
tissue inflammation, up regulates IL-23R and IL-1R, which also promotes Th17 differentiation 
and expansion in humans. Th17 are unique in their ability to block the generation of Tregs, 
through the production of IL-6, IL-1 and TGF-β, however high concentrations of IL-6 can also 
inhibit Th17 differentiation. In vitro studies have also shown that IFN-y can negatively regulate 








































Figure 1.3.3: Differentiation of naive T-cells. The differentiation of naive CD4+ T-cells is 
dependent on proinflammatory milieu. The early secretion of Il-4 promotes the differentiation of 
Th2 T-cell subset. However the production of IL-12 inhibits Th2 and promotes the differentiation 
of Th1 cells, whilst the production of TGF-β promotes the generation of Tregs. Reciprocally IL-6 
inhibits Treg generation, while helping promote Th17 differentiation with the help of IL-1β and 




1.3.4 Tolerance mechanisms 
 
Central and peripheral tolerance mechanisms exist as homeostatic measures to ensure that 
the immune system can adequately recognise self and prevent autoimmune responses. Central 
tolerance  or  otherwise  known  as  recessive  tolerance  involves  the  negative  selection  of 
thymocytes with a high affinity for self-peptide/MHC complexes, which occurs in the thymus 
[100]. Negative selection can arise from various mechanisms including receptor editing, clonal 
diversion and clonal deletion, the later being the predominant form of negative selection [101]. 
Peripheral tolerance on the other hand controls immune responses in the periphery outside the 
thymus  once  T-cells  have  matured,  which  can  involve  different  mechanisms  as  described 
below.   
 
T cell anergy 
T cell anergy is a tolerance mechanism defined by an unresponsive T-cell state as shown in 
figure 1.3.4A. Presentation of MHC to the TCR in the absence of co-stimulation, such as 
CD80/CD86, renders T-cells anergic. Subsequently, these T-cells become unresponsive to the 
presented allo-peptide, even upon re-counter with the same peptide presented by an equipped 
APC expressing co-stimulation [102]. Cytotoxic T lymphocyte associated antigen (CTLA-4) is a 
example of a inhibitory molecule, which blocks co-stimulation signalling between CD80/CD86 
expressed by APC and CD28 expressed by T-cells to induce T-cell anergy [103].  
 
Activation induced cell death 
Immune responses are also regulated by a mechanism known as activation-induced cell death 
(AICD)  (Figure  1.3.4B),  after  repeated  encounters  with  a  specific  antigen  at  a  high   34 
concentrations [104]. AICD is mediated by the surface expression of FAS (CD95) and its ligand 
(FASL or CD95L), The interaction of FAS/FASL between proliferating cells activates a cascade 
of caspase enzymes that induce apoptosis induced cell death [105]. Gene disruptions to FAS 
and FASL result in lymphoproliferative disease in mice and autoimmune lymphoproliferative 
syndrome in humans [106]. 
 
T regulatory cells 
 Immune regulation via suppression by T regulatory cells (Tregs), is a concept that was initially 
proposed in the late 1960s, but failed to be accurately defined. However over recent years their 
existence has been proven by numerous studies. In particular, the description of CD4+ CD25+ 
Foxp3+ Tregs have been of the greatest interest. Foxp3 or otherwise known as forkhead box 
P3 from the forkhead family of DNA binding factors, is the master gene associated with the 
differentiation of these Tregs  [107]. The function of Foxp3 as a primary regulator of Treg 
function was displayed in the scurfy mouse, where mutations to Foxp3 resulted in a fatal 
autoimmune and inflammatory disorder [108]. A similar disorder is also known in humans, 
called IPEX (immune dysregulation, polyendocrinopathy, enteropathy and X-linked) syndrome, 
which  is  associated  with  poor  T-cell  activation  and  impaired  suppressive  function  of 
CD4+CD25+ T-cells [109]. The Treg pathway reciprocally develops to the Th17 T-cell sub-set 
as explained in section 2.3. Foxp3 Tregs also require TGF-β to differentiate, while IFN-γ has 
























Figure 1.3.4: Tolerance Mechanisms. Tolerance induction can be mediated through three 
major  cellular  mechanisms.  A)  Priming  of  T-cell  in  the  absence  of  co-stimulatory  signals 
generates anergic T-cells, rendering reactive T-cells no longer responsive. B) Apoptosis of 
antigen primed T-cells can be mediated through the interaction of Fas and Fas L, thus causing 
its deletion. C) Tolerogenic signals can convert reactive T-cells to generate CD4+ CD25+ 
FOXP3+ T-regs, which have suppressive properties that can inhibit other effector T-cells. 
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1.3.5 Immune reactions to islet allograft 
 
Loss of islet cell mass post transplantation is the leading cause of islet graft failure in recipients. 
Only 10-20% of the original mass remains post transplantation, therefore recipients require 
multiple islet infusions before they become insulin independent. Graft survival is dependent on 
the number of transplanted islets, quality of islets post mechanical and enzymic digestion, re-
vascularisation  post  transplant  and  the  toxicity  of  immunosuppressive  drugs.  Moreover, 
allogeneic islets are susceptible to the innate, adaptive and recurrent autoimmune response, 
which affects graft function and survival. 
 
Innate 
The  innate  immunity  is  responsible  to  the  loss  of  islet  cell  mass  immediately  post 
transplantation. The infusion of islets into the portal vein of the liver, places islets into direct 
contact with blood. This initiates the „instant-blood mediated immune response‟ (IBMIR), and 
within minutes of transplantation there is a rapid  activation and binding of platelets trapping 
islets  in  clots,  activation  of  the  coagulation  and  complement  systems,  causing  the  rapid 
infiltration of leukocytes, [111, 112]. This reaction is primarily driven by the inflammatory factors 
that  are  endogenously  produced  by  human  islets  such  as  tissue  factor,  Interleukin  1-β, 
Interleukin-8,  MIP-2,  MIF  and  Monocyte  Chemotactic  protein-1[113,  114].  Accordingly  the 
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Adaptive 
Islet transplantation like any other allogeneic transplantation is susceptible to allorecognition as 
described in section 1.3.2. However the non-specific inflammation driven by the innate immune 
response  and  in  particular  the  „cytokine  storm‟  potently  activates  the  adaptive  immune 
response. Subsequently the release of cytokines such as Tumour Necrosis-alpha, Interleukin-1 
and Interferon gamma activates donor (resident in islets) and recipient APC promoting T cell 
activation as described in section 1.3.1. The adaptive immune response plays a crucial role in 
promoting the destruction of the islet cells as evidenced in many mouse models of islet allograft 
transplantation, which have shown that the blocking of co-stimulation prolongs allograft survival 
[117-121]. Moreover, in human islet transplant recipients that reach insulin independence is 
associated with a T-regulatory cytokine profile [122], thus demonstrating the key role of the 
adaptive immunity in regulating the success and survival of islet allografts. 
   
Recurrent autoimmunity 
The  autoimmunity  that  initially  destroys  the  islets  of  T1D  patients  creates  the  problem  of 
recurrent autoimmunity to the newly transplanted islets.  Studies have shown that auto-reactive 
T-cells and auto-antibodies play an important role in the dysfunction and loss of islets, which 
prevents receipts reaching insulin independence [123]. The use of immunosuppressive drugs, 
therefore appears to be more effective in controlling allo-immune responses. Accordingly there 
is need to develop therapies that target both the allo-immune and auto-immune responses, to 
promote allograft tolerance.  
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1.4 Immune modulation towards tolerance induction 
 
The severe side-effects associated with the use of immunosuppressive drugs have prompted 
the explosion of research into the development of novel therapies to target allograft rejection. In 
particular, research has aimed to achieve the holy grail of „transplant tolerance‟, by promoting 
allograft acceptance without the use of systemic immunosuppression.  Islet transplantation has 
the added task of developing therapies that target both the allo- and auto- immune responses 
concurrently. The immunomodulation of cellular-mediated rejection with the use of „tolerogenic 
DC‟ (Tol-DC) and the genetic modification of allografts, are novel strategies that have great 
potential to promote tolerance induction as discussed below.  
  
1.4.1 DC cellular immunotherapy – a key to tolerance induction 
 
In 1973, Steinman and Cohn described a novel cell type with distinct morphological features 
which they termed dendritic cells (DC) [124]. Since their identification, DC have been shown to 
play a crucial role as sentinels of our immune system [125-128]. Despite taking up less than 
<0.1% of the total cell population, they play an important role as potent antigen presenting cells 
which can promote either „immunogenic‟ or „tolerogenic immune responses. It is this plasticity, 
which make them great candidates for tolerance induction.  
 
Dendritic cell origin and function - mature vs immature   
DC  differentiate  from  precursor  cells  derived  from  haematopoietic  CD34+  bone  marrow 
progenitor cells. DC precursors migrate from the bone marrow to nonlymphoid / peripheral 
tissues, including commonly transplanted organs where they reside as immature DC (iDC)   
[126, 129].  These tissue resident iDC are specialised in antigen uptake and processing, where 
they use receptor dependent and independent endocytic mechanisms to do so. Immature DC 
have  low  surface  expression  of  co-stimulatory  and  MHC  molecules  making  them  poor   39 
stimulators of T-cell activation [130, 131].   Microbial products like bacterial lipopolysaccharide 
(LPS),  unmethylated  cytosine  poly-guanine  (CpG)  motifs  and  double  stranded  RNA  can 
stimulate the maturation of iDC.  Other danger signals such as pro-inflammatory cytokines GM-
CSF,  IL-1β,  TNF-ʱ  and  IFN-ʱ  can  also  initiate  the  maturation  of  resident  iDC  [132-134], 
Necrotic death and ischemia/reperfusion injury during transplantation induce the release of a 
variety  of  factors  including  pro-inflammatory  cytokines  that  promote  DC  maturation  of 
passenger iDC transferred with the allograft[135, 136]. This cytokine and chemokine insult also 
recruits  recipient  DC-precursors  and  iDC  to  the  site  of  injury.  Donor  and  recipient  iDC 
subsequently take up allo-antigens and mature to potent antigen presenting cells.  
 
Maturation of DC is defined by a variety of changes both phenotypic and functional.  Immature 
DC switch from an antigen capturing cell to antigen presenting cells by losing their endocytic 
activity  [137].  Immature DC  function  by  loading  antigen-peptides  to  their  MHC  molecules 
forming MHC-peptide complexes, which translocate to the cell surface. As iDC mature they 
rapidly increase their expression of co-stimulatory molecules and migrate to draining lymphoid 
tissues, where they activate and prime T-cells causing clonal T-cell expansion [138, 139]. 
However resting iDC can prime T-cells in the absence of co-simulation to promoting antigen-
specific  tolerogenic  immune  responses  [140].    The  terminal  arrest  of  DC  maturation  may 
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DC maturational arrest  
A large amount of research has gone into the development of novel strategies to arrest DC 
maturation, as a potential way of inducing tolerance. In particular, pharmacological agents have 
been used to generate maturation arrested DC for the treatment of autoimmunity and allograft 
rejection. Glucocorticoids (GC) are potent immunosuppressive agents, initially described for 
their  ability  to  inhibit  T-cell  responses.  However  GC  also  has  a  profound  effect  on  the 
production of proinflammatory cytokines by monocytes and macrophages. Moreover GC have 
the  distinct  ability  to  modify  DC  function  [141].  Dexamethasone  (Dex)  is  the  most  widely 
investigated GC, which down regulates components of NF-κB signalling molecules involved in 
DC maturation including RelB [142]. Vitamin D3 [1,25(OH)2D3] has shown similar effects to 
induce the differentiation of phenotypically immature DC, which do not mature in response to 
maturation  stimuli.  These  phenotypically  tolerogenic  DC  also  have  a  reduced  capacity  to 
stimulate T-cells [143, 144]. Rapamycin also has been extensively investigated in its ability to 
promote the generation of iDC. Unlike Dex and Vitamin D3, rapamycin inhibits the mammalian 
target of rapamycin (mTor), which acts as a serine/threonine protein kinase. It has a diverse 
role as a regulator of cell growth and proliferation, transcription, ribosomal biogenesis, vesicular 
trafficking, autophagy, cytoskeletal organization and cell size [145]. Studies using bone marrow 
derived DC have shown that rapamycin down regulates the IL-4 receptor complex, suppressing 
IL-4 dependent DC maturation. This in turn results in the inhibition of co-stimulatory molecule 
expression and the production of IL-4 induced IL-12 and TNF-ʱ [146]. The effects of rapamycin 
on DC maturation have also been demonstrated in human studies, where monocyte-derived 
and  CD34+progenitor-derived  DC  fail  to  mature  [147,  148].  Cytokines  also have  a  role  in 
producing  maturation  arrested  iDC,  for  example  IL-10  treatment  of  DC-precursors  during 
differentiation results in phenotypically immature DC. Similarly, these DC have an inhibited 
capacity to up regulate the expression of CD86 and CD83, which reduces their capacity to   41 
stimulate CD4+ T-cells, resulting in the induction of antigen-specific T cell anergy [149]. Many 
other reagents and strategies have been used to generate tolerogenic iDC including siRNA KO 
of RelB, the use aspirin and curcumin to name a few, which have been proven to be tolerogenic in 
vitro and in vivo[150-152]. Moreover, in the NOD mice the use of maturation arrested DC generated by 
targeting  CD40,  CD80  and CD86  with  anti-sense  oligonucleotides,  has  been  proven  successful in 
delaying the onset of diabetes [153].  So successful in fact the University of Pittsburgh is running a 
phase  I  clinical  safety  study,  the  first  of  its  kind  to  use  maturation  arrested  autologous  DC.  The 
randomized trial proposes to evaluate the safety of using autologous tolerogenic monocyte-derived DC 
in  type  1  diabetic  patients  (www.clinicaltrials.com  –  Identifier  NTC00445913).  The  tolerogenic  DC 
accordingly  are  generated  from  the  recipient‟s  monocytes  and  treated  ex  vivo  with  antisense 
phosphorothioate-modified oligonucleotide targeting CD40, CD80 and CD86 costimulatory molecules. 
Similarly the University of Queensland plans to run a Phase I trial using monocyte-derived DC for the 
treatment of rheumatoid arthritis (RA). Whist in England the University of Newcastle plan to undergo 
second phase I trial using Vitamin D3 maturation arrested DC for also the treatment of RA [154]. These 
translational studies will further define the applicability of using tolerogenic vaccines in humans as a 
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Donor vs Recipient Dendritic cells 
Tolerogenic  DC  research  may  ultimately  be  used  in  „negative  vaccination‟  protocols.  This 
concept  is  still  in  early  development,  however  it  may  hold  great  promise  in  the  field  of 
transplantation as a way to promoting allograft tolerance [155]. The use of either donor-derived 
or  recipient-derived  DC  and  timing  of  DC  treatment  still  remains  debatable.  Using  donor-
derived DC is advantageous as it targets the direct pathway of allorecognition as described in 
section 1.3.2, thus playing a critical in preventing acute allograft rejection and promoting donor-
specific  tolerance.  However,  many  models  describing  the  use  of  donor-derived  Tol-DC, 
administer DC therapy 7 days prior to transplantation and current protocols for generating 
human monocyte-derived DC takes 7-10 days [155, 156]. This type of cellular therapy would 
only  be  available  in  cases  of  living  donor  transplantation.  On  the  other  hand  modulated 
recipient-DC have been shown to be affective in promoting tolerance, even if administered at 
the day of transplantation. There is also evidence emerging that donor-derived DC therapy may 
provide a source of alloantigen in the draining lymph nodes promoting indirect allorecognition 
and the risk of sensitization [157, 158], this however still remains to be fully characterised 
especially in larger non-human primate models. Moreover there is a great body of evidence 
demonstrating that donor-derived Tol-DC can promote allograft tolerance in vivo rather than 
immunity.  
 
1.4.2 Immunomodulation of the graft – a gene therapy approach 
 
The introduction of genes into the allograft itself has been among the popular approaches to 
protect the allograft from rejection. Several inhibitory molecules have been investigated using 
this gene therapy approach. Cytotoxic T lymphocyte associated antigen-4 (CTLA4) for example 
is an  immunomodulatory molecule  involved  in  blocking  the  interaction  of  CD86/CD80  with 
CD28.  Its  induced  expression  as  CTLA-4Ig  (fused  to  Fc  portion  of  human  IgG1) in  islets   43 
improves allograft survival as shown by numerous in vivo models [159].  The successes of 
CTLA4Ig  to prevent  T-cell  activation  has  permitted  its  use  in  the  treatment of  rheumatoid 
arthritis, while a second generation drug known as Belatacept is currently in phase III clinical 
trials  for  renal  transplantation  [160].  Th2  cytokine  IL-10  viral  vector  mediated  systemic 
production in an islet transplant model, is also successful in prolonging allograft survival by 
suppressing  autoimmune  responses  [161].  In  NOD  mice,  adeno-associated  virus  (AdV) 
mediated gene expression of IL-4 by islets, prevents the development of hyperglycaemia and 
reduces  the  severity  of  insulitis.  Thus  preventing  the  destruction  of  islets  and  inhibiting 
autoimmune processes, by regulating T-cell function [162].  
 
Programmed cell death 1 (PD-1) is also an inhibitory molecule known to regulate the onset of 
diabetes in the NOD mouse [163] and thus important in maintaining peripheral tolerance [164]. 
Stimulation of the PD-1 pathway in an islet allograft transplantation model, promoted allograft 
survival in presence of co-stimulation blockade [165]. So far there have been lack of human 
studies which have examined the effects of the over expression of PD-1 ligands in the survival 
of human islet allograft, which warrants investigation given the important role of PD-1 pathway 
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1.5 The Programmed Cell Death 1 (PD-1) Pathway 
 
1.5.1 Programmed Cell Death-1: a negative regulator of T-cell activation  
 
Programmed  cell  death  1  (PD-1)  is  a  T-cell  receptor  known  to  negatively  regulate  T-cell 
proliferation. PD-1 binds to PD-1 ligands 1 and 2 (also commonly known as B7-H1 and B7-DC 
respectively). This emerging negative co-stimulatory pathway is of great interest and is being 
heavily investigated as a novel avenue for the development of therapies to target autoimmunity, 
cancer, opportunistic infection, and of interest to this study, alloimmunity.   
 
1.5.2 Programmed Cell Death-1 receptor 
 
PD-1 was initially described by Ishida and colleagues in 1992 when isolating the murine PD-1 
gene. Its expression was upregulated in a T-cell hybridoma that was undergoing cellular death, 
thus named programmed cell death 1.  PD-1 shares amino acid homology with other members 
of  the  CD28/CTLA4  immunoglobulin  super  family.  Despite  its  given  name,  PD-1  it  is  not 
involved in classical programmed cell death [166]. Rather PD-1 was found to be responsible for 
arresting the cell-cycle of proliferating T-cells at the Go/ G1 phase [167].    
 
1.5.3 PD-1 protein and gene structure 
 
The murine PD-1 receptor is a 50 to 55 kDa type 1 monomeric transmembrane glycoprotein. 
Within its immunoglobulin (Ig) super family member it shares approximately 20% sequence 
homology with other members such as CD28, CTLA-4 and ICOS (inducible costimulatory), 
however  unlike  CTLA-4  and  ICOS,  PD-1  lacks  the  extra  cellular  cysteine  which  allows 
homodimerization [168].  Human PD-1 shares 70% nucleotide homology and 60% amino acid 
sequence homology with murine PD-1. The human 288 amino acid PD-1 protein consists of an   45 
Ig variable type extracellular domain, a transmembrane domain and a cytoplasmic domain 
[169].  Stimulation through the TCR or BCR (B-cell receptor) induces the expression of PD-1 
and the translocation of compartmentalized PD-1 to the cell surface of T-cells and B-cells 
respectively [169, 170].  
 
1.5.4 Signalling through PD-1 mediates the inhibition of TCR activation 
 
Functional studies of PD-1 show that the cytoplasmic tail of this receptor has two signalling 
tyrosine  residues.  The  tyrosine  residue  proximal  to  the  membrane  is  located  in  an 
immunoreceptor tyrosine-based inhibitory motif (ITIM), while the distal tyrosine is found in an 
immunoreceptor tyrosine-based switch motif (ITSM). Mutation studies have demonstrated that 
the inhibitory action of PD-1 is mediated by the ITSM rather than the ITIM [171].  Engagement 
with PD-L1 or PD-L2, induces the ITSM to recruit Src homology region 2 domain-containing 
phosphotase -1 (SHP-1) and SHP-2 to the PD-1 cytoplasmic tail [167]. Subsequently T-cell 
effector  molecules  are  phosphorylated  by  SHP-1  and  SHP-2  to  inhibit  T-cell  activation.  
Similarly  in  B-cells  SHP-2  is  recruited  upon  PD-1  engagement  to  inhibit  B-cell  receptor 
mediated activation [172].  Signalling through PD-1 receptor also inhibits Akt phosphorylation 
by  preventing  CD28-mediated  activation  of  phosphatidylinositol  3-kinase  (PI3K),  which  is 
dependent on the PD-1 ITSM [173]. Subsequently, causing a decrease T-cell proliferation, cell 

























Figure 1.5.1: Ligation of PD-1 Ligands expressed by APC promotes PD-1 signalling. Binding of 
the ITSM of the PD-1 cytoplasmic tail by SHP-1 /SHP-2 causes the dephosphorylation  of 
proximal signalling molecules. This results in the reduction of PI3K activation subsequently 
affecting the AKT pathway. PD-1 signalling can therefore decrease T-cell proliferation, cell 
survival and cytokine and protein production.   
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1.5.5 PD-1 deficient mice develop auto-immune diseases 
 
Animal functional studies have demonstrated that PD-1 plays a vital in maintaining peripheral 
self  tolerance.  PD-1  deficient  C57BL/6  (B6)  mice  develop  autoimmune  diseases,  such  as 
lupus-like proliferative arthritis and glomerulonephritis [174]. The disruption of PD-1 gene in 
BALB/c mice, similarly mediates the development of autoimmune dilated cardiomyopathy [175]. 
In the NOD mouse PD-1 pathway blocking studies have also demonstrated the inhibitory role of 
PD-1  in  regulating  the  onset  of  diabetes.  It  was  demonstrated  that  blocking  of  the  PD-1 
pathway resulted in the rapid development of diabetes regardless of the mouse age. Moreover, 
blocking significantly increased the frequency of Interferon gamma producing GAD-reactive 
splenocytes [163].  Likewise in PD-1 ligand KO models, have demonstrated that the PD-1 
pathway  specifically  regulates  CD4+  auto-reactive  T-cell  mediated  tissue  destruction  and 
cytokine production in the development of diabetes  [164]. These in vivo functional studies 
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In 2000 the first ligand for PD-1 was described, which was found to induce the inhibition of T-
cell receptor mediated T-cell proliferation [176]. The human and murine Programmed death 
ligand 1 (PD-L1) was identified through B7 homology-based searches of the NCBI database. 
The identified PD-L1 of 290 residues however, was also described as B7-H1 by Dong and 
colleagues the previous year in 1999, where they conversely showed this molecule to have a 
positive  stimulatory  capacity  [177].  However  subsequent  data  indicate  that  PD-L1  has  a 
dominant role as a negative regulator of T-cell activation. More recently it was discovered that 
PD-L1  also  binds  to  positive  co-stimulatory  molecule  CD80,  otherwise  known  as  B7-1,  a 
phenomenon present in murine models and humans [178].  The interaction of CD80 and PD-L1 
appears to be at intermediate affinities compared to that of CD80 to CD28 and to CTLA-4. The 
area which PD-L1 binds with CD80 overlaps with the area used to bind PD-1. Vice-versa the 
area of CD80 binding to PD-L1 overlaps with the area used to bind CD28. Furthermore the 
interaction between PD-L1 and CD80 leads to the specific inhibition of T-cell activation [179], 
demonstrating the ability of PD-1 ligands to work independently to PD-1 to also inhibit T-cell 
proliferation. 
 
Gene and protein structure 
Analysis of PD-L1 sequences has shown that this B7-family member has a IgV and IgC domain 
in its extra cellular region with a hydrophobic transmembrane domain and a short charged 
intracellular  region  [176,  177].  Although  PD-1  is  structurally  similar  to  CTLA-4,  PD-L1 
specifically binds to PD-1 and not CTLA-4. Furthermore the human PD-L1 is also able to bind 
to the murine PD-1 orthologue [176], demonstrating high evolutionary conservation of PD-1   49 
between  species.  Overall  many  studies  have  demonstrated  that  PD-L1  binding  with  PD-1 
mediates the inhibition of T-cell proliferation [176, 180]. 
1.6.2 Discovery of PD-L2 and protein structure 
 
Latchman  and  colleagues  in  2001  were  the  first  to  identify  the  second  ligand  for  PD-1 
Programmed Death Ligand 2 (PD-L2), which also inhibits T cell activation [167]. Similar to the 
discovery of PD-L1, PD-L2 was found though sequence homology searches on GenBank, 
which identified a mouse PD-L1 homologue. Likewise human cDNA was also identified, which 
shares a 70% amino acid identity with murine PD-L2. The B7 family members therefore share a 
21 to 27% amino acid homology and are structurally similar in their organization. Unlike PD-L1 
there  is  poor  conservation  of  the  PD-L2  cytoplasmic  tail  between  the  human  and  murine 
orthologue.  Accordingly  the  human  PD-L2  has  a  longer  cytoplasmic  tail,  which  may  be 
responsible for some functional differences between the human and murine PD-L2. PD-L1 and 
PD-L2 are closely located to each other on the human chromosome 9p24.2 separated by 42kb.     
1.6.3 Tissue distribution of PD-1 Ligands 
 
Messenger RNA 
PD-1 Ligand mRNA in human and murine tissues have similar mRNA expression patterns. PD-
L1  appears  to  have  high  expression  levels  in  placenta,  heart,  skeletal  muscle  and  lung, 
however lower expression is also found in the thymus, spleen, kidney and liver [167, 177]. PD-
L1  mRNA  however  is  not  expressed  in  human  monocytes  unless  stimulated  with  pro-
inflammatory  cytokine  IFN-γ,  where  it  is  quickly  up-regulated  [167].  PD-L1  mRNA  is 
constitutively expressed on DC and macrophage [181]. The mRNA expression of PD-L2 is 
similar to that of PD-L1; however mRNA transcripts do not correlate with the protein expression 
of these ligands, as the protein expression of PD-L1 is broadly expressed compared to PD-L2 




PD-L1 protein is broadly expressed compared to PD-L2. PD-L1 is constitutively expressed on a 
wide  variety  of  hematopoietic  and  non-hematopoietic  cells  including  mononuclear  small 
intestine cells, placental syncytiotrophoblasts, vascular endothelium, epithelia, pancreatic islet 
cells, astrocytes, neurons and lung macrophage [182, 183]. Dendritic cells also have high 
protein expression of PD-L1. PD-L2 protein expression however is restricted to macrophage 
and DC [181, 182, 184], and more recently B1 cells, B memory cells, bone marrow-derived 
mast cells were also found to express PD-L2 [183, 185].  PD-L2 is also strongly expressed on 
placental endothelial cells rather then syncytiotrophoblasts [184]. Thus the expression of PD-L1 
and  PD-L2  in  the  placenta  suggests  that  these  ligands  may  play  an  active  role  in  the 
establishment of fetal-maternal tolerance [186]. 
 
 
1.6.4 Regulation of PD-1 Ligand expression 
 
The expression of PD-L are largely dependent on the inflammatory environment, subsequently 
cytokines play an important role in the stimulation of their expression. Both type 1 and type 2 
interferons (IFN) and TNF-ʱ induce the expression of PD-L1 on T-cells, B-cells, endothelial 
cells and epithelial cells [187]. Common γ chain cytokines such as Il-2, Il-7 and Il-15 have all 
been shown to upregulate PD-L1 expression on human T-cells, whereas Il-21 can induce its 
expression on PBMNC CD19+ B cells but not on T-cells[188].  IFN-γ also upregulates the 
expression  of  PD-L1  and  PD-L2  in  human  monocytes,  however  it  appears  to  have  more 
profound effect on PD-L1 rather than PD-L2. [181, 184]. The up-regulation of PD-L2 protein 
expression in macrophage is highly dependent on IL-4, which suggests that PD-L1 and PD-L2   51 
are differentially regulated by Th1 and Th2 immune responses respectively [181]. Thus PD-L1 
and PD-L2 may function differently in the setting of transplantation. The transcription of the PD-
L1 is thought to be regulated by IRF-1, which is involved in its constitutive and inducible 
expression [189]. Lack of STAT3 activity by siRNA has demonstrated that STAT3 is required 
for the expression of PD-L1 [190]. Little is known about the transcriptional regulation of PD-L2, 
however  there  is  evidence  that  shows  IFN-y  induced  expression  of  PD-L2  is  partially 
dependent on the NF-κB-binding sites, situated upstream of the transcriptional  start site[182]. 
 
1.6.5 Evidence of second receptor for PD-1 Ligand 
 
In 1999 PD-L1 was identified by Dong et al and described as a third B7 family member that 
stimulates  T-cell  proliferation  and  IL-10,  however  they  still  showed  the  inhibition  of  IL-2 
production, thus concluding that PD-L1 molecule may also have negative regulatory properties. 
Also in 2001 Tseng and colleagues, claimed the discovery of B7-DC, which is identical to PD-
L2. In a murine model, PD-L2 was shown to have potent co-stimulatory properties causing the 
activation of T-cells [191]. In a separate study, PD-L2 had positive co-stimulatory properties, 
however they were independent to the engagement of PD-1, as PD-L2 was able to co-stimulate 
PD-1 deficient CD4+ T-cells, providing evidence of a possible second ligand for PD-L2 which 
mediates the stimulatory response rather than negative one [192]. However in other mouse 
models both PD-L1 and PD-L2 appear to mediate inhibitory signals. A study using C57BL/6 
mice showed that blocking of PD-L1 and PD-L2 expressed by iDC, significantly increased the 
stimulatory capacity of iDC [193]. A human study demonstrated similar results backing the 
concept that PD-L are vital inhibitory molecules.  More importantly this study described PD-L2 
as the more potent PD-1 ligand compared to PD-L1 [184]. The different reported functions of 
PD-L to either act as a stimulatory or inhibitory molecule are still currently under debate and 
may be a reflection of the background of the mice used in those studies. Never the less some   52 
studies  have  demonstrated  that  PD-L1  can  increase  T-cell  activation  by  inhibiting  IFN-γ 
induced nitric oxide [194]. Further to that there is evidence which suggests that PD-L1 may be 
bi-directional in its signalling capacity [178]. However there is a general consensus in the 
literature that PD-L1 and PD-L2 play an important inhibitory role in immune regulation [183].  
 
1.6.6 Functional differences between PD-L1 and PD-L2 
 
Although many studies suggest that PD-L1 and PD-L2 have overlapping functions in mediating 
negative regulation of T-cells, other studies have also revealed distinct functional differences 
between the two ligands. Comparative molecular modelling and site directed mutagenesis was 
used to demonstrated that the A‟GFCC‟C” protein face, which interacts with PD-1 has poor 
residue conservation between the two ligands. Furthermore these ligands differentially bind to 
different locations on the PD-1 receptor. Accordingly through the use of flow cytometry and 
surface  plasmon  resonance  it  was  established  that  PD-L1  and  PD-L2  both  have  different 
affinities for the PD-1 receptor. PD-L2 has a 2-6 times higher affinity for the PD-1 receptor 
compared to PD-L1, indicative that these two ligands make a differential contribution to immune 
responses [195]  PD-L2 in humans appears to be a far more potent negative regulator of T-cell 
activation,  as  blocking  of  PD-L2  in  a  mixed  lymphocyte  reaction  was  able  to  significantly 
increase the proliferation of CD4+ T-cells, whilst the blocking of PD-L1 only had a modest 
effect almost comparable to its controls. Furthermore PD-L2 blockade was able to reverse the 
tolerogenic effects of IL-10 treated DC, even though its expression levels found in these cells 
are considerably low, thus clearly demonstrating its potent negative regulatory properties in 
humans [184].  
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1.7 The PD-1 pathway and immunological tolerance 
 
As highlighted previously, PD-L interaction with PD-1 mediates inhibitory signalling that results 
in T-cell hyporesponsiveness, which is vital in the induction of self tolerance. PD-L signalling 
through PD-1 results in the inhibition of the production of cytokines such as IFN-γ and IL-10, IL-
4 and also IL-2, which are required for the proliferation of T-cells [167, 176, 180]. 
 
1.7.1 PD-1 pathway and peripheral tolerance  
 
In vivo animal studies have further substantiated the role of the PD-1 and PD-L pathway as a 
negative regulator of T-cell mediated immune responses and its crucial role in immunological 
tolerance.  Both  PD-L1  and  PD-L2  deficient  mice  have  shown  dramatic  increases  in  the 
proliferation of CD4+ and CD8+ T cells both in vitro and in vivo [196, 197] via the increased 
ability  of  these  cells  to  produce  IL-2  and  IFN-γ  [164].  Furthermore  in  an  experimental 
autoimmune encephalomyelitis resistant strain, PD-L1 deficiency causes this strain to become 
susceptible to autoimmune disease [196]. However the blocking of the PD-1 pathway does not 
appear to be as severe as the KO of CTLA-4. PD-L1 also appears to be important in the 
maintenance of semi-allogeneic pregnancy, as PD-L1 deficient mice have poor fetal survival 
due to the increased ability of these mice to reject allogeneic foetus [186].  PD-L2 is also vital in 
tolerance induction, as CD4+ T-cells of PD-L2 deficient mice show enhanced T-cell activation 
when co-cultured with antigen presenting cells (APC) compared to WT mice, which also feature 
increased production of IFN-γ and IL-4. Furthermore, the immunization of PD-L2 deficient mice 
with chicken ovalbumin, increases the activation of CD4+ and CD8+ T cells in vivo compared to 
their WT controls. Subsequently the lack of PD-L2 in these mice abrogated tolerance to oral 
antigens, thus further supporting the role of PD-L2 as a critical ligand in the regulation of T-cell   54 
tolerance [197]. Although there is significant evidence to suggest PD-Ls are important in the 
maintenance of tolerance, there is a clear lack of studies using models that are more clinically 
relevant to the human setting.  
 
1.7.2 PD-1 pathway and allograft transplantation  
 
The  function  of  PD-1  to  negatively  regulate  T-cell  clonal  expansion  and  tolerance  has 
encouraged  investigations  in  the  field  of  transplantation.  The  modulation  of  alloimmune 
responses via the PD-1 and PD-1 ligand pathway may therefore serve as a therapeutic tool in 
the prevention of allograft rejection. 
 
Kinetics of PD-1 and its ligands in allograft transplantation 
PD-1  and  its  ligands  are  known  to  be  upregulated  during  allograft  rejection  of  fully  MHC 
mismatched cardiac transplantation [198]. Interestingly PD-1 mRNA expression is observed 
late in the rejection response. PD-L1 on the other hand increases significantly the day after 
transplantation, whilst PD-L2 had a similar expression pattern to PD-1. The expression of these 
molecules continued to be expressed despite the treatment with immunosuppressive agents 
[198]. 
 
PD-1 Ligand 1 fusion proteins prolong allograft survival 
Systemic administration of PD-L1Ig fusion protein is able to prolong allograft survival in the 
absence  of  CD28  co-stimulation  and  in  conjunction  with  the  administration  of 
immunosuppressive agents. PD-L1Ig therefore acts synergistically with co-stimulatory blockade 
to induce long-term islet allograft survival [165].  Furthermore, PD-L1 expressed in corneal 
endothelial cells induces the apoptosis of effector cells within the cornea to maintain long-term 
acceptance of corneal allografts [199].  PD-L1Ig transduced rat cardiac allografts also prolong   55 
allograft  survival  compared  to  controls.  The  synergistic  effects  of  a  sub-therapeutic 
immunosuppressant regime were also observed in this study, as the combination of treatments 
was  better  than  immunosuppressive  treatment  and  gene  transfer  alone.  PD-L1Ig  genetic 
modification of the graft reduced CD4+ T-cells, monocyte and macrophage infiltration [200].  
 
 
PD-1 and ligands required for allograft acceptance 
MHC class II mismatched skin grafts in vivo, result in accelerated rejection with the blockade of 
PD-L1, which is similar to the rejection seen in CTLA-4 blocking studies [201]. In a separate 
study the targeting of PD-1 in fully MHC mismatched transplantation models also accelerates 
the rejection of allografts [202].  Furthermore interruption of the PD-1 and PD-L1 interaction is 
associated with the regulation of Graft Arterial disease in cardiac allografts [203]. These studies 
demonstrate  that  PD-1  and  PD-L1  is  associated  with  induction  of  allograft  acceptance. 
However the literature in this area lacks the description of PD-L2 and its association with 
allograft tolerance. A recent study using human PD-L transduced pig B-cell line, demonstrated 
that  both  PD-L1  and  PD-L2  over  expression  in  pig  antigen  presenting  cells  was  able  to 
significantly inhibit the proliferation of human CD4+ T-cells, which was accompanied with the 
reduced production of IL-2, IFN-γ, TNF-ʱ, Il-4 and IL-5. Moreover, the induced expression of 
PD-L promoted the generation of CD4+CD25HIFoxp3+ T-cells [204]. Thus, suggesting that 
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8.1 Thesis study rationale  
 
The success of islet transplantation as a curative therapy for T1D relies on the development of 
novel strategies to preserve islet cell mass post transplantation. Targeting both the auto- and 
allo- immune responses concurrently may prolong the survival and function of allogeneic islets 
long-term. However the currently available immunosuppressive regimes are associated with 
severe side-effects. Moreover they cannot inhibit the reoccurrence of autoimmunity or chronic 
rejection.  As  reviewed  in  this  chapter,  maturation  arrested  DC  have  potential  to  promote 
tolerogenic responses. The use of „tolerogenic vaccines‟ in human clinical trials enforces the 
translational potential of developing  DC  based  therapies  for islet  transplantation.  Currently 
these  clinical  trials  are  focused  on  using  autologous  monocyte-derived  DC.  In  order  for 
„tolerogenic  vaccines‟  to  be  used  in  allotransplantation,  to  target  the  direct  pathway  of 
allorecognition, it requires the use of allogeneic tolerogenic DC derived from the donor, which 
adds to the complexity of DC based therapies in transplantation. Nevertheless, they hold great 
potential in promoting allograft acceptance. To overcome this problem and in particular in the 
setting of deceased organ donor, the development of a novel propagation strategy is also 
required.  Like  many  therapeutic  regimes,  a  combination  of  therapeutic  strategies  may  be 
required to promote long-term graft acceptance. The genetic modification of the graft with 
inhibitory molecules is novel approach to confer direct protection to the graft from allo- and 
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9 Thesis aims and hypothesis 
 
The  work  presented  in  this  thesis  aimed  to  investigate  novel  therapies  that  may  promote 
allograft  tolerance  without  the  use  of  immunosuppressive  agents  in  the  context  of  islet 
transplantation. In order to do this the following aims and hypothesis were investigated: 
 
 
Aim 1 - To investigate the immunomodulatory effects of IFN-γ on the development and function 
of human monocyte-derived DC using ‘standard’ propagation techniques (Chapter 3) 
Hypothesis:  
IFN-γ mediates its regulatory effect by inhibiting allogeneic T-cell activation through the 
modification of dendritic cell function 
 
Aim 2 - To examine the propagation of tolerogenic DC in a short-time frame using a ‘Fast-DC’ 
approach to make tolerogenic DC therapy more clinically applicable to islet transplantation. 
(Chaper4) 
Hypothesis:  
The combination of IFN-γ and a FAST-DC protocol would generate DC with 
tolerogenic function in 48h 
 
Aim 3- To induce the transgenic expression of inhibitory molecule PD-L2 by human islets and 




The induced expression of human PD-L2 by human islets may promote signalling through 
inhibitory PD-1 pathway causing the inhibition of T-cell activation 
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2.1 CELL ISOLATION PROTCOLS 
2.1.1 Peripheral blood mononuclear cell isolation 
 
Peripheral blood mononuclear cells (PBMNC) were isolated from healthy human blood donors 
(Australian Red Cross Blood Service, Adelaide, South Australia). Ten millilitres (mL) of buffy 
coat was diluted with 25mL of PBS. Diluted blood was under laid with 12mL of Ficoll Paque. 
Samples were spun at 600g (No brake) for 20min at RT. Monolayer was harvested and washed 
with PBS at 300g for 10min at 4°C, this was repeated 3 times.  
 
2.1.2 Nylon Wool T cells 
 
Approximately 10g of teased nylon wool was packed into sterile 10ml syringes after removing 
the plunger. All nylon wool columns (NWC) were autoclaved for sterility and allowed to dry. 
Prior to purification NWC was equilibrated with 7ml of RPMI at 37°C for 20min.  PBMNC were 
panned as described in 2.2.1, however the non-adherent fraction was collected. Approximately 
108 non-adherent cells in s10g (10% FCS in RPMI containing 1% glutamine – see section 15) 
placed into RPMI equilibrated NWC. Columns were incubated in an up-right position at 37°C / 
5% CO2 for 30min. Nylon wool T-cells were then eluded with 12.5ml s10g.  
 
2.1.3 CD4+ T-cells 
 
CD4+ T-cells were purified using a magnetic bead depletion kit by stem cell technologies 
(catalogue 19052) according to the manufacturer‟s instructions.  In brief PBMNC were isolated 
as described as in 2.1.1. Cells were resuspended in recommended suspension media (PBS 
with  2%  FCS)  at  a  concentration  of  5x107/ml  and  max  of  2ml  was  transferred  to  sterile 
polystyrene FACS tube. Recommended volume (50ul/ml) of human CD4+ T-cell enrichment   60 
cocktail was added to tube and incubated at RT for 10min. Then 100ul/ml of provided magnetic 
beads (EasySep magnetic particle D) was mixed into cells and allowed to incubate for 5min at 
RT. Mixture of cells and magnetic beads were resuspended and transferred to the EasySep 
magnet (catalogue# 18000) and incubated for 5min. Enriched CD4+ T cells were decanted into 
clean tube and counted. 
 
2.1.4 CD3+ T cells 
 
Post primary MLR T-cells were separated from DC using the magnetic bead depletion kit by 
stem cell technologies (catalogue# 18051) according to the manufacturer‟s instructions.  In 
brief  cells  were  harvested  from  96well  plates  and  pooled  into  a  25ml  tube.  Cells  were 
centrifuged for 5min at 600g and resuspended in recommended media (PBS with 2% FCS) at 
108/ml. A maximum of 2.5ml was transferred into sterile polystyrene FACS tubes and incubated 
with  100ul/ml  of  EasySep  positive  selection  cocktail  for  15min  at  RT.  Then  100ul/ml  of 
magnetic  nanoparticles  was  added  thoroughly  mixed  and  incubated  for  10min  at  RT. 
Suspension was topped-up to 2.5ml and transferred to the EasySep magnet for 5min. Non 
CD3+ cells were discarded in one swift motion with tube being inverted for 2-3 seconds. Tube 
was removed from magnet and CD3+ cells were resuspended with 2.5ml of recommended 
media. To increase purity cell suspension was returned to the magnet for a further 5 minutes. 
Once again non CD3+ cells were discarded. CD3+ cells were resuspended in s10g media and 
counted.  
 
2.1.5 Positive CD25 selection  
 
CD25+ T-cells were isolated using Easysep positive selection kit according to manufacturer‟s 
instructions.  In  brief,  cells  were  resuspended  in  EasySep  buffer  (PBS  with  2%  FCS)  and   61 
incubated with CD25+ cocktail for 15min at RT (5ul/100ul). Then magnetic beads were added 
and incubated at RT for 10min (5ul/100ul of cell suspension). Suspension was then topped up 
to 2.5ml and tube was then placed into magnet for 5 min at RT. Non CD25+ were decanted 
and fresh 2.5ml of Easysep buffer was added to the tube. This was repeated 2 times to enrich 
CD25+ cells or 1 time if depleting CD25+ T cells. 
 
2.2 IN VITRO DC GENERATION  
 
2.2.1 Standard- 7 day generation protocol of human monocyte-derived dendritic 
cells  
 
PBMNC were prepared as per 2.1.1. and resuspended in RPMI supplemented with 1% FCS at 
a concentration of 5x106 per ml. Approximately 5x107 PBMNC were transferred into 75-cm2 and 
incubated for 1h at 37°C under 5% CO2. Non adherent cells were thoroughly washed away 
with PBS. Adherent monocytes were cultured in RPMI  1640 containing 10% FCS, 800U/ml 
(1.2x107 U/mg)  of  granulocyte colony stimulating factor (GMCSF)-LeucomaxTM and 400U/ml 
(1x107 U/mg)  of IL-4, monocytes were allowed to differentiate into immature DC for 5 days at 
37°C under 5% CO2. Immature DC were matured with 10ng/ml of TNF-ʱ for 2 days 
 
2.2.2 Fast – 2 day generation protocol of human monocyte-derived dendritic cells  
 
PBMNC were prepared as per 2.1.1. and resuspended in RPMI supplemented with 1% FCS at 
a concentration of 5x106 per ml. Approximately 5x107 PBMNC were transferred into 75-cm2 and 
incubated for 1h at 37°C under 5% CO2. Non adherent cells were thoroughly washed away 
with PBS. Adherent monocytes were cultured in RPMI 1640 containing 10% FCS, and a higher 
concentration  of  GMCSF-LeucomaxTM  (1000U/ml)  and  IL-4  (500U/ml).  Monocytes  were   62 
allowed to differentiate into immature DC for 24h at 37°C under 5% CO2. Immature DC were 
matured with 10ng/ml of TNF-ʱ and 1µM PGE2 for 24h.  
 
2.3 Fluorescence Activated Cell Sorting (FACS) 
  
2.3.1 Surface staining Conjugated mAb 
 
Cells  were  thoroughly  washed  with  PBS.  FACS  wash  was  used  to  resuspend  cells  at 
approximately 2x106/ml. Rabbit serum (10%) was used as a blocking agent for 20min at 4°C. 
Then 100µl of cell suspension and recommended amount of mAb was aliquoted into FACS 
tubes and incubated at 4°C for 30min. Samples were equilibrated to room temperature for 5 
min. One ml of FACS lysing solution was then added to fix cells. Samples are then washed with 
FACS wash and spun at 300g for 5 min. Cells were resuspended with 200µl of FACS wash. 
 
2.3.2 Primary mAb staining with secondary antibody detection 
 
 Cells  were  thoroughly  washed  with  PBS.  FACS  wash  was  used  to  resuspend  cells  at 
approximately 2x106/ml. Rabbit serum (10%) was used as a blocking agent for 20min at 4°C. 
Then 100µl of cell suspension, mAb was added into FACS tubes and incubated at 4°C for 
30min.  Cells  were  then  washed  with  FACS  wash  and  spun  at  300g  for  5min  at  4°C, 
supernatant  was  decanted  and  cells  resuspended.  Appropriate  amount  of  conjugated 
secondary antibody (50ul of 1:50) was added and incubated for 25min at 4°C. Samples were 
equilibrated to room temperature for 5 min. One ml of FACS lysing solution was then added to 
fix cells. Samples are then washed with FACS wash and spun at 300g for 5 min. Cells were 
resuspended with 200µl of FACS wash. 
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2.3.3 Intracellular staining of Foxp3  
 
T cells were stained for intracellular expression of Foxp3, using Foxp3 staining kit as per 
manufacturer‟s instruction.  Briefly, cells were permeabilised and fixed before blocking with 
normal  rat  serum.  Cells  were  then  incubated  with  anti-human  Foxp3  PE-conjugated  mAb 
(PCH101) for 30min at 4°C.  Expression of Foxp3 was assessed by flow cytometry (FACS 
CANTO). 
 
2.3.4 Intracellular staining of phosphorylated STAT-6 
 
Approximately 5x105 cells were incubated with IL-4 (500U/ml) and GMCSF (1000U/ml) plus or 
minus IFN-γ (500U/ml) in 0.5ml RPMI for 10 minutes in FACS tubes at 37°C. BD cytofix was 
pre-warmed at 37°C and then 0.5ml was added to treated tubes. Tubes were then incubated 
for a further 10min in 37°C water-bath. Cells were surfaced stained with CD14-PE for 25min at 
4°C. Then 1ml of BD permeabilisation buffer was added and tubes were incubated for 30min 
on ice.  Cells were washed with FACS wash and spun for 5min at 300g 4°C. Cells were stained 
with 5ul of anti-STAT-6 antibody for 30min at RT in the dark. Cells were finally washed with 
FACS wash and spun for 5min at 300g 4°C and resuspended in 200ul of saline.  
 
 
2.3.5 PI Staining 
 
Islet cells were stained with propidium iodide (20µg/ml) in 100µl for 15min on ice and then 
immediately analysed on FACS CANTO II (BD Bioscience, USA).  
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2.3.6 Cytometric Bead Array (CBA) 
 
 A human TH1/TH2 BD bioscience CBA cytokine kit was used to determine the concentration 
of IFN-γ, IL-2, IL-10 and IL-4 in supernatants from DC-T cell co-cultures. DC were co-cultured 
with T-cells and 50ul of supernatant from each sample was assayed according to 
manufacture‟s instructions  
2.4 MIXED LYMPHOCYTE REACTION (MLR) 
 
2.4.1. Primary MLR 
 
DC were washed with PBS three times, irradiated (30Gy) and used as stimulators in the MLR. 
DC were co-cultured with T-cell responders in 96-well round bottom plates, at stimulator to 
responder ratios of 1:10, 1:100 and 1:1000. After 4 days cells were pulsed with 1µCi [3H]-
Thymidine for 18 h and then harvested onto glass-fibre filters and counted in β-scintillation fluid 
using a Wallac Microbeta Counter. Proliferation was expressed as counts per minute (mean of 
5 replicates, +/- SD).  
 
2.4.2 Suppression assay by [3H]-Thymidine 
 
CD4+ Naïve T-cells and DC were co-cultured at a ratio of 10:1 for 5 days. Then CD3+ primed T-
cells  were  isolated  (Stem  Cell  Technologies,  Vancouver,  Canada)  and  co-cultured  with 
autologous un-primed CD4+ T-cells at varying ratios and UT-DC were used as stimulators. 
After 4 days cells were pulsed with 1µCi [3H]-Thymidine (Amersham, Biosciences LTD, Bucks, 
UK) for 18 h and  harvested onto glass-fibre filters and counted on a Wallac Microbeta Counter 
(Turku, Finland). Proliferation was expressed as counts per minute (mean of 5 replicates, +/-
SD).  
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2.5 Immunohistology  
 
Slides were fixed with cold acetone for 5 min and air dried. Slides were washed with PBS for 
5min at RT. Primary antibody, was applied after blocking with 3% goat serum (30min at RT) for 
2h at RT or O/N at 4°C. Slides were washed with PBS for 5min at RT. Optimal concentration of 
conjugated secondary antibody was applied and incubated at RT for 1h. Blocking serum used 
was adjusted according to the animal for which the secondary antibody was raised in. All 
antibody dilutions were prepared in blocking solution.   
 
2.6 ELISA 
 2.6.1 IL-12 ELISA  
 
DC were in 24 well plates (1x106 cells/ml) were stimulated with CD40L (500ng/ml) and IFN-γ 
(1000U/ml) for 48h as previously published methods [205]. Supernatants were harvested and 
assayed for the biologically active human IL12p70, using Ready-SET-go® ELISA Kit according 
to  manufacturer‟s  instructions,  sensitivity  4pg/ml-500pg/ml  (eBiosciences,  San  Diego,  CA, 
USA). 
2.6.2 IL-2 ELISA 
 
Transduced human islets (10 IEQ) were co-cultured with hPD-1/mCD28 chimera T-cell murine 
hybridoma (2x104) per well in a 96 well plate at an approximate 1:1 islet cell to T-cell ratio. 
Supernatants were harvested after 3 days of culture in 37°C / CO2.  Samples were stored at -
80°C  prior  to  analysis.  Mouse  IL-2  ELISA  Ready  set  go  kit  was  used  according  to 
manufacturer‟s instructions. The ability of transduced islets to induce signalling though PD-1 
was measured as depicted in Appendix D.  
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2.7 CELL LINES 
2.7.1 HEK 293 
 
Human embryonic kidney 293 cells were obtained from Cell Biolabs (Catalogue# AD-100). 
Thawed and expanded in DMEM complete media. Cells were allowed to a maximum of 70-80% 
confluence. To split cells, adherent cells were washed with PBS and 1ml/75cm2 of pre-warmed 
Accutase (Sigma, St Louis, USA) was applied. Cells were incubated at 37°C for 2-3min. Light 
tapping of the sides of the flask results in HEK-293 detachment. Cells were centrifuged for 10 
min at 400g. Cell aggregates were dispersed using a 18G blunt needle and a 30ml syringe. 
Cells were resuspended and seeded into 75cm2 flasks at concentration of 2x105/ml.  
 
2.7.2 PD-1/CD28 murine T-cell hybridoma 
 
Murine T-cell hybridoma cell line expressing human PD-1 extracellular portion fused to murine 
origin intracellular portion of CD28 (DO.11.10) was obtained from Dr. Simon Davis from the 
Weatherall Institute of Molecular Medicine part of The University of Oxford.  Cells were thawed 
and expanded in JMEM media. In general DO11.00 cells were cultured at concentration of 104- 
105/ml. These cells grow in suspension, when of 60 - 80% confluent cells were split 1 into 3 
flasks, i.e. 3ml of cell suspension into 6ml of fresh media per 75cm2 flask.  
 
2.8 MOLECULAR BIOLOGY METHODS 
2.8.1 RNA extraction 
 
Total  RNA  was  extracted  using  RNAspin  mini  kit  (GE  Healthcare,  UK)  according  to 
manufacturer‟s instructions. In brief cells were washed with PBS to remove traces of FCS.  A 
maximum  of  5x106  cells  were  transferred  to  a  1.5ml  eppendorf  and  micro-centrifuged  at 
13,000rpm  for  5min.  Cells  were  resuspended  in  350ul  of  lysis  buffer  and  3.5ul  of  β-  67 
mercaptoenthanol and vortexed until suspension was homogenous. Samples were stored at -
80°C until multiple samples were accrued. When sufficient samples were collected, samples 
were allowed to equilibrate to RT, as the rest of the protocol is performed at RT. Samples were 
then placed through a RNAspin mini filter and micro-centrifuged at 11,000g for 1min.  The 
filtrate was transferred to a 1.5ml eppendorf and mixed with 350ul of 70% ethanol after careful 
vortexing (2x 5sec), sample was placed into a RNAspin mini column and spun at 8000g for 
30sec. Filter with bound RNA was transferred to a new collection tube and 350ul of desalting 
buffer was added and centrifuged at 11000g for 1 min. To digest any present DNA, 100ul of 
DNase1 was added directly to the filter membrane and allowed to digest for 15min. Filter was 
then washed with 200ul of wash buffer 1 and spun at 11000g for 1min. Then filter was washed 
with 600ul of wash buffer II and centrifuged. Finally filter is washed with 250ul of wash buffer II 
and  spun  at  11000g  for  2min.  RNA  was  eluded  with  25-100ul  of  RNase-free  water  after 
spinning at 11000g for 1min. This step was repeated to improve yield. RNA quantity and quality 
was determined by NanoDrop 1000 absorbance at 260nm.  
 
2.8.2 Reverse Transcription using Oligo dT 
 
RNA samples of good quality were chosen for cDNA synthesis. In order to do this 1ug of total 
RNA was mixed with 4ul of Oligo dT and headed for 5 minutes at 60°C.  Samples were 
transferred to ice and cooled. Then 14ul of master mix (as per table 2.1) was added. Finally 





   68 
 
Table 2.1: Reverse Transcription Master mix 
Reagent  Volume per reaction (µl) 
5x First Strand Buffer  8 
40nM dNTP  4 
RNAsin  1 
MMLV reverse transcriptase  1 
TOTAL  14 
 
Samples  were  mixed  well  by  vortex.  Pulsed  samples  were  incubated  for  60min  at  37°C. 
Sample inactivation was performed at 70°C for 10min and then transferred directly to ice. 
Samples were pulsed to collect precipitate, then 60ul of nuclease free water was mixed into 
each samples. All samples were stored at -80°C. 
 
2.8.3 Reverse Transcription using Random Hexamers  
 
Reverse transcription using random hexamers was used to reverse transcribe, RNA extracted 
from mouse transplant tissue, according to the following table: 
Table 2.2: Reverse Transcription Master mix using random hexamers 
Reagent  Volume per reaction (µl) 
10x Buffer  2 
 dNTP (5mM each)  2 
Random hexamers (10µM)  0.9 
RNase inhibitor  1 
Omniscript Reverse Transcriptase  1 
RNA 1µg  2* 
Nuclease free water  11.1** 
TOTAL  20 
* varies according to RNA concentration 
  ** Varies according to volume of RNA added. 
Samples were prepared in 0.2ml PCR tubes and incubated at 37°C for 1h. Samples were then 
transferred to ice and pulsed, prior to adding 80µl of nuclease water. Throughly mix samples 
were then stored at -20°C.   69 
2.8.4 Western Blot 
 
Samples were harvested and washed well with PBS to remove FCS residue. Samples were 
then lysed with western blot lysis buffer (refer to section 2.15). Vortex was used to homogenize 
sample. Samples were stored at -80°C prior to analysis.   Samples were thawed at RT and 
then mixed with 5µl of loading buffer and 2µl of reducing agent and run through invitrogen pre-
cast gels as per manufacturer‟s instructions at 200mV for 45min. Chemiluminescence kit was 
used to visualise blot, in brief membrane was incubated with 1:1000 anti-mouse HRP for 1h at 
RT and then visualised with kit as per manufacturer‟s instructions.  
 
2.9 POLYMERASE CHAIN REACTION  
2.9.1 Standard PCR 
PCR master mixes were prepared as per table 2.2 in a strictly DNA free area of laboratory.  
Master mix (22.5μl) was aliquoted per reaction into DNA free 0.5ml PCR tubes. In order to 
prevent liquid evaporation 1 drop of sterile mineral oil was carefully placed on top of master 
mix.  2.5μl of cDNA as per prepared in section 2.8.2 was mixed into master mix.  Tubes were 
vortex mixed and then pulsed. Standard PCR were run in Perkin Elmer DNA Thermal Cycler.  
2.9.2 Quantitative Real-time PCR using standard primers 
RNA was extracted as per section 2.8.1 and cDNA was produced by reverse transcription PCR 
(section 2.8.2). Quantitative Real-Time PCR based on a standard curve of copy numbers for 
each  specific  gene.  PCR  was  conducted  according  to  optimised  conditions  as  shown  in 
APPENDIX A. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the house-
keeping gene in order to verify RNA integrity and cDNA synthesis.   
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Table 2.3. Standard PCR Master mix 
Reagent  Volume per Reaction  
(ul) 
Sterile Water  15.9* 
10x Tth Buffer  2.5 
25mM MgCl2   2.5* 
dNTP (0.2 mM)  0.5 
Forward Primer (50uM)  0.5* 
Reverse Primer (50uM)  0.5* 
Tth Polymerase  0.1 
cDNA  2.5 




Table 2.4 Real-time PCR Master mix 
Reagent  Volume per Reaction  
(ul) 
Sterile Water  15.7* 
10x Tth Buffer  2.5 
25mM MgCl2   2.5* 
dNTP (0.2 mM)  0.5 
Forward Primer (50uM)  0.5* 
Reverse Primer (50uM)  0.5* 
Tth Polymerase  0.1 
cDNA  2.5 
Syber green  0.8 
TOTAL VOLUME   25 
 





   71 
 
2.9.3 Quantitative Real-time PCR using TAQMAN primers 
 
Taqman primers were used according to the manufacturer‟s instructions. Briefly, PCR reaction 
was prepared according to the following table: 
      Table:2.5 Taqman PCR reaction  
Reagent  Volume 
per Reaction (µl) 
Taqman master mix  5 
Taqman primer  0.5 
Water  3.7 
cDNA  0.8 
TOTAL  10 
 
Samples were run on Corbbett Real-time machine according to manufacturer‟s recommended 
cycling conditions. Gene expression was determined according to a standard curve.   
 
2.10 AGAROSE GEL ELECTROPHORESIS 
2.10.1 PCR product Electrophoresis 
 
 2.5µl of PCR product was mixed with 6x Loading buffer to make a total  of 15µl sample. 
Samples were loaded into a 2% agarose gel and run for approximately 1h at 80mV, using a 
Bio-Rad Mini-gel Apparatus. 
2.10.2 Restriction digest product electrophoresis 
 
Approximately 10µl of restriction digest products was mixed with 2ul of 6x loading buffer. 
Samples were run on a 1% w/v agarose gel. 
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2.10.3 Adenoviral digests product electrophoresis 
 
 All adenoviral digest products were run in a 0.8% w/v agarose gel. 
 
2.10.4 DNA markers 
 
SPP1/EcoRI and pUC19 were used as appropriate size markers according to product size that 
was expected in the gel. In general 2.5µl of markers were mixed with 10µl water (DNA free) 
and 2.5µl of 6x loading buffer.  
 
2.11 GENERATION OF ADENOVIRAL CONSTRUCT  
 
2.11.1 Bioinformatics and Primer Design 
 
Primers were designed to incorporate an EcoR1 restriction site in the forward primer. Both full 
length and soluble isoforms of PD-L2 were amplified with the same forward primers but used 
different reverse primers. Both reverse primers had a BamHI restriction site incorporated into 
them. The soluble isoform was designed to amplify a truncated transcription product with the 
transmembrane  region  interrupted.      Designing  of  primers  were  designed  with  the  aid  of 
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2.11.2 Endonuclease restriction enzyme digestion  
 
Enzyme digestion reactions were conducted in 20µl volumes as demonstrated in the table 
below for 18 hours at 37°C.  
Table 2.6: Single Digest Reaction 
Reagent  Volume (µl) 
10x Buffer  2 
10xBSA  2 
Enzyme  1 (10 Units) 
H20  5* 
DNA   10 (1µg)* 
Total  20 
 
 
Table 2.7: Double Digest Reaction 
Reagent  Volume (µl) 
10x Buffer  2 
10xBSA  2 
Enzyme 1  1 (10 Units) 
Enzyme 2  1 (10 Units 
H20  4* 
DNA   10 (1µg)* 
Total  20* 
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2.11.3 Agarose gel product restriction digest purification 
 
 Digested produced were run on 1% w/v Agarose gel. Digests were divided into equal amounts 
and run in separate well. The exterior wells flanking were removed and stained with gel red. 
These gel regions were visualised under UV light to identify band and marked by cutting gel 
piece out of where the band is situated. Unstained gel portion was covered with cling wrap and 
stained portions were re-aligned in the original position over the cling wrap. Using the mark 
from the stained gel and a new blade gel was cut to excise the ban from unstained gel. DNA 
was then purified according to section 2.11.4.  
 
2.11.4 Purification of DNA from gels 
 
DNA from gels was purified using the UltracleanTM DNA purification Kit as per manufacturer‟s 
instructions.  
 
2.11.5 DNA ligation 
 
In order to conduct ligation reactions a mix as described in table below was prepared and 
incubated at RT for 2h or at 4°C for 18h. 
 Table 2.8:  DNA Ligation Reaction 
Reagent  Volume (µl) 
10x Buffer  1 
T4 Ligase Enzyme  1  
H20  3* 
DNA insert  5* 
Total  10 
*=Volume will vary according to DNA concentration 
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2.11.6 Preparation of Competent E.coli TG1-alpha and DH10β cells 
 
Competent E.coli were prepared as per standard laboratory protocol. In brief bacterial were 
taken from glycerol stocks and streaked on to LB agar plates. E.coli were grown for 18h at 
37°C. Single colonies were selected and inoculated into LB media and were grown under 
shaking conditions at 37°C (200rpm) overnight. Overnight cultures were then transferred (1ml) 
into 25ml LB media. Then allowed to grow until they reached an OD600nm of 0.42 (log phase of 
growth) under 37°C shaking at 200rpm. E.coli were transferred onto ice for 15min and then 
centrifuged  for  280g  for  10min  at  4°C.  Supernatants  were  discarded  and  cells  were 
resuspended with 2ml of 0.1M CaCl2 / 20mM MgCl2 solution. E.coli were then incubated on ice 
for no less then 1h before use. All competent E.coli were used within 18h post competence was 
induced.  
2.11.7 Transformation of competent E.coli cells 
 
Competent E.coli (200ul) were transformed with 5ul of ligation reaction (as per prepared in 
section 2.11.5). Cells and ligation mix were incubated on ice for 30min and then were heat 
shocked for 90s at 42°C and snap cooled on ice for 10min. This mix was then transferred to V-
bottom 20ml tubes, which contained 0.5ml LB media and incubated for 1h at 200rpm 37°C. 
Volume of cell suspension was reduced to 200-300ul and spread on LB agar supplemented 
with the appropriate antibiotics. Agar plates were incubated at 37°C for 18h.  
 
2.11.8 Plasmid Mini-preparation 
 
Positive single colonies were selected from plates generated in section 2.11.7.  These colonies 
were placed into 2ml LB media supplemented with the appropriate antibiotics and incubated at 
37°C under shaking conditions (200rpm) for 18h.  Approximately 1.5ml of cell suspension was 
transferred  into  2ml  eppendorf  and  microcentrifuge  at  11,600g  for  1min.  Pellet  was   76 
resuspended in 100ul of mini-prep solution-1 for 5min. Then 200ul of solution-2 was added and 
cells transferred for 5 min onto ice (causing cell lysis). Lysis was neutralized with 150ul of 
solution-3 and this was allowed to incubate for another 5 min on ice. Cells were centrifuged for 
10min at 11,600g, supernatant was transferred into a new 2ml eppendorf tube. DNA phenol 
(225ul) and chloroform (225ul) were added to cell lysate and mixed thoroughly. Mixture was 
centrifuged for 10min (11,600g), then approximately 300-400ul of the upper phase layer was 
transferred  into  new  tubes  and  mixed  with  2  x  volumes  of  100%  ethanol  (600-800ul)  to 
precipitate DNA plasmids. Precipitates were centrifuged for 10min (11,600g). DNA pellets were 
washed with 250ul of 70% ethanol and centrifuged for 10min (11,600g) an then air-dried. DNA 
was resuspended in 45ul of TE8 (TRIS-HCL EDTA Ph 8 refer to section 15) and 5ul of DNase 
inactivated RNase A (200ug/ml) and stored at -80°C.  
  
2.11.9 Plasmid midi preparation 
 
Single colonies were selected and transferred to 2mlof LB media containing corresponding 
antibiotics. Bacterial colony was grown at 37°C in a shaking incubator (200rpm) for 18h. This 
2ml bacterial culture was transferred to 100ml of LB media (containing the same antibiotic) and 
incubated for a further 18h at 200rpm 37°C. Jetstar 2.0 plasmid midi kit was used to isolate 
plasmid according to the manufacturers‟ instructions. Approximately 1ml of the plasmid elution 
was transferred into eppendorf tubes. Then 700µl cold isopropanol was mixed in to precipitate 
plasmid. Precipitate was centrifuged at 4°C, 11600g for 30min. Plasmid pellet was washed with 
1.5ml of 70% ethanol and centrifuged at 4°C, 11600g for 20min, this was repeated twice with 
drying of pellet between each wash. Pellet was resuspended in 30µl of sterile water. Plasmid 
concentration  was  determined  by  absorbance  at  260nm  on  the  Nanodrop  1000  (Thermo 
Scientific, USA). 
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2.11.10 DNA sequencing 
 
Dideoxy based DNA sequencing with chain-terminating inhibitors was  used for sequencing 
recombinant pShuttle vectors. Sequencing was performed by the Flinders Sequencing Facility, 
which is part of the Department of Haematology at the Flinders Medical Centre.   
 
2.11.11 LipofectAMINE Transfection into HEK 293 
 
HEK293 cells (2x106) were seeded into a 25cm2 flask 18-20h prior to transfection, allowing 
cells to get 50-70% confluent. Approximately 16-18h prior to transfection recombinant plasmid 
was  digested  with  PacI  (5U/1µg  of  Plasmid) in  a  20µl reaction.    Approximately 4-5µg of 
digested plasmid was used to transfect HEK-293.  Digested plasmid was mixed with equal 
volume of LipofectAMINE 2000, this was then mixed with 500ul of DMEM media and incubated 
for  30min  at  RT.  Cells  were  washed  with  serum  free  DMEM  to  remove  residual  FCS.  
Approximately  2.5ml  of  serum  free  DMEM  was  added  to  flask  and  then  0.5ml  of 
DNA/LipofectAMINE was added drop wise to flask. Cells were transfected for 4h at 37°C at 
5%CO2. Transfection media was replaced with 7ml of complete DMEM media (see section 
2.15). Transfected cells were incubated (at 37°C at 5%CO2) for 10-12 days.  
 
2.11.12 Adenoviral HEK-293 viral lysate production 
 
Infected HEK-293 were used to produce viral lysates. All cells were scraped and spun at 600g 
for 10min. Pellet was then resuspended in 3ml of DMEM (serum free). Cell suspension was 
frozen using liquid nitrogen and then thawed in 37°C water bath until just thawed. Lysate was 
vigorously vortexed for 30-60sec. The lysate underwent freeze/thaw/vortex cycle for 3-4 times 
prior to spinning at 600g for 10min to remove cell debris.   Viral lysates were stored at -80°C in 
10% glycerol if not used immediately.  
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2.11.13 Viral particle up-scale 
 
HEK-293 cells were used for virus production. Virus was amplified via multiple rounds of HEK-
293 as described below:  
Round 1: 
HEK-293 cells at a confluence of 80-90% in a 25cm2 was infected with 1/3 of viral lysate from 
cells prepared in section 2.11.12. In brief cells were washed to remove FCS residue. Lysate 
was carefully run down side of flask to avoid detaching cells. Then carefully the lysate was 
evenly spread to cover all cells and incubated for 4h at 37°C at 5%CO2. Cells were then 
supplemented with 5ml of complete DMEM. When 50-70% of cells from round 1 have rounded 
and detached, cells were collected into 50ml tube. Viral lysate was then prepared as described 
in section 11.12. This round was repeated 3 times prior to moving on to round 2, with repeat 
the number of flasks were doubled. 
 
Round 2: 
HEK-293 of early passage (less then10) was used to prepare 6 x 75cm2 of approximately 80-
90% confluency. Viral lysate prepared from round 1 was used to infect these cells. 
Approximately 3-4ml was used per flask. Cells were infected for 4h at 37°C at 5%CO2 and then 
supplemented with 7-8ml of complete DMEM media. Cells were cultured until 50% of cells had 
rounded and detached. Cells were harvested and viral lysates were prepared as per section 
11.12.  
 
Round 3 (final): 
HEK-293 cells of low passage were used to prepare 5x 175cm2 of 80% confluency. Viral titres 
were determined by flow cytometry (see section 11.13) and an MOI of 10 was used to infect 
HEK-293.  Cells were infected for 4h at 37°C at 5% CO2. After this incubation cells were   79 
supplemented  with  complete  DMEM  media.    Cells were  incubated  until  50%  of  cells  had 
rounded and detached. Lysate was prepared as per in section 11.12. 
 
2.11.14 Viva pure virus purification and concentration 
 
Lysate was collected from 5 T175 infected HEK-293 cells. Lysate was filtered through 5 µm, 
1.2 µm and 0.8/0.2 µm filters prior to proceeding. Virus was purified with Cell biolabs Vivapure 
kit as per manufacturer‟s instructions. In brief, filtered lysate was treated with 12.5U/ml of 
benzonase nuclease and incubated for 30min at 37°C.  Treated lysate was then loaded into the 
vivaclear maxi column and spun for 5min at 500g. Appropriately calculated volume of 10x 
loading buffer was added to lysate. The adenopack 20 maxi-spin column was equilibrated with 
5ml of 1x wash buffer. Lysate was then transferred to equilibrated column and spun for 5min at 
500g to allow virus binding to membrane. Column was then washed twice with 18ml of wash 
buffer (spun in between at 500g for 5min). Column was then transferred to a clean column 
holder provided by kit. Then 1ml of elution buffer was applied to the membrane of the column. 
Column was briefly centrifuged for 30sec at 500g, and then incubated for 10min, prior to 
complete elution with a 5min spin at 500g. Buffer exchange and concentration was performed 
using  a  concentrator  column  also  provided  in  kit.    Virus  was  loaded  into  buffer  and 
concentration column chamber and topped up to 10ml with virus storage buffer (25mM Tris, 
25mM  NaCl,  2.5%  glycerol,  pH8).  Centrifuged  for  30min  at  800g,  concentrated  virus  was 
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2.11.15 Adenoviral titre determination by flow cytometry 
 
 Serial dilutions of virus was prepared in 0.5ml and 80-90% confluent HEK-293 in 25cm2 flask 
were infected for 4h at 37°C at 5%CO2. Cells were then supplemented with complete DMEM 
and incubated for 24h. Cells were then harvested and approximately 106 cells were transferred 
into FACS tubes and fixed with 1ml FACS lysing solution. Samples were analysed on FACS 
CANTO.  Viral titre was calculated according to previously published formula [206]:  
 
TITRE (GFU/ML) = %INF x TOTAL CELL x DIL 
        100 x VOL 
 
%INF = Percentage of positive cells 
TOTAL CELL = The initial number of cells infected 
DIL= dilution factor 
VOL= Initial infection volume (during the 4h incubation) 
 
2.11.16 Viral titre determination by ELISA 
 
Once the virus had been purified and concentrated the viral titer was determined by ELISA 
using the QuickTiterTM  Adenovirus Titer ELISA Kit. ELISA was conducted according to the 
manufacturer‟s instructions. In brief, HEK-293 cells at a concentration of 5x105/ml was seeded 
into 96 well plate provided (100µl/well). Cells were allowed to attach for 1h at 37°C. Serial 
dilution of positive control, which formed the standard curve and dilutions of purified virus were 
prepared as per instructions. Drop wise dilutions were placed into appropriate cells (50µl/well). 
Each dilution was performed in duplicate.  Cells were incubated for 2 days at 37°C 5%CO2. 
Then media was carefully removed without disturbing attached cells. The cells were fixed with 
100µl of cold methanol and incubated at -20°C for 20min. Cells were washed with PBS 3 times   81 
for 5min.  BSA (1%) in PBS (200µl/well) was used to block for 1h at RT on a orbital shaker. 
Then 100µl of provided anti-hexon antibody was added and incubated at RT on orbital shaker 
for 1h. Plate was washed 3 times with PBS for 5min each time. Provided secondary antibody 
(HRP-conjugated) was used to detect the hexon antibody. One hundred micro litres was placed 
into each well and incubated for 1h at RT on orbital shaker.  Plate was then washed 5 times 
with  PBS  for  5min  each  time.  TMB  solution  was  then  added  and  incubated  for  10min 
(100µl/well), the reaction was then stoped with the provided stop solution (100µl/well). Optical 





 Prism statistical software was used for statistical analysis, where T-test and ANOVA analysis 
were used. With statistical significance considered to P < 0.05. 
 
2.13 ISLET ASSOCIATED CULTURES  
 
2.13.1 Culture conditions 
 
Human islets clusters were maintained in CMRL media supplemented with 10% human serum 
(Albumex  20)  and  1%  glutamine.  Media  exchange  was  performed  daily,  unless  otherwise 
indicated. All use of human islet tissue has been approved by the Royal Adelaide Human 
Ethics Committee and was kindly given research consent by the donor families. All human 
islets were sourced from isolating centres that form the „Australian Islet Consortium‟. Prior to 
shipping, islets underwent clinical grade testing at the isolating centres with ethidium bromide / 
acridine  orange  staining  and  FACS  analysis  to  determine  islet  and  beta  cell  viability   82 







2.13.2 Islet dissociation 
 
Islets were washed with PBS to remove serum and centrifuged at 300g for 2 min, supernatant 
was decanted. Accutase (0.5ml) was used to resuspend islets and incubated in water bath at 
37°C in order to disaggregate islet cell clusters for 10min. Cells per agitated every 3-4min. 
Islets were further dissociated with gentle pipetting . Accutase was inactivated with the addition 
of 2ml of complete CMRL media. Cells were centrifuged to remove accutase (300g for 5min). 




2.13.3 Viral transduction 
 
Islets were transduced in a minimal volume to just resuspend islets in serum free CMRL. Islets 
were  infected for 2-4h  at 37°C at  5%CO2. After incubation  islets  were  supplemented  with 
complete CMRL media.    83 
 
2.14  NOD-SCID model of islet transplantation 
 
2.14.1 Animal housing 
 
NOD-SCID mice were housed in a pathogen free environment. Mice were purchased from the 
ARC, Perth. Mice were used in accordance and overseen by the animal ethics committee of 
the University of Adelaide and the IMVS approval number: M-2009-124 (The University of 





2.14.2 STZ diabetes induction 
 
Diabetes was induced in mice according to previously published data and according to the 
standard operating protocol of the Australian Islet Consortium.  In brief, mice of a minimum of 
20g were injected with 180mg/kg of STZ intra peritoneal. STZ was prepared immediately prior 
to reconstitution with sodium citrate buffer pH 7.8. All mice were injected within 10 minutes of 
reconstitution. Mice were monitored twice daily, with regular re-hydration with 0.5ml S.C or I.P 
saline, as required. Mice with 2 consecutive readings of high BGL were treated with insulin 
pellet or insulin injection of 1U.  
2.14.3 Human islet transplantation   
 
Mice were anaesthetised with ketamine (100mg/kg) and xylazine (6mg/kg) via IP, and kept on 
a heat mat for the entirety of the procedure. Eye ointment was applied to eyes to prevent drying 
out of the retina, while under anaesthesia. Under aseptic conditions and in a pathogen free 
environment, the left side at the cost vertebral angle was wiped and cleaned with sterile swabs. A 
1cm incision on the left side was made to expose the kidney. With a sterile scalpel a small nick   84 
was made to the kidney capsule and a glass rod was used to create a pocket for the islets. The 
kidney was covered with wet gauze during islet pellet preparation. Islets were prepared by gently 
spinning at 800 rpm for 1min. Islets were then transferred to a pre-loaded gel-foam  tip and spun 
further at 1000rpm for 2min. Excess media was removed and tip was unplugged prior to insertion 
under the kidney capsule. Using an insulin syringe plunger, islets were gently and carefully pushed 
under the capsule. Islets were spread by gently rubbing with the glass rod. The kidney was 
returned to its natural position and the muscle and skin was sutured using 4.0 catgut suture. Plain 
relief (temegsic) was administered sub-cut for long lasting relief.   
 
 
2.15 BUFFERS AND SOLUTIONS 
 
DMEM complete media 





CMRL complete  
CMRL Media 






RPMI Complete media (s10g) 
RPMI media 




GelRed TM Nucleic Acid gel Stain (1x) 
5ul of 10,000x stock GelRed  
50ml of 0.1M Sodium Choride 
 
Agarose gel per 100ml 
0.8% = 0.8g 
 
1% = 1g   85 
 
2% = 2g 
 
In a conical flask required amount was weight out and mixed with distilled water to measure 
100ml. Agarose gel was heated in microwave until agarose gel had dissolved.   
 
50x TAE per 100ml 
Trizma base -193.8g [1.6M] 
Sodium acetate – 65.6g [800mM] 
EDTA – 14.9 [40.27mM] 
pH to 7.2 
 
6x loading Buffer per 10ml 
200ul of 50x TAE 
5ml glycerol (50%) 
2.4ml Bromophenel Blue (24%) 
2.4ml Water 
 
TE8 per 100ml 
0.5ml 2M TRIS-HCL pH 8 
0.2ml 0.5M EDTA pH 8 
Make up to 100ml with water 
 
Luria Broth (LB) per 1L 
5g Bacto-Yeast Extract 
10g Bacto-tryptone 
10g Sodium Chloride 
Make up to 1L with water 
 
LB Agar 
15g Bacteriological Agar 
LB to 1L 
 
Autoclave mix prior to use. To melt agar heat in microwave. Then add 1ml of 30mg/ml 
kanamycin stock to bring final concentration of kanamycin to 30ug/ml. Make sure antibiotic is 
added when agar is 55°C or less. 
 
1M CaCl2 solution per 100ml 
14.7g of  CaCl2 
Mix with water and make up to 100ml autoclave the solution prior to use 
1M MgCl2 per 100ml 
20.33g MgCl26H20 
Mix with water and make up to 100ml autoclave the solution prior to use 
 
0.1M CaCl2/ 20mM MgCl2 Transformation Solution per 10ml 
1ml 1M CaCl2 
0.2ml 1M MgCl26H20 
8.8ml water 
 
Mini-preparation solution 1   86 
50mM D-Glucose  
25mM Tris-HCL 
10mM EDTA 
pH to 8 
 
Mini-preparation solution 2 
0.2M Sodium Hydroxide 
1% SDS 
 
Mini-preparation solution 3 
3M Potassium acetate  
11.5% Glacial acetic acid 
Adjust pH to 4.8 
 
Mini-preparation storage solution 
200ng /5ml DNase inactivated RNaseA 
5ml TE8  
 
SOC Media per 1L 
5g Bacto-Yeast Extract 
20g Bacto-Tryptone 
2ml 5M NaCl 
2.5ml 1M KCl 
Water make up to 1L 
Adjust pH to 7  
 
Western Blot lysis buffer  






10mM EDTA  
 
10x Tris buffered Saline (TBS) 
24.2g Tris base 
80g NaCl 
pH to 7.6 with HCL 
 
Western blot blocking buffer  
1x TBS 
0.1% Tween-20 
5% w/v nonfat dairy milk   87 
 






Conjugate  Clone  Source 
CD83  n/a  HB15e  Serotec LTD, 
Oxford, UK 
CD86  n/a  BU63  Serotec LTD, 
Oxford, UK 
CD80  n/a  MAB104  Immunotech, 
Mareille, France 
CD40  n/a  LOB7/6  Santa Cruz 
Biotechnology, 
Santa Cruz, CA, 
USA 





mouse IgG   FITC  -  Southern Biotech, 
Birmingham, AL, 
USA 
mouse IgG   PE  -  Southern Biotech, 
Birmingham, AL, 
USA 
CD-14  FITC   MY-4  Beckman Coulter, 
Fullerton, CA, 
USA 
ILT2  PE  HP-F1  Beckman Coulter, 
Fullerton, CA, 
USA 





Foxp3   PE  PCH101  eBioscience, San 
Diego, USA 




CD83   FITC  HB15e  eBioscience, San 
Diego, USA 
CD86  FITC  FUN1  BD Bioscience,   88 
San Jose, 
California, USA 
CD80   FITC  L307.4  BD Bioscience, 
San Jose, 
California, USA 
DC-SIGN  FITC  DCN46  BD Bioscience, 
San Jose, 
California, USA 
HLA-DR  PE-Cy5  G46-6  BD Bioscience, 
San Jose, 
California, USA 
PD-L2  n/a  MIH18  eBiosciences, 
USA 
PD-L1  n/a  MIH1  eBiosciences, 
USA 
ILT4  n/a  42D1  Santa Cruz, USA 
rat IgG  FITC  -  Silenus, Australia 
pY641  Alexa488  clone: 18  BD Bioscience, 
California, USA 
CD14  PE  M5E2  BD Bioscience, 
California, USA 
CD25  PE-Cy7  M-A251  eBiosciences, 
San Diego, USA 
CD4  Percp5.5  OKT4  eBiosciences, 
San Diego, USA 
CD3  FITC  SK1  BD Bioscience, 
California, USA 
RelB   n/a  polyclonal  Santa Cruz 
Biotechnology, 
USA 
anti-rabbit IgG   FITC  -  Santa Cruz 
Biotechnology, 
USA 
human F(ab‟)2  PE  -  Immunex 
France 
CD124  PE  hIL4R-M57  BD Bioscience, 
California, USA 
Asialo GM1  n/a  polyclonal  Wako, Japan 




IL-4 (eBiosciences, USA)  
IFN-γ (eBiosciences) 
Prostaglandin E2   (Sigma, USA)    89 
TNF-ʱ (R&D Systems, USA) 
CD40L (R&D Systems, Minneapolis, USA) 
(GMCSF)-LeucomaxTM (Sandoz Australia, Australia) 
 
2.16.3 FACS Reagents 
 
FACS lysing solution (BD Bioscience, USA)  
Rabbit serum cytofix buffer (BD Bioscience, USA)  
BD perm-buffer (BD Bioscience, California, USA)  
2.16.4 Molecular Reagents 
 
Agarose – DNA Grade (Progen, Australia) 
Ampicillin (Roche, Germany) 
Custom Oligo-nucleotides (Sigma-Genosys, USA) 
BamH I restriction endonuclease (New England Biolabs, USA) 
EcoR I restriction endonuclease (New England Biolabs, USA) 
Kanamycin (Life Technologies, USA) 
LipofectAMINE 2000TM (Invitrogen, USA) 
MgCl2 25mM Solution (Fisher Biotech, USA) 
Mineral Oil (Sigma-Aldrich, USA) 
MMLV Reverse Transcriptase (Life Technologies, USA) 
Not I Endonuclease (New England Biolabs, USA) 
Oligo dT (Amersham, Australia) 
Pac I restriction endonuclease (New England Biolabs, USA) 
pUC19 (Bresatec, Australia) 
RNase A (Sigma-Aldrich, USA)   90 
RNAsin (Promega, USA) 
Random Hexemers (Qiagen, USA) 
Sal I restriction endonuclease (New England Biolabs, USA) 
SPP1/EcoRI (Geneworks, Adelaide, Australia) 
T4 Ligase (Promega, USA) 
 
Tth Polymerase (Fisher Biotech, USA) 
 
Tth PCR buffer (Fisher Biotech, USA) 
 
GelRedTM Nucleic Acid Gel Stain (Biotium, USA) 
 
 
2.16.5 Plasmid vectors  
 
Pshuttle-CMV (Vogelstein, B, The John Hopkins University, Baltimore, USA) 
 
pAdEasy-1 (Vogelstein, B, The John Hopkins University, Baltimore, USA) 
 
pEGFP-N1 Vogelstein, B, The John Hopkins University, Baltimore, USA) 
 
 
2.16.6 Tissue Culture Reagents 
 
Accutase (Sigma-Aldrich, USA) 
RPMI 1640 (Invitrogen, USA)  
DMEM (Invitrogen, USA) 
Albumex 20 (Australian Red Cross, Australia) 
[3H]-Thymidine (Amersham, Biosciences LTD, Bucks, UK)  
CMRL (Invitrogen, USA) 
2.16.7 Kits 
 
CD4+ enrichment kit (Stem Cell Technologies, Canada)  
CD3+ positive selection kit (Stem Cell Technologies, Canada)  
RNAspin mini kit (GE Healthcare, USA)    91 
IL12p70 ELISA (eBiosciences, San Diego, USA). 
Human Insulin Elisa (Mercodia, Uppsala, Sweden)  
 
Mouse IL-2 ELISA (eBiosciences, San Diego, USA). 
Cytometric bead array kit, (BD Bioscience, USA) 
UltracleanTM DNA purification Kit (Mo Bio Laboratories, USA) 
Jetstar 2.0 Plasmid midi kit (Genomed, Germany) 
QuickTiterTM Adenovirus Titer Kit (Cell Biolabs, San Diego, CA, USA) 
 
2.16.8 Other Reagents 
 
Dimethyl sulphoxide (DMSO) (Ajax Chemicals, Australia) 
Trypan Blue (BDH, Australia) 
Tween-20 (Bio-Rad, USA) 
Dithizone (Sigma-Aldrich, USA) 
Streptozocin (Sigma-Aldrich, USA) 
Propidium Iodine (Invitrogen, USA) 
2.16.9 Equipment  
 
Cytospin II Shandon (Thermo scientific, USA) 
NanoDrop 1000 (Thermo Scientific, USA) 
Perkin Elmer DNA Thermal Cycler (USA) 
Bio-Rad Minigel Apparatus 
Wallac Microbeta Counter (Turku, Finland)  
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Cytokines  are  small  non-structural  proteins  that  regulate  the  response  to  infection, 
inflammation, trauma and immune responses [207]. Classically cytokines that are known to 
promote disease severity are called „proinflammatory‟ whereas those that promote healing are 
regarded  as  „anti-inflammatory.  Interferon-gamma  (IFN-γ),  a  type  II  cytokine,  classically 
considered as proinflammatory is the primary focus of this chapter [208]. IFN-γ (also known as 
macrophage  –activating  factor)  plays  an  important  role  in  macrophage  stimulation,  which 
induces  anti-microbial  and  anti-tumour  mechanisms.  Its  capacity  to  upregulate  antigen 
processing and presentation pathways as well as supporting leukocytes attraction, growth, 
differentiation and maturation of many cell types, it is well known as a proinflammatory cytokine 
[209, 210].  Initially,  IFN-γ was thought to be exclusively released by CD4+ T-helper cell Type 1 
(TH1) lymphocytes, CD8+ cytotoxic lymphocytes and natural killer cells [211, 212]. However B-
cells and professional APC have also been found to produce IFN-γ. The secretion of IFN-γ by 
APC such as DC, may be important in self-activation and the activation of nearby cells in their 
local environment [213] [214-216].  IFN-γ release by NK cells is important in the early phase of 
infection defence mechanisms. T-cells on the other hand are the primary source of IFN-γ, in the 
adaptive immune response [213, 217].  
 
IFN-γ is well known in the field of allograft transplantation for promoting antigen-specific Th1 
differentiation involved in cell-mediated rejection.  It does this by inhibiting the growth of Th2 T 
cell subsets and by promoting T-cell and APC interactions. Thus it upregulates the presentation 
and  stimulatory  capacity  of  APC,  which  increases  CD4+  T-cell  differentiation  [218].  The 
presence  of  IFN-γ  in  the  micro  environment  of  naive  T-cells  during  TCR  engagement,  is 
thought to heavily influence Th1 T-cell differentiation. Subsequently the production of IFN-γ and   94 
IL12 further inhibits the secretion of Th2 cytokine IL-4, driving a Th1 response [219-221].  Thus 
the  presence  of  IFN-γ  at  the  graft  site  is  associated  with  acute  allograft  rejection  [222]. 
However there is a large body of work which suggests that IFN-γ has a paradoxical role as an 
anti-inflammatory cytokine.  
 
Studies in the mid 1990s elucidated the unexpected protective role of IFN-γ in models of 
autoimmune disease. Initially the disruption of the IFN-γ gene in mouse models of experimental 
autoimmune encephalomyelitis and collagen induced arthritis, demonstrated that IFN-γ was 
required for protection against disease onset and severity rather than promoting the disease 
state [223-226].  In models of skin and cardiac allograft transplantation, it was observed that 
the supplementation of IFN-γ was essential for prolonging graft survival and inducing tolerance 
by co-stimulatory blockade [227-229].  More recently, in 2008 in vitro studies by Feng showed 
that the addition of IFN-γ into murine DC-allogeneic T-cell co-cultures promotes the enrichment 
of CD4+ CD25+ Foxp3+ T-regulatory cells, by converting and eliminating T-effector cells [230], a 
phenomenon  that  contradicts  the  view  that  IFN-γ  solely  drives  Th1  mediated  immune 
responses.    Moreover,  IFN-γ  KO  models  have  demonstrated  that,  IFN-γ  is  required  to 
negatively regulate the stimulatory capacity of DC, an occurrence that has only been vaguely 
described in humans.  
 
In  the  past  decade  some  human  studies  have  also  suggested  that  IFN-γ  may  negatively 
regulate monocyte differentiation into mature DC [231, 232]. These studies however failed to 
accurately phenotype the resultant APC and they did not investigate the effect of IFN-γ on 
inhibitory molecule or Lineage marker expression, nor did they assess the tolerogenic capacity 
of these APC.  As discussed in section chapter 1.4.1, DC are crucial regulators of the immune 
responses and are capable of directly inhibiting allograft rejection by promoting tolerogenic   95 
immune responses. Therefore the aim of this chapter was to investigate the tolerizing capability 
of IFN-γ to modulate DC function to promote tolerance. 
 
It was hypothesised that: 
  The capacity of IFN-γ  to negatively regulate DC function lies with the timing of IFN-γ 
exposure during DC differentiation (day 0 treatment)  and maturation (Day 5 treatment) 
 
  The  negative  regulation  of  DC  function  is  related  to  IFN-γ  inducible  negative  co-
stimulatory molecule expression 
The capacity of IFN-γ to negatively regulate DC function was shown to be dependent on the 
timing of exposure during DC development. IFN-γ treatment only at day 0 of DC differentiation 
inhibited  the  capacity  of  DC  to  efficiency  prime  T-cells,  thus  causing  T-cell 
hyporesponsiveness.  Moreover,  IFN-γ  treatment  at  day  0  upregulated  the  expression  of 
inhibitory Immunoglobulin-Like Transcript (ILT) family molecules and inhibited the expression of 
maturation marker CD83, which in part may have contributed to the poor capacity of DC to 
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3.2 MATERIALS AND METHODS 
 
3.2.1. Generation of human monocyte-derived dendritic cells  
 
Monocytes were isolated from healthy human blood donors as described in chapter 2 section 
1.1 and 2.1. Monocytes were cultured in RPMI  1640 containing 10% FCS, 800U/ml (1.2x107 
U/mg)  of  recombinant human granulocyte colony stimulating factor (GMCSF)-LeucomaxTM 
(Sandoz  Australia,  Australia)  and  400U/ml  (1x107  U/mg)  of  recombinant  human    IL-4 
(eBiosciences, USA) in the absence (UT-DC) or presence of  500U/ml  of IFN-γ (eBiosciences, 
USA) (IFN-γ-DC0) for 5 days to generate immature DC (iDC). At day 5 of culture, iDC were 
treated with 10ng/ml of TNF-ʱ (R&D Systems, USA) for 2 days to generate mature DC (mDC). 
In some experiments iDC were matured with TNF-ʱ (R&D Systems, USA)in the presence of 
IFN-γ (eBiosciences, USA) (500u/ml) (IFN-γ-DC5).  All cell cultures were incubated under 5% 
CO2 at 37°C. 
3.2.2 Phenotypic analysis of DC by flow cytometry  
 
The phenotypic profile of DC was defined using the following primary mAb: anti-CD83 (HB15e) 
(Serotec Ltd, UK) and anti-CD86 (BU63) (Serotec Ltd, UK), anti-CD80 (MAB104) (Immunotech, 
France) anti-CD40 (LOB7/6) (Santa Cruz Biotechnology, USA), anti-MHC Class II (In house 
tissue supernatant), anti-ILT3 (ZM3.8) (Kind gift from Dr. Marco Colonna, Washington State 
University,  St  Louis,  USA)  anti-PD-L1(MIH1)  and  anti-PD-L2  (MIH18)  (eBioscience,  USA).  
Unconjugated  mouse  mAb  were  detected  with  FITC  or  PE  conjugated  anti-mouse  IgG 
secondary antibody. Conjugated mAb were used to assess the expression of CD-14-FITC 
(MY4) (Beckman Coulter, USA), ILT2-PE (HP-F1) Beckman Coulter, USA), and DC-SIGN-FITC 
(DCN46) (BD Bioscience, USA). Rat anti-human ILT4 (42D1) (A gift of Dr. Marco Colonna, 
Washington State University, St Louis, USA) was also used as a primary mAb, whist FITC-  97 
conjugated anti-rat IgG was used for detection. For antibody details please refer to chapter 2 
section 16.1.  
 
3.2.3 Mixed lymphocyte reaction 
 
DC were washed with PBS three times, irradiated (30Gy) and used as stimulators in the MLR. 
Allogeneic T-cells were purified from PBMNC using nylon wool packed columns as described in 
chapter 2 section 1.2. DC were co-cultured with T-cell responders in 96-well round bottom 
plates, at stimulator to responder ratios of 1:10, 1:100 and 1:1000. After 4 days cells were 
pulsed with 1µCi [3H]-Thymidine (Amersham, UK) for 18 h and then harvested onto glass-fibre 
filters and counted in β-scintillation fluid using a Wallac Microbeta Counter (Tuku, Finland). 
Proliferation was expressed as counts per minute (mean of 5 replicates, ± SD).   
 
3.2.4 Messenger RNA expression analysis 
 
RNA was extracted was as per described in the methods (Chapter 2 section 2.8.1) cDNA was 
synthesized  using  1μg  total  RNA  by  reverse-transcription  (Chapter  2,  section  2.8.2). 
Quantitative Real-Time PCR, based on a standard curve of copy numbers for each specific 
gene was generated and used to analyse the expression of  RelB, IL-12p40, IDO and HLA-G.  
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the house-keeping gene 
in order to verify RNA integrity and cDNA synthesis.  Please refer to appendix A for sequence 
details and cycling conditions. 
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3.2.5 T-cell cytokine and phenotype analysis 
 
Purified  T-cells  were  co-cultured  with  DC  at  a  ratio  of  100:1,  for  6  days  in  RPMI  1640 
supplemented with 10% FCS at 37ºC under 5% CO2.   T-cells (5x105) were stained for CD4 
and  intracellular  expression  of  Foxp3  or  IL-17A  (eBioscience,  USA).    Briefly,  cells  were 
permeabilised and fixed (with buffer provided in kit) before blocking with normal rat serum. 
Cells were then incubated with anti-human Foxp3-FITC mAb or IL-17-FITC. CD4+ T cells were 
gated and analysed on BD FACSDIVA Software, quadrant gates were set according to isotype 
control.    In  addition,  supernatants  from  co-cultures  were  collected  and  assayed  for  the 
production of IL-2, IFN-γ, IL-4 and IL-10 by using a cytometric bead array kit (BD Bioscience, 
USA).  Cells  and  supernatants  were  analysed  by  flow  cytometry  on  a  FACS  CANTO  (BD 
Bioscience, USA).  
 
3.2.6 Statistical analysis  
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3.3. RESULTS 
3.3.1 IFN-γ modifies the expression of positive co-stimulatory molecules and 
negative regulatory molecules on DC during differentiation and maturation 
 
In preliminary experiments a range of 50 to 1000U/ml of IFN-γ was used to determine the 
effects on DC differentiation and maturation from monocyte precursors.  The concentration of 
500U/ml was considered as optimal as no cytopathic effects were observed and 1000U/ml did 
not significantly improve the capacity of DC to further inhibit T cell proliferation (see appendix 
B), thus 500U/ml was used in subsequent experiments.  IFN-γ treatment of monocytes at day 0 
prior to DC differentiation or at day 5 during maturation caused phenotypic changes (Figure 
3.3.1A). DC differentiation was observed by the loss of the monocyte marker and the high 
expression of the DC lineage marker DC-SIGN (>92%+ve cells for all groups).  IFN-γ treatment 
at day 0 (IFN-γ-DC0) however reduced the CD83 percentage positive population to 6%, which 
was considerably less compared to UT-DC, in which 74% of its population expressed CD83. 
IFN-γ-DC0 also caused the down regulation of co-stimulatory molecules. CD86 saw a 9% 
reduction in the percentage of IFN-γ-DC0 expressing this molecule. Moreover, only 33% of the 
IFN-γ-DC0 population expressed CD80 compared to 93% of the UT-DC population (Figure 
3.3.1A). Treatment with IFN-γ at day 5 (IFN-γ-DC5) on the other hand did not modify the 
expression profile of co-stimulatory molecules compared to UT-DC.  
 
Flow cytometric analysis of negative regulatory molecules showed that both IFN-γ-DC0 and 
IFN-γ-DC5 had induced expression of PD-L1 (Figure 3.3.1B). IFN-γ increased the MFI of PD-L1 
to 325 in IFN-γ-DC0 and 245 in IFN-γ-DC5 from 136 in UT-DC. However, ILT4 expression was 
exclusively upregulated in IFN-γ-DC0 from negative UT-DC to 22% of the IFN-γ-DC0 population. 
The MFI of ILT2 and ILT3 were also upregulated in IFN-γ-DC0 compared to UT-DC. IFN-γ-DC5 
and UT-DC had similar expression levels of inhibitory receptors ILT2, ILT3 and ILT4. Both IFN-  100 
γ treated groups had reduced PD-L2 expression (68%+ve UT-DC vs 34% +ve IFN-γ-DC5 vs 
9%+ve IFN-γ-DC0). The surface expression of HLA-G, an inhibitory ligand for ILT2 and ILT4 
associated in regulating DC and T-cell responses, was not present in UT-DC and IFN-γ-DC0, 
whilst IFN-γ-DC5 showed a negligible upregulation to 3%. Overall IFN-γ-DC0 appears to have 
an immature DC phenotype despite stimulation with maturing agent TNF-ʱ. This coincided with 
reduced expression of positive co-simulation and the upregulation of inhibitory molecules a 

































































FIGURE 3.3.1A. IFN-γ modifies the expression of positive co-stimulatory molecules by 
DC during differentiation and maturation.  DC were treated with IFN-γ at day 0 (IFN-γ-DC0) 
and at day 5 (IFN-γ-DC5) or cultured in the absence of IFN-γ (UT-DC) for 5 days, then matured 
with TNF-ʱ for 2 days. Flow cytometry was used to analyse the phenotype of IFN-γ treated DC 
and compared to UT-DC. The following costimulatory and lineage markers were examined: 
CD83, CD86, CD40, MHC class II, DC-SIGN and CD14. The expression of all markers was 
analysed by flow cytometry. Solid line indicates the isotype control and dash line shows the 
tested mAb. Mean Fluorescence Intensity (MFI) is indicated in the top-right corner of each 
graph  and  percentage  positive  cells  are  shown  below  the  MFI.  Representative  of  10 
independent experiments.  
 



































FIGURE 3.3.1B. IFN-γ upregulates the expression of inhibitory co-stimulatory molecules 
from the ILT family and PD-L1. To further study the phenotype, the expression of negative 
co-stimulatory molecules was examined including: PD-L1, PD-L2, HLA-G, ILT-2, ILT-3 and ILT-
4. The expression of all markers was analysed by flow cytometry. Solid line indicates the 
isotype control and dash line shows the tested mAb. Mean Fluorescence Intensity (MFI) is 
indicated in the top-right corner of each graph and percentage positive cells are shown below 
the MFI. Representative of 4 independent experiments.   103 
3.3.2 Monocyte-derived DC differentiated in the presence of IFN-γ induce 
allogeneic T cell hyporesponsiveness 
  
The effect of IFN-γ on the stimulatory function of DC, was examined in a DC mixed lymphocyte 
reaction (MLR). After DC maturation with TNF-ʱ, cells were harvested and extensively washed 
to minimise the transfer of residual factors into the MLR. In comparison to UT-DC, IFN-γ-DC0 
inhibited the proliferation of T-cells by 33% (P=0.02) at a stimulator : responder ratio of 1:100 
and 97% (P=0.007) at a 1:1000 ratio (Fig. 3.3.2A).  The stimulatory capacity of IFN-γ-DC5   
remained unchanged compared to UT-DC. The addition of IL-2 (100U/ml) to T-cells co-cultured 
with IFN-γ-DC0 (Figure.3.3.2B), did not revert T-cell proliferation, suggesting that T-cells co-
cultured with IFN-γ-DC0 are not anergic in nature [233]. 
 
3.3.3 IFN-γ treatment at day 0 prior to DC-differentiation produces maturation-
arrested DC 
In order to confirm the maturation status of phenotypically immature DC the gene expression of 
NF-κB  transcription  factor  RelB  and  proinflammatory  cytokine  IL-12  were  assessed  by 
quantitative real-time PCR (Figure 3.3.3). Expression of RelB was significantly inhibited by 79% 
(P=0.01) in IFN-γ-DC0 when compared to UT-DC. However exposure to IFN-γ at day 5 during 
DC maturation resulted in a significant increase of 48% in RelB expression, when compared to 
both other groups (UT-DC and IFN-γ-DC0).  IFN-γ-DC0 failed to upregulate the gene expression 
of IL-12, instead a significant inhibition was observed by 97% (P=0.02) in comparison to UT-























FIGURE  3.3.2A:  Monocyte-derived  DC  differentiated  in  the  presence  of  IFN-γ  induce 
allogeneic T-cell hyporesponsiveness. DC were treated with IFN-γ at day 0 (IFN-γ-DC0) and 
at day 5 (IFN-γ-DC5) or cultured in the absence of IFN-γ (UT-DC) for 5 days, then matured with 
TNF-ʱ for 2 days. T cells (1x105) were incubated with DC, at a DC to T-cell ratio of 1:10, 1:100 
and 1:1000 for 5 days. Proliferation was determined by [3H] thymidine incorporation (CPM). 
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FIGURE  3.3.2B.  IFN-γ-DC0  cause  T  cell  hyporesponsiveness  independent  of  T  cell 
anergy. To test the ability of IFN-γ-DC0 to induce T cell anergy, 100U/ml of exogenous IL-2 
was added to the co-culture of DC and T cell at a ratio 1:100 for 5 days.  Proliferation was 
determined by [3H] thymidine incorporation (CPM) (n=10) (B). *=p<0.05, NS= No Significance. 
±SD of 5 replicates within the experiment. Figure representative of 5 independent experiments 
 
 















FIGURE 3.3.3: IFN-γ treatment at day 0 prior to DC-differentiation produces maturation-
arrested DC. DC were treated with IFN-γ (500U/ml) at day 0 (IFN-γ-DC0) and at day 5 (IFN-γ-
DC5) or cultured in the absence of IFN-γ (UT-DC) for 5 days, then matured with TNF-ʱ for 2 
days. Quantitative real-time PCR was used to analyse the mRNA expression levels of NF-κB 
transcription factor RelB (A) and IL-12 (B) to confirm the maturation status of IFN-γ-DC0 as 
immature. Mean ± SD of quadruplicates, *=p<0.05, **=p<0.01, NS= No Significance. Figure 
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3.3.4 T-cell hyporesponsiveness induced by IFN-γ-DC0 is independent of the 
generation of total Foxp3+ T regulatory cells. 
 
To investigate other possible mechanisms causing T-cell hyporesponsiveness by IFN-γ-DC0, 
the ability of IFN-γ-DC0 to generate Foxp3+ T-regulatory cells and IL17-secreting TH17 cells 
was assessed. The proportion of CD4+Foxp3+ T-cells and CD4+IL17+ T cells (Figure 3.3.4A) 
after co-culturing DC and T-cell for 6 days was determined by FACS. UT-DC on average  64% 
of the CD4+ T-cell population were Foxp3+ compared to 38% generated by co-cultures with 
IFN-γ-DC0 (p=0.017 based on 4 independent experiments). The presence of IL17 producing 
CD4+ T-cells in the resultant co-cultures was similar in both groups. IFN-γ-DC0 promoted on 
average 4% of CD4+IL17+ T-cells which was not significantly different to UT-DC (mean = 4%) 
(p=0.43).  Analysis of supernatants (Figure 3.3.4B) from IFN-γ-DC0 and T-cell co-cultures had 
significantly reduced concentration of IL-2 (p=0.0097) and IFN-γ (p=0.037) production by 67% 
and 73% respectively, when compared to UT-DC. The production of IL-4 and IL-10 was not 
statistically different in IFN-γ-DC0 co-cultures compared to UT-DC. IFN-γ responsive regulatory 
molecules  indoleamine  2,  3-dioxygenase  (IDO)  and  HLA-G  (Figure  3.3.4C),  were  also 
examined as they are known to regulate T-cell responses.  IDO and HLA-G mRNA expression 
in IFN-γ-DC0 were not significantly upregulated compared to UT-DC. However IDO and HLA-G 
























FIGURE 3.3.4A:  T-cell hyporesponsiveness induced by IFN-γ-DC0 is independent of the 
generation of Foxp3+ T regulatory cells and the generation of IL-17 producing T-cells. DC 
were treated with IFN-γ at day 0 (IFN-γ-DC0) and at day 5 (IFN-γ-DC5) or cultured in the 
absence of IFN-γ (UT-DC) for 5 days, then matured with TNF-ʱ for 2 days. IFN-γ-DC0 were co-
cultured for 6 days with 1x105 T-cells (1:100, DC to T-cell ratio), then stained for surface 
expression of CD4 and intracellular expression of Foxp3 (A) or IL17 (b) (n=4). *=p<0.05, NS= 






















FIGURE 3.3.4B: IFN-γ-DC0 co-cultured with T-cells inhibits the production of IL-2 and 
IFN-γ.  DC  were  co-cultured  for  6  days  with  1x105  T-cells  (1:100,  DC  to  T-cell  ratio). 
Supernatants from co-cultures were harvested and analysed by cytometric bead array assay 
(as described in chapter 2.3.6) for the production of IL-2 (A), IFN-γ (B), IL-4 (C) and IL-10 (D) 
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FIGURE 3.3.4C:  IFN-γ-DC0 do not have upregulated expression of soluble inhibitory 
molecules IDO and HLA-G. DC were treated with IFN-γ at day 0 (IFN-γ-DC0) and at day 5 
(IFN-γ-DC5) or cultured in the absence of IFN-γ (UT-DC) for 5 days, then matured with TNF-ʱ 
for 2 days. DC total RNA was extracted and reverse transcribed. The mRNA expression of 
immunomodulatory molecules IDO (A) and HLA-G (B) were determined by quantitative PCR 
(n=5). *=p<0.05, **=p<0.01, ***=p<0.001. Mean ± SD of quadruplicates. Figure representative 
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IFN-γ has classically been considered as a proinflammatory molecule known to primarily drive 
Th1 allo-responses [218]. In this chapter the timing of IFN-γ exposure during DC development 
was investigated, in order to examine its capacity to negatively regulate DC function.   In this 
study an in vitro model of DC differentiation with GMCSF and IL-4 was used to assess the 
immunomodulatory effects of IFN-γ at day 0 and day 5 of DC propagation, to define its effects 
during DC differentiation and maturation. It was found that the anti inflammatory function of 
IFN-γ was time dependent. Treatment at day 0 (IFN-γ-DC0), but not at day 5 down regulated 
positive  costimulatory molecule  expression and  remarkably inhibited  the expression  of  DC 
maturation marker CD83, which also known to play an important role in the activation of T-cells 
[234, 235]. This study also observed an up regulation of inhibitory molecules ILT2, ILT3 and 
ILT4, a finding which has not been previously  described. It is speculated, that the known 
antagonistic effects of IFN-γ on IL-4 may play role in the mechanism, by which IFN-γ exerts its 
regulatory function.  
 
IFN-γ is known to inhibit IL-4 activated STAT-6 phosphorylation, which reduces IL-4 receptor 
expression [236]. The promoter region of DC development factor IRF4 has a STAT-6 binding 
element, which helps to regulate its expression. Therefore it is speculated that the reduction of 
STAT-6 phosphorylation may inhibit the downstream expression of IRF4 [237, 238]. IRF4 also 
binds to PU.1 a negative regulator of ILT2/ILT4. Thus inhibited IRF4 expression may also 
reduce binding of PU.1 resulting in increased expression of ILT2 and ILT4. The expression of 
immunoglobulin like transcript (ILT) molecules and in particular ILT3 and ILT4 are important in 
regulating allo-immune responses. ILT4 and ILT2 are known to bind to HLA-G, which has   112 
immunosuppressive functions relevant to transplantation [239], ILT3 on the other hand has no 
known ligand [240-242]. Tolerogenic dendritic cells have been shown to inhibit allogeneic T-cell 
proliferation in a ILT3 and ILT4 specific manner as shown by mAb mediated blocking. High 
expression of these molecules is also important in the induction of CD4+CD25+ Treg cells 
[243, 244]. Moreover, signalling through these receptors causes a calcium-dependent down 
regulation of NF-κB transcription factor [240, 242, 243], which may contribute to the reduced 
expression of RelB observed in IFN-γ-DC0. 
 
RelB is a NF-κB transcription factor, and its nuclear expression is related to DC maturation 
[245, 246]. RelB is known to target genes that control the expression of MHC class II, CD80, 
CD86, CD40 and CD83 [247-249]. The reduced expression of co-stimulatory molecules and 
CD83 in IFN-γ-DC0, may therefore be a downstream effect of RelB inhibition. Inflammatory 
cytokine IL-12p40 mRNA expression was also significantly lower in IFN-γ-DC0 compared to 
UT-DC, suggestive of decreased production of IL-12 protein. Previously published data have 
demonstrated that IL-12 protein production positively correlates with mRNA expression of IL-12 
[250]. These factors combined render IFN-γ-DC0 immature with a reduced capacity to activate 
T-cells causing T-cell hyporesponsiveness.   
 
T-cell hyporesponsiveness induced by IFN-γ-DC0 is supported by previously published studies, 
which reported similar effects of IFN-γ on monocyte-derived APC [231, 232]. In contrast to 
these studies, it was demonstrated that IFN-γ-DC0 are of  DC lineage, through the expression 
of DC specific marker DC-SIGN [251].  In this chapter we have extended this observation of 
induced  T  cell  hyporesponsiveness  to  examine  the  polarization  to  either  a  Th2  or  Th1 
response. We did this by examining the secretion of Th1 and Th2 cytokines during a DC-MLR. 
We found that IFN-γ-DC0 reduced the production of IL-2 and IFN-γ in comparison to UT-DC.     113 
Suggesting a de-polarization from Th1 response, however there is no evidence to suggest that 
a Th2 response was present. The reduced production of IL-2 and IFN-γ may be a factor 
contributing to the inhibition of T-cell proliferation by IFN-γ-DC0 affecting the polarization of Th1 
responses [219, 252, 253]. Although this assay did not take into account the differences of final 
number of cells, the overall immune response was blunted by IFN-γ-DC0 in comparison to UT-
DC.  However  this  also  does  not  exclude  the  induction  of  T-cell  anergy  by  IFN-γ-DC0,  as 
mechanism of inducing T-cell hyporesponsiveness.   
 
T-cell anergy is characterized by the induction of an unresponsive state in T-cells, where T-
cells become functionally inactivated following stimulation through the T-cell receptor, in the 
absence  of  co-stimulation  [254].  Given  that  IFN-γ-DC0  have  reduced  co-stimulation  in 
comparison  to  UT-DC,  it  was  hypothesised  that  IFN-γ-DC0  may  induce  T-cell  anergy. 
Surprisingly, the addition of exogenous IL-2 did not reverse the T-cell hyporesponsiveness, 
unlike other studies [233], suggesting that IFN-γ-DC0 does not induce IL-2 reversible T-cell 
anergy. However, this does not exclude cell division-arrest, whereby the IL-2 receptor is not 
induced by TCR signals [255, 256]. In addition, there is no evidence to suggest that IFN-γ-DC0 
induced T-cell hyporesponsiveness, correlates with the total number of Foxp3+ T-cells or the 
deviation to a Th17 response. 
 
T-cell  mediated  immunoregulation  is  the  primary  mechanism  known  to  maintain  antigen-
specific tolerance in vivo [257]. In particular CD4+ Foxp3+ T-regulatory cells (Tregs), have been 
described as the most potent suppressive T-cell subtype. Initially described in murine models 
as CD4+CD25+ highly suppressive T-cells by Sakaguchi [258], this T-cell subtype was later also 
described in humans [259-264].  Foxp3 has been described as the master gene, involved in the 
development and function CD4+ Tregs [107, 265] [266]. Recent studies however have shown   114 
that,  unlike  in  murine  models  Foxp3+  cells  are  not  homogenous  in  their  function  to  be 
suppressive. Various studies have now shown that TCR stimulation alone can induce Foxp3 
expression in naive CD4+Foxp3- T-cells, without conferring any suppressive function [267-270]. 
More recently it was described that activated human CD4+ T-cells expressing low levels of 
Foxp3  fail  to  be  suppressive  and  rather  are  cytokine  producing  effector  T-cells,  whereas 
activated  CD4+  Foxp3HI  T-cells  are  highly  suppressive  [271].  Thus  measuring  the  total 
CD4+Foxp3+ population alone does not define the suppressive capacity of this T-cell population 
in humans. This suggests that the reduced capacity of IFN-γ-DC0 to promote Foxp3+ cells is a 
reflection of the its reduced capacity to activate T-cells rather than their ability to promote the 
generation of suppressive Tregs. Therefore this study was limited in its capacity to determine 
the ability of IFN-γ-DC0 to promote a suppressive Treg population. However the reciprocal 
relationship that exists between Foxp3 Tregs and Th17 cells, and the observation that IFN-γ-
DC0 depolarizes a Th1 response and do not  induce a significant generation of IL-17, suggests 
that Foxp3 Tregs are more like to be promoted by IFN-γ-DC0 rather than UT-DC.  However this 
does  not  exclude  the  possibly  of  IFN-γ  inducible  inhibitory  soluble  molecules  or  enzymes 
playing a role in IFN-γ-DC0 mediated T-cell hyporesponsiveness.  
 
Immunomodulatory  molecules  Indoleamine  2,3-Dioxygenase  (IDO)  and  HLA-G  are  
upregulated by IFN-γ [272-274].  IDO is an enzyme that catabolises tryptophan to inhibit T-cell 
proliferation [274]. HLA-G is a ligand for ILT2 and ILT4, where binding to its receptors mediates 
its  immunomodulatory effects  [275,  276].  Surprisingly,  mRNA  of  IDO  and  HLA-G  was  not 
induced  in  IFN-γ-DC0,  thus  unlikely  to  play  a  role  in  IFN-γ-DC0  induced  T-cell 
hyporesponsiveness. Significant increases of HLA-G and IDO mRNA in IFN-γ-DC5 did not 
affect their ability to stimulate T-cells when compared to UT-DC. A surprising result given the 
inhibitory function of these molecules, but not uncommon given that other studies have shown   115 
the same phenomenon [277-279]. However, the regulatory effects of IDO and HLA-G may be 
overcome by the robust positive co-stimulation provided by IFN-γ-DC5.  Munn and colleagues 
have suggested that IDO can be also be present in enzymatically active and inactive states 
[278].  Accordingly, IDO  may  be present  in IFN-γ-DC5  in  an  inactive  state, thus  unable to 
contribute to the T-cell regulation.  
 
 
In  summary  this  chapter  has  demonstrated  that  the  timing  of  IFN-γ  exposure  during  DC 
development  is important  for its  function as  either a  pro-inflammatory or anti-inflammatory 
cytokine.  IFN-γ exposure only at day 0 during DC differentiation (IFN-γ-DC0) was able to down 
regulate the expression of positive co-stimulatory molecules and most importantly maturation 
marker CD83, a function not seen in IFN-γ-DC5. It is speculated that early monocyte exposure 
to IFN-γ during differentiation, antagonistically inhibits IL-4 activated STAT-6 phosphorylation, 
and the downstream expression of IRF4, which precipitates in a cascade of events leading to 
maturation  arrest.  It  is  believed  that  IRF4  gene  inhibition  promotes  the  expression  of  ILT 
inhibitory molecules, which signal to inhibit RelB expression. Inhibited expression of RelB in 
turn arrests DC maturation resulting in CD80/CD86 down regulation and inhibition of CD83. 
Subsequently,  the  immature  phenotypic  features  of  these  DC,  in  particular  their  poor 
stimulatory capacity contributes to the observed T-cell hyporesponsiveness. However this is 
speculative and warrants confirmation at the molecular level, in particular it is important to 
demonstrate that STAT-6 phosphorylation and IRF4 are inhibited in addition to RelB protein 
expression and translocation into the nucleus. The ability of IFN-γ-DC0 to generate T-regs still 
remains elusive due to the limitations associated with the T-cell assay used in this chapter. 
Human Treg populations should therefore in future be defined according to recent publications, 
which have defined the Foxp3HI population as suppressive, in addition to in vitro suppression   116 
assays to show functionality. Nevertheless IFN-γ-DC0, may potentially serve as a tolerogenic 
DC for the cellular therapy of allograft rejection.  The standard DC propagation protocol to 
generate IFN-γ-DC0, which takes 7-10 days is suitable for living donor kidney transplantation, 
where  there  donor  and  recipient  pairs  are  identified  well  in  advance.    However  it  is  not 
applicable to deceased donor transplantation and in particular islet cell transplantation, where 
living  donors  are  not  suitable.  Therefore,  a  novel  propagation  strategy  to  generate  IFN-γ 

























CHAPTER 4 - IFN-γ inhibits STAT-6 
signalling in human monocytes 
promoting the rapid generation of 































Dendritic cells (DC) play a key role as sentinels of the immune system for the detection of 
pathogens  and  disturbance  of  the  immunological  milieu  [280].  All  transplantable  organs 
possess a cellular component of passenger leukocytes, which migrate from the allograft to 
initiate rejection via the direct pathway of allorecognition  [126, 129, 281, 282]. DC are an 
important component of the passenger leukocyte population [135, 136, 283]. However, under 
certain conditions DC may be modulated to become tolerogenic and inhibit T-cell function. In 
particular, immature DC (iDC) have been shown to inhibit allogeneic T-cells proliferation [184, 
284, 285], while the injection of antigen pulsed iDC block T-cell responses in humans [286]. 
However, iDC undergo maturation in vivo limiting their tolerogenic potential. The modification of 
DC to stably inhibit maturation has been extensively studied in recent years. A variety of 
pharmacological  and  immunological  approaches  including  interleukin  10,  vitamin  D3, 
dexamethasone, aspirin and most recently the NF-κB inhibition by curcumin was shown to 
arrest DC in an immature state and promote tolerance in vitro and in vivo. [143, 144, 149, 150, 
152, 287]. 
 
The  use  of  tolerogenic  DC  to  modify  the  recipient  immune  system  to  promote  allograft 
acceptance is a potential alternative therapeutic approach, which has the advantage of not 
requiring conventional immunosuppressive therapy. However their use in the clinic has faced 
significant hurdles - current protocols to generate monocyte-derived DC take 7-10 days [288] 
while rejection begins within hours of transplantation and is well established within 7 days 
[289].  Clinically useful DC must be generated in a short period of time. In 2003, Dauer and 
colleagues  published  a  „FAST-DC‟  protocol  to  generate  potent  immunostimulatory  mature   119 
monocyte-derived DC for the purpose of cancer immunotherapy in 48hr [205].  In the present 
study a complementary approach to rapidly generate stable immature DC was developed.  
 
 
IFN-γ is regarded as a potent proinflammatory cytokine and is secreted by CD4+ T-helper type 
1  (Th1)  lymphocytes,  CD8+  cytotoxic  lymphocytes  and  NK  cells,  which  play  key  roles  in 
allograft destruction [290, 291]. IFN-γ also plays an essential role in allograft acceptance. IFN-γ 
KO models of skin and cardiac allograft transplantation demonstrate that IFN-γ is essential for 
prolonging  graft  survival  and  inducing  tolerance  [227-229].  However,  IFN-γ  also  has  an 
immunomodulatory  role  as  illustrated  by  knockout  (KO)  mouse  models  of  experimental 
autoimmune  encephalomyelitis  and  collagen  induced  arthritis  where  IFN-γ  is  required  for 
protection against disease onset and severity [223-226].  Moreover, a recent study by Wu and 
colleagues showed IFN-γ was required for the negative regulation of DC migration and T-cell 
priming [292]. In chapter 3 it was demonstrated that the timing of IFN-γ exposure is critical in its 
function to either inhibit or promote the stimulatory potential of DC. It was shown that negative 
regulation of DC stimulatory capacity is only mediated by IFN-γ if exposure occurs early during 
DC differentiation at the monocyte level [156].    
 
In  this  chapter  the  mechanism  of  action  by  IFN-γ,  where  by  the  maturation  arrest  of  DC 
maturation was further examined, extending chapter 3 by developing a „rapid‟ DC protocol to 
produce  tolerogenic  DC  in  the  clinically  applicable  timeframe  of  48  hours.  Here  it  was 
demonstrated that the effect of IFN-γ is mediated by the inhibition of STAT-6 phosphorylation 
and NF-κB activation resulting in DC maturational arrest and the development of a tolerogenic 
DC  phenotype.    These  rapidly  generated  IFN-γ  modulated  DC  support  the  generation  of 
antigen specific T-regulatory cells in vitro. These cells were then used in a surrogate NOD-  120 
SCID chimeric model of islet transplantation. However poor human cell engraftment into the 
NOD-SCID mouse model, failed to demonstrate the tolerogenic potential of IFNγ-DC. 
 
 
4.2 METHODS AND MATERIALS 
4.2.1 Antibodies 
 
The phenotypic profile of DC was defined using the following directly conjugated mAb: anti-
CD83-FITC (HB15e) (eBioscience, USA), anti-CD86-FITC (FUN1) (BD Bioscience, USA), anti-
CD80-FITC  (L307.4)  (BD  Bioscience,  USA),  anti-DC-SIGN-FITC  (DCN46)  (BD  Bioscience, 
USA), anti-HLADR-PE-Cy5 (G46-6) (BD Bioscience, USA), anti-PD-L2 (M1H18) (eBioscience, 
USA) and rat anti-human ILT4 (42D1) used as a primary mAb and FITC-conjugated anti-rat IgG 
was used for detection.  STAT-6 phosphorylation was detected by intracellular staining, using 
anti-pY641-Alexa488  (Clone  18)  (BD  Bioscience,  USA)and  surface  staining  with  CD14-PE 
(M5E2) (BD Bioscience, USA). T-cell phenotypes were determined using anti CD25-PE-Cy7 
(M-A251) (eBioscience, USA), anti CD4-Percp5.5 (OKT4) (eBioscience, USA)and anti-human 
Foxp3  PE-conjugated  mAb  (PCH101)  (eBioscience,  USA).  IL-4  receptor  expression  was 
detected using anti-human CD124 PE conjugated (hIL4R-M57) (BD Bioscience, USA). Anti-
human RelB polyclonal antibody (Santa Cruz Biotechnology, USA) was used as the primary 
antibody to detect localisation of RelB by immunohistology. For further antibody details please 
refer to chapter 2 section 2.16.1.   121 
 
 
4.2.2 Generation of ‘FAST’ human monocyte-derived dendritic cells  
 
Peripheral blood mononuclear cells (PBMNC) were isolated from buffy coat of healthy human 
blood donors (Australian Red Cross Blood Service, Adelaide, South Australia) by Ficoll Paque 
density  gradient  centrifugation  as  described  in  chapter  2  section  2.1.1.    DC  were  rapidly 
generated as described in section 2.2.2, chapter 2. Monocytes were cultured in RPMI  1640 
containing  10%  FCS,  1000U/ml  (1.2x107  U/mg)    of    granulocyte  colony  stimulating  factor 
(GMCSF)-LeucomaxTM  (Sandoz  Australia,  Australia)  and  500U/ml  (1x107  U/mg)  of  IL-4 
(eBioscience, USA) in the absence (UT-DC) or presence of  500U/ml  of IFN-γ (eBioscience, 
USA)  (IFNγ-DC) for 24h.  Cells were then treated with 10ng/ml TNF-ʱ (R&D Systems, USA) 
and 1  µM  Prostaglandin E2 (Sigma-Aldrich,  USA)  for a  further 24h. All  cell  cultures  were 
incubated under 5% CO2 at 37°C. 
  
4.2.3 FACS Analysis  
 
DC surface staining.  (Please refer to section  2.3.1 and 2.3.2 of chapter 2). To determine 
terminal differentiation of IFN-γ modulated DC, cells were harvested and extensively washed to 
remove all residual cytokines. Then DC were either analysed by FACS (Day 0 post wash-out) 
or were placed back into culture for 12 days in complete S10g media and then analysed 
(Day12 post wash-out). 
Intracellular  STAT-6  phosphorylation  staining.    Please  refer  to  chapter  2  section  2.3.4. 
Monoclonal antibody targeting phosphorylated STAT-6 (pY641) (BD Bioscience, USA) was 
used to examine STAT-6 phosphorylation. Samples were analysed within 1hr of staining.    122 
Treg phenotyping. For the enumeration of Foxp3+ cells, T-cells from the primary MLR were 
harvested and stained with directly conjugated mAb targeting CD25 (eBioscience, USA) and 
CD4 (eBioscience, USA) for 25 min at RT.  Cells were stained for the intracellular expression of 
Foxp3 as per manufacturer‟s instructions.  Briefly, cells were permeabilised and fixed (Fix/Perm 
buffer provided by kit) before blocking with normal rat serum to prevent non-specific binding. 
Cells were incubated with anti-human Foxp3.  Numbers of CD4+CD25+Foxp3+ T regulatory 
cells were assessed by flow cytometry. For detailed methods refer to section 3.1 and 3.3 of 
chapter 2.   
Cytokine Cytometric Bead Array (CBA). A human TH1/TH2 CBA cytokine kit (BD Bioscience, 
USA) was used to determine the concentration of IFN-γ, IL-2, IL-10 and IL-4 in supernatants 
from  DC-T  cell  co-cultures.  DC  were  co-cultured  with  purified  T-cells  (1:10  stimulator  to 
responder ratio) for 5 days in complete RPMI medium (10% FCS and 1% glutamine) in 96 
round well bottom plates (under 5% CO2 at 37°C). Supernatant was harvested and assayed, 
according to the manufacturer‟s instructions. The lower detection limits for the tested cytokines 
were: IL-2: 2.6 pg/ml, IFN-γ: 7.1 pg/ml, IL-4: 2.6 pg/ml, IL-10: 3.0 pg/ml. 
 
 4.2.4 Allogeneic mixed lymphocyte reaction assay  
 
Primary  MLR.  DC  were  washed  with  PBS  three  times,  irradiated  (30Gy)  and  used  as 
stimulators in the MLR. Allogeneic T-cells were purified from PBMNC using nylon wool packed 
columns (85% CD3+ T-cells) as described in section 2.1.2 chapter 2. DC were co-cultured with 
T-cell responders in 96-well round bottom, at stimulator to responder ratios of 1:10, 1:100 and 
1:1000. After 4 days cells were pulsed with 1µCi [3H]-Thymidine (Amersham, UK) for 18h and 
harvested onto glass-fibre filters and counted in β-scintillation fluid using a Wallac Microbeta 
Counter (Turku, Finland). Proliferation was expressed as counts per minute and expressed as 
the mean of 5 replicates, +/- SD.    123 
Suppression  Assay.  Primary  MLR  were  performed  using  naïve  CD4+  T-cells  purified  from 
PBMNC using a human CD4+ T cell enrichment kit (Stem Cell Technologies, Canada) (95-98% 
CD4+ T-cells)(see methods chapter 2 sections 2.1.3).  Naïve CD4+ T-cells and IFNγ-DC were 
co-cultured at a ratio of 10:1. After 5 days, primed CD3+ T-cells were harvested using a CD3+ 
positive selection kit (Stem Cell Technologies, Canada) (see methods chapter 2 section 2.1.4). 
These IFNγ-DC primed T-cells were co-cultured with naïve CD4+ T-cells (105 cells per well) at 
varying ratios of 1:1, 1:2, 1:4 or 1:8 from the same donor. In addition, at the 1:1 ratio an 
irrelevant non-related donor 3rd party DC was used to determine the antigen specificity of Treg 
cells.  Cells  were  cultured  for  5  days  and  thymidine  incorporation  was  used  to  measure 
proliferation following an 18h pulse with 1μCi of [3H] thymidine (Amersham, UK). 
 
4.2.5 Gene expression analysis 
 
RNA was extracted from DC using RNAspin mini kit (GE Healthcare, UK) (see methods 2.8.1 
chapter 2) and cDNA was synthesized using 1μg total RNA by reverse-transcription using an 
oligo-dT primer (materials and methods 2.8.2 chapters 2). Quantitative Real-Time PCR based 
on a standard curve of copy numbers for each specific gene generated was used to analyse 
the expression of RelB, IL-12, IRF4 and GAPDH. PCR was conducted according to optimised 
conditions  (Please  refer  to  appendix  A  for  PCR  conditions  and  primer  sequences. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the house-keeping gene 




 DC (2x105) were spun onto slides at 20g (400 rpm) for 5 min using a Shandon Cytospin II 
(Thermo Scientific, USA). Staining conditions are described in section 5 chapter 2. Anti-RelB   124 
polyclonal antibody was used as the primary antibody, and goat-anti-rabbit IgG-FITC (Santa 
Cruz Biotechnology, USA) was used to detect the protein localisation of NF-κB transcription 
factor RelB. Frozen spleen sections (5µm) from humanely killed mice islet transplanted mice, 
were stained with mouse anti-human CD3-FITC (20µg/ml) overnight in humid chamber at 4°C, 
after blocking (3% mouse serum in PBS) for 25min at RT.   
 
4.2.7 IL-12 ELISA 
 
DC were in 24 well plates (1x106 cells/ml) were stimulated with CD40L (500ng/ml) and IFN-γ 
(1000U/ml)  for  48h.  Supernatants  were  harvested  and  assayed  for  the  biologically  active 
human IL12p70 by ELISA (eBioscience, USA). For details please refer to section  2.6.1 in 
chapter 2. 
4.2.8 Islet transplantation 
 
NOD-SCID female mice of >20g of weight were I.P injected with 180mg/kg Streptozocin (STZ)  
(Sigma-Aldrich, USA) a dose previously published to be effective in inducing diabetes and 
optimised by our laboratory and shown to have an induction rate of 70% with low morbidity (see 
Appendix  C). Diabetes was diagnosed by 3 consecutive readings of BGL of >16.6mmol/L. 
Diabetic mice were transplanted with approximately 3000IEQ of human islets 80% pure under 
the kidney capsule. All human islets used in this project had research consent given by donor 
families. This project was approved and over seen by the University of Adelaide (Approval 
number: M-2009-124) and IMVS (Approval number: 91_09) animal ethics committees. 
 
4.2.9 Allogeneic challenge of islet transplant 
 
DC  were  generated  from  monocytes  obtained  from  the  islet  donor  at  the  time  of  organ 
procurement. In order to so approximately 100ml of donor peripheral blood was collected into   125 
9ml lithium heparin tubes (approximately 12 altogether). Blood was pooled and diluted 1 part 
blood 2 parts PBS, then 30ml of diluted blood was under laid with 15ml of ficoll (GE Healthcare, 
UK)  and processed as described in section 2.2 (approximately 6-7 million DC were generated 
per donor).  Prepared DC were mixed with allogeneic PBMNC (isolated as per chapter 2, 
section 2.1.1) at a 1:100 ratio (106 DC to 108 PBMNC) and resuspended with 300µl of sterile 
PBS, containing 50µl of anti-asialo GM1 (Wako BioProducts, Japan) as per manufactures‟ 
instructions. Using a 27 gauge insulin syringe mice were injected with DC: PBMNC via I.P 1 
day post islet transplantation. Mice were sacrificed at 21 and 30days post allogeneic challenge. 
Spleen and transplanted kidney were harvested and placed into OCT. Approximately 200µl of 
blood serum was stored for human c-peptide analysis. Serum samples were analysed by the 
IMVS, Frome Road, Adelaide, which used IMMUNOLITE 2000 C-PEPTIDE, a solid phase two-
site  chemiluminescent  immuno  assay  for  the  detection  of  human  c-peptide  (Siemens 
Healthcare, Llanberis, Gwyneed, UK). 
 
4.2.10 mRNA analysis of transplanted islet tissue 
 
Total  RNA  was  extracted  from  frozen  sections  of  tissue  RNA  spin  column  as  per 
manufacturer‟s  instructions  (chapter 2,  section  2.8.1).  A  total  of 1µg  of  RNA was  reverse 
transcribed  using  random  hexamers  (Qiagen,  USA)  (refer  to  chapter  2,  section  2.8.3). 
Quantitative Real-Time PCR based on a standard curve using taqman primers according to the 
manufacturers‟  instructions  (Applied  Biosystems,  USA)  was  used  to  analyse  the  mRNA 
expression of CD8A, CD4, IL-2 and IFN-γ (see chapter 2, section 2.9.3). 
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4.2.11 Statistical analysis  
 
T-test and ANOVA statistical tests were conducted using Prism Statistical Software where 




4.3.1 IFN-γ in combination with the FAST-DC protocol generates phenotypically 
tolerogenic dendritic cells 
 
The phenotype of monocyte-derived DC generated via the FAST-DC protocol (TNF-ʱ and 
PGE2  maturation)  following  pre-treatment  with  IFNγ  (IFNγ-DC)  was  examined  using  flow 
cytometry (Figure 4.3.1A). Monocyte-derived DC that did not receive IFNγ pre-treatment (UT 
DC) were used as a control. Both groups  showed marked upregulation of the DC-specific 
marker  CD209  (DC-SIGN)  and  HLA-DR  molecules.  Pre-treatment  with  IFNγ,  reduced  the 
number of cells expressing the DC maturation marker CD83 to 22% (compared to 76% in UT-
DC), without affecting CD209 expression. IFNγ-DC showed decreased expression of positive 
co-stimulatory molecules CD80 and CD86 by 17% and 10% respectively compared to UT-DC.  
The negative co-stimulatory molecule ILT4 was upregulated from 19% of UT-DC expressing 
ILT4 to 35% of IFNγ-DC, thus IFN-γ treatment increased ILT4 by 1.8 fold.  
 
At the transcriptional level, quantitative real-time PCR demonstrated that IFNγ-DC produced 
60% fewer transcripts of NF-κB transcription factor RelB, which was confirmed at the protein 
level (Figure 4.3.1B). Immunohistology also showed that UT-DC had distinct co-localisation of 
RelB in the nucleus; indicative of typical DC maturation in response to maturation stimuli. 
However,  IFNγ-DC  had  reduced  expression  of  RelB  in  the  cytoplasm,  with  little  to  no 
translocation  into  the  cell nucleus  (Figure  4.3.1B).  Similarly,  pro-inflammatory molecule  IL-  127 
12p40 gene expression was markedly reduced in IFNγ-DC both at the level of messenger RNA 
(decreased by 86% compared to UT-DC) and protein (IFNγ-DC produced 62% less biologically 
active  IL-12p70  compared  to  UT-DC)  (Figure  4.3.1C).The  ability  of  DC  to  terminally 
differentiate and stably maintain in their differentiated state is important for its applicability as a 
DC therapy. Thus the ability of IFNγ-DC to terminally differentiate was examined. IFNγ-DC 
were  harvested  after  stimulation  with  maturation  stimuli  (after  24  hours)  and  washed 
extensively  to  remove  all  residue  cytokines.  IFNγ-DC  were  then  returned  to  culture  and 
maintained for 12 days in complete media without cytokines. After this wash-out period IFNγ-
DC showed a marginal decrease in the expression of Lineage marker-DC sign by 2%, whilst 
CD83  expression  changed  by  only  0.3%  (Figure  4.3.1D).  Thus,  pre-treatment  of  human 
monocytes with IFN-γ prior to exposure to maturation stimuli, produces DC with a phenotype 
that  has  been  associated  with  tolerogenic  properties,  shown  by  cell  surface  molecule 



























Figure 4.3.1A: IFN-γ in combination with the FAST-DC protocol generates phenotypically 
tolerogenic DC. Monocytes were isolated from peripheral blood and cultured in the without 
(UT-DC) or with IFN-γ (IFNγ-DC) in the presence of IL-4 [500U/ml] and GMCSF [1000U/ml] for 
24h.  DC  were  subsequently  treated  with  TNF-ʱ  and  PGE2  for  another  24h  period.  Flow 
cytometry was used to analyse the phenotype of IFN-γ treated DC and compared to UT-DC. 
The following co-stimulator and Lineage markers were examined: CD83, CD80, CD86, HLA-
DR and DC-SIGN. Solid line indicates the isotype control and solid histogram shows the tested 
mAb. This figure is representative of 6 independent experiments  
 
 















Figure  4.3.1B:  IFN-γ  treated  DC  have  reduced  expression  and  production  of  RelB. 
Isolated monocytes were treated with IFN-γ (IFNγ-DC) or without (UT-DC) in the presence of 
IL-4 [500U/ml] and GMCSF [1000U/ml] for 24h and matured for another 24h period with TNF-ʱ 
[10ng/ml] and PGE2 [1μm]. (A) Quantitative real-time PCR was used to determine the gene 
expression  of  NF-κB  transcription  factor  RelB.  (B)  Fluorescence  microscopy  was  used  to 
visualise the protein co-localisation of RelB, where blue depicts DAPI nucleus staining and 


















                                         
      mRNA            ELISA   
 
 
Figure  4.3.1C:  IFN-γ  treated  DC  have  reduced  expression  and  secretion  of 
proinflammatory cytokine IL-12. Isolated monocytes were treated with IFN-γ (IFNγ-DC) or 
without  (UT-DC)  in  the  presence  of  IL-4  [500U/ml]  and  GMCSF  [1000U/ml]  for  24h  and 
matured for another 24h period with TNF-ʱ [10ng/ml] and PGE2 [1μm]. (A) Quantitative real-
time PCR was used to determine the gene expression of IL-12. (B) ELISA was used for the 
detection of biologically active IL-12p70. Mean ± SD **=p<0.001. This figure is representative 



















Figure 4.3.1D: IFN-γ treatment does not affect the ability of DC to terminally differentiate. 
Isolated monocytes were treated with IFN-γ [500U/ml] in the presence of IL-4 [500U/ml] and 
GMCSF [1000U/ml]  for 24h. DC were then stimulated with TNFʱ [10ng/ml] and PGE2 [1μm].  
After another 24h  cells  were  harvested  and  washed  to  remove  cytokines and  returned  to 
culture (wash-out period). Cells were surfaced stained for DC Lineage marker DC-SIGN and 
maturation  marker  CD83,  at  day  0  (A)  and  day  12  (B)  post  wash-out  period.  Black  line 
represents  isotype  control  and  solid  histogram  depicts  tested  mAb.    Representative  of  5 
independent experiments. 
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4.3.2 IFN-γ inhibits IL-4 driven STAT-6 in monocytes 
 
To  investigate  the  mechanism  of  IFNγ-mediated  effects  on  monocyte-derived  DC,  human 
PBMNC were treated with or without IFN-γ in the presence of IL-4 and GMCSF to induce the 
activation mediated phosphorylation of STAT-6. Flow cytometric analysis showed that IFN-γ 
pre-treatment inhibited the phosphorylation of STAT-6 in monocytes by 65% compared to IL-4 
and GMCSF alone (Figure 4.3.2A).  STAT-6 is known to be involved in the transcription of IRF-
4 molecule, which is upregulated during DC maturation [237]. Accordingly, the downstream 
effects  of  STAT-6  inhibition  on  the  transcription  of  IRF-4  gene  were  investigated.    PCR 
demonstrated that the inhibition of STAT-6 in IFNγ-DC reduced the expression of IRF4 by 78%-
95% compared to UT-DC as determined by 6 independent experiments (Figure 4.3.2B). The IL-
4ʱ chain of the IL-4 receptor is essential in the recruitment and phosphorylation of STAT-6, 
which  in  turn  regulates  its  own  IL4ʱ  chain  expression  [293].  Therefore  the  cell  surface 
expression  of  IL-4ʱ  receptor  subunit  was  examined.  IFN-γ  down  regulated  the  protein 
expression of IL-4ʱ chain subunit in treated monocytes to 29% compared 42% in IL-4 and 






























Figure 4.3.2A: IFN-γ treatment of monocytes inhibits the phosphorylation of STAT-6. 
Isolated PBMNC treated with or without IFN-γ [500U/ml] in the presence of IL-4 [500U/ml] and 
GMCSF [1000U/ml] for 10 minutes. Cells were then immediately fixed and then permeabilised 
(using BDTM Cytofix (containing formaldehyde) and  BDTM Phosflow perm buffer, see materials 
and methods section 2.3.4 - chapter 2). Cells were surface stained for CD14-PE and intra-
cellularly  stained  for  STAT-6(pY641)-AF-488,  to  determine  STAT-6  phosphorylation. 
Representative of 6 independent experiments. 
 
















Figure 4.3.2B: IFN-γ treatment of monocytes inhibits the downstream gene expression of 
IRF4. Quantitative real-time PCR was used to analyse the mRNA expression of IRF4 in DC 
post maturation with [10ng/ml] and PGE2 [1μm]. The mean ± SD of quadruplicate samples 





















Figure 4.3.2C: IFN-γ regulates the expression of IL-4 receptor. IL-4 receptor expression 
was determined by FACS analysis using anti-CD124 24h post treatment with + or - IFNγ 
[500U/ml]   in the presence of IL-4 [500U/ml] and GMCSF [1000U/ml]. Solid black line defined 
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4.3.3 IFNγ-DC induce T-cell hyporesponsiveness that is associated with a 
reduction of IL-2 and IFN-γ 
 
The stimulatory capacity of rapidly generated DC to induce T-cell proliferation was measured in 
primary MLRs.  IFNγ-DC significantly inhibited the proliferation of allogeneic T-cells by 71% at 
1:10,  89%  at  1:100  and  95%  at  1:1000  DC  to  T-cell  ratios  (Figure  4.3.3A).  Analysis  of 
supernatants demonstrated that T-cell co-cultures with UT-DC contained significantly greater 
quantities of IFN-γ (UT-DC: 2300pg/ml vs IFNγ-DC: 240pg/ml, p=0.003) and IL-2 (UT-DC: 




4.3.4 IFNγ-DC promote the generation of antigen-specific T-regulatory cells 
 
T-cells from a primary MLR were assayed for the enumeration of Tregs. IFNγ-DC increased the 
frequency  of  Foxp3Hi  CD4+CD25+ T-cells  from  7%  by  UT-DC  to  17%  by  IFNγ-DC  (Figure 
4.3.4A). When IFNγ-DC primed T-cells were co-cultured with naïve T-cells at varying ratios, T-
cell proliferation was suppressed at a 1:1 and 1:2 ratio, by 70% and 49% respectively (Figure 
4.3.4B). Moreover at a 1:1 ratio, when stimulated instead with an irrelevant 3rd party donor DC, 
there  was  a  significant  increase  in  proliferation  compared  to  naïve  T-cell  alone  by  30% 
















































Figure 4.3.3A: IFNγ-DC induce T-cell hyporesponsiveness. Human monocytes were treated 
with IFN-γ (IFNγ-DC) or cultured in the absence of IFN-γ (UT-DC) for 24h in the presence of IL-
4 and GMCSF, then matured with TNF-ʱ [10ng/ml] and PGE2 [1μm] for another 24h. Nylon 
wool T-cells (1x105) were incubated with DC, at a DC to T cell ratio of 1:10, 1:100 and 1:1000 
for 5 days. Proliferation was determined by [3H] thymidine incorporation (CPM). The mean ± 













































Figure 4.3.3B: IFN-γ modulated DC inhibit the production of IL-2 and IFN-γ. DC were co-
cultured with purified T cells at 1:10 stimulator to responder ratios for 5 days. Supernatants 
from co-cultures were harvested and analysed by cytometric bead array for the production of 
IL-2 (i), IFN-γ (ii), IL-4 (iii) and IL-10 (iiii). The mean ± SD  *p<0.02, NS= Not Significant. 
Representative of 4 independent experiments. 
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Figure 4.3.4A: IFNγ-DC promote the generation of antigen-specific Tregs. A, DC were co-
cultured with CD3 T-cells for 5 days at a 1:10 DC to T-cell ratio and then stained for surface 
expression  of  CD4,  CD25  and  intracellular  expression  of  Foxp3.  Cells  were  gated  for 
CD4+CD25+Foxp3HI  population.  Samples  were  analysed  by  flow  cytometry.  B  shows  the 
percentage of positive cells for CD4+CD25+Foxp3HI population (Mean ± SD of 4 independent 
experiments).*=p<0.05 
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Figure 4.3.4B: IFNγ-DC primed T-cells are suppressive and antigen-specific Tregs. IFNγ-
DC primed T-cells were isolated from primary MLR and co-cultured with unprimed CD4+ T-cells 
at varying ratios of 1 naïve (remained constant at 103 per well) to 1 primed (1:1), 1:0.5, 1:0.25 
or 1:0.125 and stimulated with UT-DC. In addition, at the 1:1 naive to primed T-cell co-cultures 
an irrelevant 3rd party DC was also used to determine the antigen specificity of Tregs. Cells 
were cultured for 5 days and proliferation was determined by [3H] thymidine incorporation 
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4.3.5 Humanised NOD-SCID mouse model of islet transplantation failed to show 
significant differences between UT-DC and IFNγ-DC in vivo 
 
STZ dosages were batch tested, using a single dose range from 170-200mg/kg to determine 
the  optimal dose  (see  appendix C).  The  STZ dose  of  180mg/kg  was  chosen  as  it  stably 
induced diabetes in 70% of animals tested, with the least amount of morbidity and a dose 
which  has  been  successfully  used  by  other  groups  [294].  Diabetes  was  established  by 
hyperglycaemia (3 consecutive readings of >16.6 mmol/L), polyuria and weight loss. Isolated 
human islets of more then 80% purity and high viability as determined by dithizone staining 
(note all preparations used were of clinical grade, which were not used for human transplant 
due to insufficient numbers) were transplanted under the left kidney capsule of NOD-SCID 
mice (3000IEQ), which resulted in the reversal of the hyperglycaemic state to normal BGL. DC 
were  propagated  from  donor-derived  monocytes,  on  the  day  of  pancreas  procurement, 
approximately 100ml of donor blood resulted in the production of 6-7million donor monocyte 
derived-DC.   The following day post transplantation, PBMNC from allogeneic donor were 
isolated and mixed at 1:100 DC to PBMNC ratio and administered via IP to transplanted mice. 
BGL were recorded on daily basis post transplantation. As demonstrated in figure 4.3.5A, from 
the 3 treatment groups there was no significant difference in BGL readings. Suggesting that 
graft function was similar between the groups, even 21 days post challenge. Plasma serum 
was taken from humanly killed mice and samples were analysed for c-peptide levels, a by-
product of insulin production (Figure 4.3.5B). Although the mean value for the IFNγ-DC treated 
group was 10 and 20% higher than the mean value of UT-DC and PBMNC alone controls 
respectively,  it  failed  to  show  significance  (p=0.988  as  determined  by  Kruskal-Wallis  non-















Days Post Transplantation 
 
 
Figure  4.3.5A:    Allogeneic  challenge  did  not  reverse  euglycaemia  21  days  post 
transplant. NOD-SCID mice were rendered diabetic by 180mg/kg of STZ via IP. Diabetic mice 
were transplanted with 3000IEQ of human islets under the  kidney capsule. One day post 
transplant mice were challenged with allogeneic PBMNC and reconstituted with donor DC at a 
DC to PBMNC ratio of 1 to 100 via IP. Blood glucose levels were taken daily for 21 days post 


























































Figure 4.3.5B: On average IFNγ-DC treated mice had improved C-peptide serum levels 
but it failed to show significance. NOD-SCID mice were rendered diabetic by 180mg/kg of 
STZ via IP. Diabetic mice were transplanted with 3000IEQ of human islets under the kidney 
capsule.  One  day  post  transplant  mice  were  challenged  with  allogeneic  PBMNC.  Plasma 
samples were isolated from blood samples and were analysed for C-peptide concentration, all 
results were tabulated in A. B, column graph of C-peptide serum levels mean ± SD of c-peptide 
level  within  treatment  group.  PBMNC  (n=2),  UT-DC  (n=6)  and  IFNγ-DC  (n=5).  NS  =  no 
significance, 0.989 (p>0.05) as determined by Kruskal-Wallis non-parameteric test.  
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4.3.6 Human PBMNC engraftment evident in spleen and at graft site 
 
Spleen  from  transplanted mice  was  stained  with  anti-human  CD3-FITC antibody  to  detect 
PBMNC engraftment. Spleen sections from all treatment groups demonstrated the presence of 
human CD3+ cells in the spleen (Figure 4.3.6A), of allo-challenged mice. Messenger RNA 
analysis of islet allograft by real-time PCR showed the presence of human CD8 and CD4 gene 
expression,  indicative of  T-cell  infiltration of the  graft  (Figure  4.3.6B).  Expression of  these 
genes, varied considerably between animals. At day 21 post transplantation, mouse 166 (+UT-
DC) showed significantly higher CD4 expression compared to 163 (+IFNγ-DC), whilst animal 
165 (+UT-DC) did not. However 166 (+UT-DC) and 165 (+UT-DC) both had significantly higher 
CD8  expression  compared  to  IFNγ-DC  treated  mouse  163  (Figure  4.3.6B).    Day  30  post 
transplantation,   there was no significant differences in the gene expression of CD4 and CD8 
between mouse 116 (+UT-DC) and 115 (+IFNγ-DC) or 117 (+UT-DC) and 114 (+IFNγ-DC). 
The gene expression of Th1 cytokine IFN-γ and IL-2 were also examined (Figure 4.3.6 C). Both 
genes were present at day 21, where IFN-γ was significantly higher in mouse 166 and 165 
(+UT-DC) compared to 163 (+IFNγ-DC). However at day 30 no IL-2 gene expression was 
observed, whilst contradictory to day 21 results mouse 115 (+IFNγ-DC) had significantly higher 

























Figure 4.3.6A: Human CD3 positive cells found in the spleen of PBMNC reconstituted 
NOD-SCID mice. NOD-SCID mice were rendered diabetic by 180mg/kg of STZ via IP. Diabetic 
mice were transplanted with 3000IEQ of human islets under the kidney capsule. One day post 
transplant mice were challenged with allogeneic PBMNC and reconstituted with donor DC at a 
DC to PBMNC ratio of 1 to 100 via IP. Mice were sacrificed 30 days post transplantation and 
the transplanted kidney was snap frozen in OCT. Frozen sections of spleen transplanted mice 
were collected and stained with anti-human CD3-FITC conjugated mAb and DAPI for nucleus 
staining. Isotype control used as a negative control.  
 













Figure 4.3.6B: Human CD4 and CD8 gene expression found at islet allograft site. NOD-
SCID  mice  were  rendered  diabetic  by  180mg/kg  of  STZ  via  IP.  Diabetic  mice  were 
transplanted with 3000IEQ of human islets under the kidney capsule. One day post transplant 
mice were challenged with allogeneic PBMNC and reconstituted with donor DC at a DC to 
PBMNC ratio of 1 to 100 via IP. Mice were sacrificed either 21 days post transplantation or 30 
days post transplantation and the transplanted kidney was snap frozen in OCT. Sections of 
islet allograft were collected and RNA was extracted and reverse transcribed. Taqman primers 
were used to detect the expression of human CD4 and CD8 by quantitative real-time PCR. 
Untreated /Un-transplanted control was used as a comparative control. HPRT1 was used as a 
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Figure  4.3.6C:  Human  proinflammatory  cytokine  gene  expression  observed  at  islet 
allograft site. NOD-SCID mice were rendered diabetic by 180mg/kg of STZ via IP. Diabetic 
mice were transplanted with 3000IEQ of human islets under the kidney capsule. One day post 
transplant mice were challenged with allogeneic PBMNC and reconstituted with donor DC at a 
DC to PBMNC ratio of 1 to 100 via IP. Mice were sacrificed either 21 days post transplantation 
or 30 days post transplantation and the transplanted kidney was snap frozen in OCT. Sections 
of  islet  allograft  were  collected  and  RNA  was  extracted  and  reverse  transcribed.  Taqman 
primers were used to detect the expression of human IFN-γ and IL-2 by quantitative real-time 
PCR. Untreated /Un-transplanted control was used as a comparative control. HPRT1 was used 
as  a  house  keeping  gene  (Mean  ±  SD  of  quadruplicate  of  sample).  *=p<0.05,  NS=  No 
Significance. 
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4.4 DISCUSSION 
 
The toxicities inherent in modern immunosuppressive therapy has prompted efforts to develop 
novel  drug  free  ways  to  manipulate  or  condition  the  immune  system  to  promote  allograft 
acceptance or tolerance. DC are a prime cell for manipulation through their unique ability to 
dampen immune responses and their known role in maintenance of self tolerance. For living 
donor transplantation, conventional 7 day protocols to generate DC may be used; however, for 
deceased organ donor transplants this is clearly not practical, in particular in the setting of islet 
transplantation.  
 
In  chapter  3  the  immunomodulatory  role  of  IFN-γ  using  a  standard  7-day  protocol  was 
established. It was demonstrated that IFN-γ modulated monocyte-derived DC have a reduced 
capacity to induce T-cell proliferation. These DC featured a maturation arrested phenotype with 
increased expression of inhibitory molecules [156].  IFN-γ released in an allogeneic MLR, has 
also been previously shown to play a key role in promoting the generation of tolerogenic 
dendritic cells (Tol-DC) [295]. 
 
In this chapter the mechanism of IFN-γ modulated DC to  suppress T cell responses was 
investigated in addition to the development a short-term DC protocol to promote the generation 
of maturation arrested Tol-DC in 48 hours. Rapidly generated IFNγ-DC express DC specific 
marker  c-type  lectin,  CD209  (DC-SIGN)  and  HLA-DR,  but  have  reduced  CD83  and  B7 
molecule expression (Figure 4.3.1A). In 1995 CD83 was characterised as a maturation marker 
for DC [296]. Early studies demonstrated that herpes simplex virus type 1 infected  iDC failed to 
induce the expression of CD83 during maturation without affecting the expression of CD80 and 
CD86, resulting in a poor capacity to stimulate T-cells. This was the first evidence to suggest 
that CD83 is essential in enhancing T-cell activation [234].   More recently the function of CD83   149 
was further investigated, with the aid of siRNA knock down of CD83. Confirming further that 
CD83 functions as an enhancer of T-cell activation [235]. The inhibition of CD83 in IFNγ-DC 
therefore is an important factor contributing to their poor stimulatory capacity.  
Mechanistically, IFN-γ reduced the expression NF-κB transcription factor RelB, which 
failed to co-localise into the nucleus of monocytes, this correlated with reduced RelB gene 
expression  (Figure  4.3.1B).  The  nuclear translocation  of  RelB  is a  known  hallmark of  DC 
maturation [246]. The importance of the NF-κB pathway in DC development was also shown in 
knockout mice lacking components of NF-κB, where these mice failed to generate mature DC 
[297]. NF-κB transcription factors are known to interact with κB sites in the regulatory region of 
target genes that control the expression of MHC class II, CD80, CD86 and CD40. [247, 248]. In 
addition, NF-κB is known to regulate the expression of CD83 [249].  Thus the down regulation 
of positive costimulatory molecules including CD83 seen in IFNγ-DC may be a downstream 
effect of the inhibition of RelB expression and nuclear translocation. Moreover, studies using 
maturation  resistant  donor-derived  RelB  silenced  DC,  functionally  induce  antigen  specific 
tolerance  in  vivo,  thus  prolonging  murine heart  allotransplantation  [151]. Others  have  also 
reported the blocking of NF-κB using pharmacological agents, such as proteasome inhibitor 
PSI, LF 15-0195, aspirin, N-acetyl-cystine, cyclosporine and tacrolimus, which subsequently 
inhibit  DC  maturation  [150,  298-301].  DC  maturation  arrest  evident  in  IFNγ-DC  was 
accompanied with low production of biologically active IL-12p70 secretion and IL12p40 gene 
expression (Figure 4.3.1C). Early administration of IFN-γ did not interfere with the ability of 
IFNγ-DC to terminally differentiate, subsequently remained maturation arrested and for positive 
for DC-SIGN 12 days post wash-out period of cytokines (Figure 4.3.1D). 
 
The previously reported antagonist effects of IFN-γ on IL-4 were also observed by this study. 
IFNγ-DC  had  significantly  reduced  STAT-6  phosphorylation  compared  to  UT-DC  (Figure   150 
4.3.2A). This is consistent with previous observations [236], showing that IFN-γ treatment of 
monocytes also reduced IL-4 activation of STAT-6, by suppressing the expression of the IL-4 
receptor [236]. In this chapter it was also found that rapidly generated IFNγ-DC in the presence 
of IL-4 and GM-CSF also resulted in the downstream inhibition of the IL-4ʱ receptor (Figure 
4.3.2C). Transcription factor Interferon Regulatory Factor 4 (IRF4) a molecule also implicated in 
DC  development  and  maturation  was  also  down  regulated  by  the  inhibition  of  STAT-6 
phosphorylation (Figure 4.3.2B). The IRF4 promoter region has a STAT-6 responsive element 
that specifically up-regulates IRF4 in response to IL-4. [237]. The poor expression of IRF4 may 
contribute to the lack of responsiveness of IFNγ-DC to mature. IRF4 also binds to transcription 
factor PU.1 to negatively regulate the expression of ILT4. Reduced expression of IRF4 may 
therefore contribute to sustained expression of ILT4 (Figure 1) [238]. As discussed in chapter 3, 
the signalling through these molecules is also known to inhibit NF-κB transcription, thus may 
also contribute to the reduced expression of RelB in these rapidly generated IFNγ-DC. Studies 
have directly demonstrated that the up-regulation of ILT3 and ILT4 is associated with  the 
inhibition of NF-κB that render human monocytes and DC, tolerogenic [243].  
 
The  T-cell  hyporesponsiveness  induced  by  IFNγ-DC  (Figure  4.3.3A)  is  due  to  reduced 
expression of positive co-stimulatory molecules and proinflammatory cytokines, that render 
IFNγ-DC poor T-cell stimulators, a characteristic that is associated with promoting a tolerogenic 
response [302].  Reduced concentration of IL-2 and IFN-γ in IFNγ-DC co-cultures (Figure 
4.3.3B) is believed to contribute to the T-cell hyporesponsiveness. The ability of the IFNγ-DC 
generated by the fast-DC protocol however appeared to have a reduced capacity to stimulate 
T-cells compared to their equivalent generated by the standard DC protocol (figure 3.32A). This 
variability may be a reflection of differences of ILT4 expression, for instance 22% of standard 
IFNγ-DC expressed ILT4 verses 35% of fast-DC generated IFNγ-DC. T-cell phenotypes from   151 
primary  MLR  were  also  examined  by  FACS  (Figure  4.3.4A).  IFNγ-DC  promoted  a  higher 
frequency of CD4+CD25+FOXP3HI T-cells compared to UT-DC. Miyara et al. demonstrated that 
in humans the Foxp3HI subpopulation of CD4+CD25+ T-cells are highly suppressive, compared 
to the Foxp3lo subpopulation, which were characterised as cytokine producing effector T-cells. 
Moreover,  IFNγ-DC  primed  T-cells  were  shown  to  be  antigen  specific  in  their  ability  to 
functionally suppress the proliferation of naive T-cells (Figure 4.3.4B). However it was observed 
in  this  assay  that  at  1:0.125  (Naïve:  IFNγ-DC  primed)  T-cell  ratio  there  was  a  significant 
increase in proliferation compared to the 1:0 ratio. This suggests that possibly the IFNy-DC 
primed  T-cells  could  be  proliferating  or  may  be  acting  as  T-APC,  which  arises  from  a 
phenomenon known as „trogocitosis‟ when DC share molecules such as HLA-DR to T-cells via 
lipid  rafts  allowing  them  to  act  as  APC  [63].  It  may  therefore  be  necessary  to  further 
characterise these IFNγ-DC primed T-cells by firstly placing them into a suppression assay 
where  they  are  labelled  with  PKH  and  co-cultured  with  CFSE-labelled  naïve  T-cells,  to 
discriminate between the proliferation of primed T-cells and naïve T-cells. Secondly, IFNγ-DC 
primed T-cells should be analysed for DC surface molecules such as HLA-DR, to determine 
their ability to act as T-APC. Never the less this non-specific proliferation was not seen at high 
ratios (1:1), where there was 8 times more primed T-cells per well compared to the 1:0.125. 
Suggesting that the suppression of the naïve T-cells was specific, and that the proliferation of 
primed T-cells to be less likely.   
 
In order to test the in vivo properties of IFNγ-DC, a surrogate NOD-SCID chimeric model of 
islet transplantation was developed. Although there are several models of islet transplantation 
that exist with human islets, including transplantation of islets into the spleen and bone marrow 
[303, 304], none of these models have used donor-derived DC, which adds to the complexity of 
the model. Firstly, a large amount of blood (100ml) is required from the donor which is obtained   152 
at the time organ procurement (with research consent from the families of the donor and 
overseen by the human ethics committee at the Royal Adelaide Hospital), to generate the 
donor-derived DC. From the time that the blood became available it was processed and DC 
were differentiated for 24 hr, during the time of islet isolation. The pancreas was shipped to 
isolating centres either in Sydney (Westmead Hospital) or Melbourne (St Vincent‟s Hospital), 
which form part of the Australian Islet consortium. The following day the islets were shipped 
back to Adelaide and transplanted as soon as possible into previously induced diabetic mice 
(note diabetic mice were stably diabetic and maintained using  insulin pellets or injections), 
concurrently the donor-DC were matured for another 24hrs (with the approval of animal ethics 
committees of the University of Adelaide and the IMVS). Day post islet transplantation, PBMNC 
and DC were administered to transplanted mice. The procedure was logistically difficult to 
achieve and therefore was limited to the use of only South Australian donors.  This NOD-SCID 
model was based on previously developed human-skin mouse transplant model, previously 
published by our laboratory, which also used donor-derived DC [305]. Nevertheless a total of 
14 mice were transplanted for this study, 6 of which were treated with control DC (UT-DC), 6 
with IFNγ-DC and 2 which were challenged with PBMNC alone no DC.     
 
 All treatment groups failed to demonstrate allograft rejection, as defined by the reversal of 
euglycaemia  (Figure  4.3.5A  and  4.3.5B).    However  mice  spleen  and  the  islet  graft  site 
demonstrated evidence of some PBMNC engraftment, with human CD3 protein expression 
(Figure 4.3.6A) and CD4, CD8 T–cell markers (Figure 4.3.6B) and Th1 proinflammatory gene 
expression (Figure 4.3.6C) in the spleen and graft site respectively.  However, the human 
PBMNC  engraftment  was  insufficient  to  cause  complete  islet  graft  rejection,  a  problem 
previously experienced in studies using the NOD-SCID humanised mouse model [306-308] 
[309]. Although anti-asialo 1 was used to inhibit the reported residual activity of NK activity in   153 
the NOD-SCID mouse [310] [311], it may have not been sufficient to prevent NK cytotoxicity, 
thus  limiting  the potential of  PBMNC  and  DC to engraft. Poor DC engraftment  may  have 
contributed to defective DC/T-cell interactions, resulting incomplete allograft rejection. It has 
been previous reported that human  myeloid cells have a reduced capacity to engraft into 
immuno-compromised  hosts,  which  limits  the  activation  of  T-cells  by  DC,  rendering  them 
anergic and ineffective in mediating graft rejection [310, 312, 313]. Secondly the DC to PBMNC 
ratio of 1:100 may have been insignificant to mediate a robust rejection response. Thus a 1:10 
ratio may have given a better response, but the ratio in this study was limited by the number of 
DC generated from donor peripheral blood (approximately 6-7 million DC per 100ml of blood) 
Furthermore the dose of human islets of 3000IEQ is substantially larger than the constitutive 
islet mass found in mice, which also may have influenced incomplete graft rejection as seen at 
days 21 and 30. However incomplete rejection has also been reported in human skin transplant 
models, where rejection was detected post-facto by histology [306-308]. Therefore incomplete 
rejection, is more likely to be related to the strain of NOD-SCID mice, as described recently by 
King et al in 2008. In this study the NOD-SCID or otherwise known as the ND/LtSz-Prkdcscid 
was compared to the NOD.cg-PrkdcscidIL2rgtmWjl/SzJ (NOD-SCID IL2rynull). NOD-SCID IL2rynull 
has a targeted mutation in the IL-2 receptor gamma chain, and in comparison to the common 
NOD-SCID  the  NOD-SCID  IL2rynull  was  shown  to  be  a  superior  for  the  use  in  islet 
transplantation. This was evidenced by better PBMNC engraftment, directly related to the fact 
that these mice do not develop NK cells and do not spontaneously start producing T- and B-
cells at an older age. Furthermore this model was able to demonstrate robust rejection of 
human islet, which is believed to be related to the more physiological CD4:CD8 T-cell ratio 
which was only achieved by the NOD-SCID IL2rynull. Finally this study also demonstrated that 
I.V route of administration also improved PBMNC engraftment [303]. Moreover, studies have 
also shown that PBMNC, administered by I.P take 7-14 days to drain from the peritoneal cavity   154 
and into circulation [314, 315]. Accordingly the I.P route of administration may also be a limiting 
factor, which affected complete islet allograft rejection. Another limiting factor associated with 
this model relates to the fact that a nephrectomy of the transplanted kidney was not performed. 
A nephrectomy or staining of the native pancreas of the transplanted mice was necessary to 
determine the source of insulin regulating the BGL, accordingly to exclude the regeneration of 
the native pancreas and thus production of mouse insulin. The re-generation of the native 
pancreas indeed may have affected BGL results in  figure 4.3.5A where all mice exhibited 
normal BGL. However in figure 4.3.5B 3 mice had low detectable levels of c-peptide, which 
may have not been enough to regulate BGL at the levels seen in figure 4.3.5A.  
  
In summary, the observations of IFN-γ mediated DC maturational arrest described in chapter 3 
were further investigated in this chapter by using a DC protocol which generates DC in 48h. It 
was  demonstrated  that  early  exposure  of  CD14+  monocytes  to  IFN-γ  inhibits  efficient 
phosphorylation  of  IL-4  activated  STAT-6  inhibiting  the  expression  of  IRF4  and  RelB 
expression. Subsequently, arresting DC maturation and promoting a tolerogenic phenotype that 
resulted  in  the  generation  of  antigen-specific  Tregs.  Although  it  failed  to  show  statistical 
significance, IFNγ-DC in vivo trends towards improved C-peptide levels compared to the other 
2  control  groups.    However  the  model  failed  to  demonstrate  overt  allograft  rejection  as 
evidenced by hyperglycaemia, which makes it difficult to be conclusive about the role of IFNγ-
DC  in  vivo.  IP  route  of  administration  and  problems  associated  with  human  PBMNC 
engraftment in the NOD-SCID mouse, are confounding factors which have limited the model to 
demonstrate complete allograft rejection. Therefore in future, the more applicable NOD-SCID 
IL2rynull mouse should be used and PBMNC should be administered by I.V to improve human 
cell engraftment and prevent inter animal variability. Overall, the ability to generate Tol-DC in a   155 
short  timeframe  is  fundamental  in  the  ability  for  translational  DC  cellular  therapy  to  be 





























CHAPTER 5 - Adenoviral mediated 
expression of PD-L2 in human islets 
maintains stable in vitro function and 
promotes signalling through 

























Type 1 diabetes mellitus is a debilitating autoimmune disorder, which is characterised by the 
destruction  of  insulin  producing  pancreatic  beta-cells,  resulting  in  insulin  deficiency  and 
hyperglycaemia. T1D is a condition commonly diagnosed in children, but which can develop at 
any age. [316]. Insulin deficiency promotes increased gluconeogenesis and lipolysis resulting in 
elevated levels of blood fatty acids and ketone bodies, that can cause hyperglycaemic comas 
and  death  [317].  Prolonged  episodes  of  hyperglycaemia  have  been  associated  with 
cardiovascular complications, renal disease, diabetic retinopathy, and peripheral neuropathy 
[318]. The current standard therapy for T1D involves the use of lifelong exogenous insulin 
replacement therapy, which is administered either multiple daily injections or by insulin pump 
[319]. However this approach is limited by the inability to achieve physiological blood glucose 
levels.  Poor  blood  glucose  control  leaves  patients  vulnerable  to  the  development  of 
complications  including  hypo-glycaemia  episodes,  which  are  life  threatening  and  severely 
compromise the life-style of patients [320]. The destruction of beta-cells is mediated by an 
array of cellular immune responses, which involves the coordinated interaction of CD4+ and 
CD8+ T-cells, B lymphocytes, dendritic cells and macrophages, which infiltrate islets [321-324]  
 
CD8+ cytotoxic T-cells (CTL) are known to play a key role in the pathogenesis of T1D. CD8+ T-
cells are the dominant cell type found infiltrating the pancreas of T1D patients and pancreatic 
grafts [325-330]. NOD mice have been instrumental in demonstrating the role of CD8+ T-cell 
mediated  development  of  T1D.  In  particular  mice  lacking  function  of  CD8+  T-cells  fail  to 
develop insulitis or diabetes [331-334]. Adoptive transfer studies have demonstrated that CD8+ 
T-cell clones isolated from NOD mice transfer T1D in the absence of CD4+ T-cells [335-337]. 
CD8+ T cells mediate the killing of their target cells by direct cell contact. They use cytolytic 
granules that contain membrane –disrupting proteins perforin and granzyme, a serine protease   158 
family  member  [338,  339].  In  vitro  studies  have  demonstrated  that  granule-mediated 
cytotoxicity is the dominant mechanism of beta-cell destruction [340-342]. CD4+ T-cells also 
play a crucial part in T1D development. In mouse models the disruption of the CD4+ T-cell 
subset, MHC or MHC II transactivator, results in protection against insulitis and diabetes [331, 
343, 344]. However the reduced insulitis seen in these mouse models suggests that in the 
absence of CD4+ T-cells, CD8 T-cells fail to become efficiently activated.   This autoimmune 
response in T1D patients can go unnoticed for many years, as the beta-cell destruction is 
progressive and asymptomatic. When symptoms do arise, it‟s not uncommon to find more than 
80% of beta-cells destroyed at diagnosis [4], resulting in the clinical manifestation of insulin 
deficiency.    Islet  transplantation  is  an  emerging  therapy,  which  aims  to  replace  insulin 
producing beta-cells and ameliorate the need for daily insulin injections. 
 
Islet  transplantation  is  a  potentially  curative  approach  to  treating  T1D,  as  it  may  improve 
metabolic control of blood glucose levels to an extent, which cannot be achieved with insulin 
injections  or  pumps.  However  patients  have  to  replace  the  use  of  insulin  for  the  use  of 
immunosuppressive agents, which are associated with severe side-effects (as discussed in 
chapter 1 section 1.2.3) including the toxicity of islets. With the adoption of the Edmonton 
protocol in 2000, the success of islet transplantation has dramatically improved, with several 
groups reporting insulin independence and normalisation of blood glucose levels [22, 23, 345-
347].  However,  long-term  insulin-independence  frequently  fails  to  persist  5  years  post 
transplantation [348, 349]. A variety of factors contribute to the short and long-term loss of islet 
graft function. Islet transplantation is a form of cell transplantation, which in comparison to solid 
whole organ transplantation, isolated islets have extended ischemia times. Furthermore, during 
the isolation process islets undergo mechanical and enzymatic digestion to separate them from 
surrounding tissue in the pancreas, which compromises their integrity [350, 351].  Islets are   159 
infused into the portal vein of the liver, which is not the natural location of islet tissue, where as 
many as 50-70% if infused islets are lost immediately post-transplantation [352]. Subsequently 
remaining islets are extremely vulnerable to the alloimmune response and to the autoimmune 
processes that initiated the original disease [348].  
 
Shortly after transplantation islets come into direct contact to blood and its elements including 
monocytes, macrophages, platelets and complement proteins, which promote a thrombotic / 
inflammatory  reaction  known  as  „Instant  blood-mediated  inflammatory  reaction  (IBMIR). 
Accordingly IBMIR is characterized by the rapid (within 5 minutes) activation and binding of 
platelets, activation of the coagulation and complement systems, with the rapid infiltration of 
leukocytes  cells  into  the  islet  graft  [111,  112].  This  reaction  is  primarily  driven  by  the 
inflammatory factors that are endogenously produced by human islets such as tissue factor, 
IL1-β,  IL-8,  Macrophage  Inflammatory  Protein-2,  Migration  Inhibitory  Factor  and  Monocyte 
Chemoattractant  Protein-1[113,  114].  Long-term  allograft  rejection  of  islets  involves  the 
activation of the adaptive immune response. The specific cytotoxic mechanisms which cause 
islet loss are believed to be similar of those involved in autoimmune-immune mediated beta-cell 
destruction as described above. Accordingly antigen presenting cells transferred with islet graft 
also play a role in activating the adaptive immune response. In order to overcome this barrier of 
allograft rejection, islet transplant recipients are subjected to a lifetime of immunosuppressive 
drugs.  
 
Current  protocols  of  immunosuppressive  therapies  for  islet  transplantation  include  a 
glucocorticoid-free regimen that consist of sirolimus, tacrolimus and daclizumab [22]. Although, 
„islet friendly‟ when compared to other immunosuppressive regimens, these drugs are still 
cytotoxic to transplanted islets [353].  In vitro studies have demonstrated that treatment of islets   160 
with tacrolimus and sirolimus inhibits the insulin secretory capacity of islets and increases the 
mitochondrial  release  of  pro-apoptotic  factors  [354].  The  University  of  Miami  is  currently 
running a phase II trial using a steroid and calcinerine free protocol to try and minimise the side 
effects associated with the use of sirolimus (www.citregistry.org – NCT 00315627). Studies 
have also demonstrated that that in addition to the Edmonton protocol the use of etanercept 
(TNF-ʱ  inhibitor)  induction  in  combination  with  extenatide  (  a  glucagon-like  peptide  1 
analogue), reduce the number of islets required for transplantation [355]. An approach, which is 
also being used in phase III clinical trials at the University of Illinois (www.citregistry.org – 
NCT00679042). However, the systemic effect and long-term use of these drugs is associated 
with  increased  susceptibility  of  recipients  to  opportunistic  infections,  development  of 
malignancies and cardiac complications [356]. Accordingly, there is a need to develop novel 
therapies that target the local environment of the graft to induce allograft acceptance without 
the use immunosuppressive regimens, which also targets the persistent autoimmunity of T1D.  
 
Gene therapy is a novel therapeutic approach, which involves the introduction of therapeutic 
molecules to cells and tissues to specifically target diseases, such as allograft rejection [159]. 
There are 4 major species of viral vectors that are commonly used in gene therapy, which 
include adenoviruses (AdV), adeno-associated viruses, herpes simplex virus and retroviruses 
(including  lenti-viruses).  AdV-based  vectors  are  among  the  most  commonly  used  vectors 
studied in clinical trials, where its efficacy as a vector has been extensively examined [357-
360]. AdV vectors originate from the human serotype 2 and 5 AdV species. In humans the wild-
type AdV infection manifests itself as a mild respiratory disease, which is otherwise known as 
„the common cold‟ [361]. Modifications to the virus via the removal of replication genes (E1-, 
E3- deleted), has enabled it to be applicable as a gene therapy vector. AdV vectors are known 
to  transduce  both  dividing  and  non  dividing  cells  (including  islets)  with  high  efficiency  for   161 
transient gene expression [362, 363]. Recombinant vectors containing the gene of interest can 
be produced in high titres and the vector itself does not integrate into the host‟s chromosomes, 
avoiding  the  risk  of  insertional  mutagenesis  [364].  AdV  vectors  require  the  presence 
coxsackie/adenovirus receptor (CAR), heparin sulphate, ʱVβ5 integin and adherin to enter the 
target cell [365, 366]. Ex vivo modification of human islets with AdV vectors, has been shown to 
be effective in promoting transgene expression without affecting their viability or function, when 
compared to others vectors [367-370]. 
 
In this chapter, an AdV vector was used to over-express the immunomodulatory molecule 
programmed cell death ligand 2 (PD-L2). PD-L2 is one of two ligands that bind to programmed 
cell death 1 (PD-1). PD-1 is an inhibitory receptor expressed by activated T-cells and B-cells 
and forms part of the immunoglobulin superfamily. As a monomeric protein, it recruits SHP-1 
and SHP-2 tyrosine phosphatases that bind to its cytoplasmic immunoreceptor tyrosine-based 
switch motif to mediate its inhibitory function. Binding of PD-1 during TCR signalling blocks T-
cell  proliferation,  cytokine  production  and  cytolytic  T-cell  function  and  also  impairs  T-cell 
survival as described in chapter 1 (section 1.5). PD-L1 is the other known ligand for PD-1, it‟s 
widely expressed by hematopoietic and non-hematopoietic cells, including islets. Unlike PD-L1, 
PDL-2 is not expressed by islets and is highly restricted to DC, macrophages, B-cells and 
bone-marrow derived mast cells. PD-L2 also has a 3-fold higher affinity for PD-1 compared to 
PD-L1 and in vitro PD-L2 appears to be the dominant inhibitory ligand in humans. 
 
Therefore, it was hypothesised that the AdV mediated expression of human PD-L2 by human 
islets may promote signalling through inhibitory PD-1 pathway inhibiting T-cell activation and 
thus T-cell mediated immune responses. In order to test this hypothesis two recombinant AdV 
vectors were generated – one encoding a full length transmembrane isoform (AdV-PDL2-FL)   162 
and another encoding a soluble isoform (AdV-PDL2-SOL). This chapter demonstrates that AdV 
transduced islets maintain stable in vitro function and are efficiently able to express PD-L2. 
However the main finding of this chapter suggests that soluble PD-L2 may potently suppress 
allogeneic and autoimmune T-cell function, as evidenced by its ability to potently induce PD-1 
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5.2. METHODS AND MATERIALS 
 
5.2.1 Generation of Adenoviral constructs containing PD-L2 isoforms 
 
PD-L2 isoforms were amplified using primers designed to incorporate EcoR1 and BamH1 (New 
England Biolabs, USA) restriction sites in the forward and reverse primers respectively (for 
primer  sequences  and  PCR  conditions  refer  to  appendix  A).  PD-L2  gene  isoforms  were 
amplified from cDNA reversed transcribed from DC RNA (see sections 8.1, 8.2 and 9.1 for 
detailed methods). Purified PCR products and pEGFP plasmid were digested with EcoR1 and 
BamH1 to allow directional cloning of the gene of interest into the plasmid, allowing correct 
orientation and fusion to EGFP. Digestion products underwent a ligation and ligated products 
were then transformed into competent TG1-ʱ E.coli. Positive colonies were screened by PCR. 
PD-L2-EGFP isoforms from pEGFP-N1 recombinant plasmids were cloned into CMV-pShuttle 
vector.  Recombinant  CMV-pshuttle  vector  underwent  homologous  recombination  with 
pADEasy-1 Vector in BJ5183 E.coli. Basic Local Alignment Search Tool was used align the 
PDL2-FL and PDL2-SOL sequences with all highly similar nucleotides sequence on the NCBI 
database. Please refer to section 11 in chapter 2 for detailed methods on the generation of 
adenoviral constructs. 
 
5.2.2 Transduction of human islets with adenoviral constructs 
 
Human source of islets was obtained from the Australian Islet Consortium from deceased 
organ donors.  Islets  were  isolated at  isolating  centres  St  Vincent‟s  Institute  in  Melbourne, 
Victoria and Westmead Hospital, Sydney and shipped to Adelaide. Islets were washed with 
serum free CMRL media and then resuspended in serum free CMRL containing the desired 
viral dilution. Infection volumes for a 24 well and 6 well plate were 0.2ml and 0.5ml respectively.   164 
Islets were transduced for 3-4h under serum free conditions at 37°C and 5% atmospheric CO2. 
Then, an equal volume of complete CMRL media containing 20% Albumex 20 (Australian Red 
Cross, Australia) was added per well and incubated for 48h (37°C and 5% CO2), with media 
exchange performed daily.   
 
5.2.3 FACS analysis 
Islets were dissociated as per described in chapter 2 section 2.13.2. Viability of islet cells was 
established  by  staining  with  propidium  iodide  (PI)  as  per  manufacturer‟s  instructions 
(Invitrogen, USA). Briefly, islet cells were resuspended with 100µl per tube of islet FACS wash 
(5% albumex 20 in PBS, Azide free) and stained with 2µl of PI per tube (20µg/ml )and placed 
on  ice.  Cells  were  analysed  on  FACS  CANTO  II  (BD  Bioscience,  USA)  within  1  hour  of 
staining. Cells were kept on ice at 4°C until analysed.  To detect the expression of PD-L2, islet 
cells were stained with PD-L2 primary mAb (eBioscience, USA) and detected with Goat anti-
mouse IgG-FITC as per described in chapter 2 sections 2.3.2.  
 
 
5.2.4. Western Blot 
Islets were transduced as described in 5.2.2 and cultured at 37°C and 5% CO2. Islets were 
harvested at days 3, 5 and 7 days post viral infection. At each time point islets were washed 
with PBS to minimise the presence of FCS proteins and then lysed with western blot lysis 
buffer (refer to chapter 2 section 2.15). Samples were collected and stored at -80°C. Samples 
for each experiment were thawed at RT and then mixed with 5µl of loading buffer and 2µl of 
reducing agent and run through Invitrogen pre-cast gels as per manufacturer‟s instructions 
(Invitrogen, USA) at 200mV for approximately 45min. A chemiluminescence kit by invitrogen 
(Invitrogen, USA) was used to visualise blot, in brief membrane was incubated with 1:1000 anti-  165 
mouse  horseradish  peroxidise  (HRP)  for  1h  at  RT  and  then  visualised  with  kit  as  per 
manufacturer‟s instructions.  
 
 
5.2.5. Static insulin release assay 
Islets were harvested and washed in low glucose RPMI (2.8mM glucose). Approximately 50IEQ 
of  islets  were  resuspended  in  0.6ml  low  glucose  solution  (2.8mM  glucose).    Half  of  islet 
suspension (0.3ml) was transferred into 1.3ml of either low glucose solution (2.8mM glucose) 
or high glucose (25mM) solution in 5ml tubes. Islet were mixed well with the glucose solutions 
and incubated with loose lids at 37°C / 5% CO2 incubator for 2 hours. Supernatants were then 
harvested and stored at -80°C prior to further analysis. Collected samples were analysed by 
human insulin ELISA as per manufacturer‟s instructions (Mercodia, Sweden). 
 
5.2.6. Immunohistochemistry 
Islets were spun onto slides using a Shandon cytospin II (Thermo Scientific, USA) and fixed 
with cold acetone for 5min. Acetone fixing was used to quench the EGFP signal. Slides were 
blocked with 3% goat serum in PBS for 30min at RT. Slides were incubated with primary 
mouse-anti PD-L2 (12.5µg/ml) (eBioscience, USA) and guinea pig-anti insulin (1:100 dilution) 
(Millipore, USA) for 2h at RT prior to washing with PBS for 5min. Primary antibodies were 
detected with anti-mouse FITC IgG (1:100 dilution) and anti-guinea pig rhodamine IgG (1:100 
dilution) (Jackson Immuno Research, USA). Slides were incubated with detection secondary 
antibodies for 1h at RT. Slides were washed with PBS for 5 min prior to mounting with DAKO 
mounting media (DAKO, Denmark).    166 
5.2.7. IL-2 ELISA  
Human islets were transduced at optimal viral concentrations for 48h. Approximately 10 IEQ 
was co-cultured with hPD-1/mCD28 chimera T cell murine hybridoma (2x104) (kindly supplied 
by Prof. Simon Davis and Dr Sara Morgan - The Weatherall Institute of Molecular Medicine, 
Oxford,  UK,  http://www.imm.ox.ac.uk/wimm-research/mrc-human-immunology-unit/simon-
davis),  per  well  in  a  96  well  plate,  thus  at  an  approximate  1:1  islet  cell  to  T-cell  ratio. 
Supernatants were harvested after 3 days of culture in 37°C / CO2.  Samples were stored at -
80°C prior to analysis. A mouse IL-2 ELISA (as per manufacturer‟s instructions) (eBioscience, 
USA), was used to measure the ability of transduced islets to induce signalling though to see 
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5.3 RESULTS 
 
5.3.1 Cloning of PD-L2 membrane-bound and soluble forms into adenoviral 
vectors 
 
Bioinformatic  tools (Primer3) were  used  to  design  primers to  amplify  either the  full  length 
truncated gene or a truncated isoform of PD-L2. Primers were designed for soluble PD-L2 to 
incorporate a stop codon within the transmembrane section of the gene sequence. Directional 
cloning was used to insert the gene of interest into the pEGFP-N1 vector. EcoR1 and BamH1 
restriction sites were incorporated into the forward and reverse primers respectively for each 
isoform.  As shown in figure 5.3.1B both the PD-L2-FL and PDL2-SOL were successfully 
amplified from human DC. These PCR products were digested and ligated into the pEGFP-N1 
plasmid as shown in figure 5.3.1A to allow fusion EGFP sequence. Recombinant plasmids 
were amplified and selected on the basis of kanamycin-neomycin resistance. Positive colonies 
were  then  screened  by  PCR  for PDL2  expression  (figure  5.3.1B).    Amplified recombinant 
pEGFP-N1 plasmids were digested and ligated into CMV p-Shuttle vector as depicted in figure 
5.3.1C.  Recombinant p-Shuttle vectors were transferred into competent TG1-ʱ E. coli. Positive 
colonies  were  selected  based  on  their  kanamycin  resistance.  These  colonies  were  also 
screened by PCR for PDL2 expression (Figure 5.3.1C). Purified recombinant p-Shuttle vectors 
were electroporated into BJ5183 containing pADEasy-1 vector. This allowed for homologous 
recombination  between  the  p-Shuttle  and  pAdEasy  vector  (Figure  5.3.1D).    Recombinant 
pShuttle vectors were DNA sequenced to confirm the correct sequence of PD-L2, prior to 
homologous  recombination.  Basic  Local  Alignment  Search  Tool  enabled  the  alignment  of 
PDL2-FL and PDL2-SOL sequences with all highly similar sequence on the NCBI database 
(Figure 5.3.1D). This search found that the gene cloned into the pShuttle had greater than 98% 
homology with the human PD-L2 molecule (NM_025239.3), this was evident for both PD-L2 





















Figure 5.3.1A: Pictorial representation of cloning strategy into pEGFP-N1 plasmid, purified 
PCR products and pEGFP plasmid was digested with EcoR1 and BamH1 to allow forced 
cloning of gene of interest into the plasmid, allowing correct orientation and fusion to EGFP. 
Digestion products were ligated and transformed into competent TG1-ʱ Ecoli.  




















Figure 5.3.1B:  PD-L2 isoforms was PCR amplified from DC cDNA and cloned into pEGFP-N1 
vector. (A) RNA was extracted from DC and reverse transcribed into cDNA. PD-L2 isoforms 
were amplified using primers designed to incorporate EcoR1 and BamH1 restriction sites in the 
forward and reverse primers respectively.  (B) Positive colonies were screened by PCR (i) 
showing PDL2-FL and (ii) PDL2-SOL.   




































Figure 5.3.1C: PD-L2-EGFP isoforms from pEGFP-N1 recombinant plasmids were cloned into 
CMV-pShuttle  vector.  (A)  Illustrates  schematically  the  digestion  of  pEGFP-N1  PDL2 
recombinant plasmid and the CMV-pShuttle vector with compatible RE enzymes to allow forced 
cloning of gene of interest into pShuttle vector. (B) PCR screening of positive colonies for PD-
L2 expression (+ = positive colonies for PD-L2).  
 







































Figure 5.3.1D: CMV-pShuttle vector underwent homologous recombination with pADEasy-1 
Vector. (A) Pictorial of cloning strategy, briefly BJ5183 E.coli containing pAdEasy-1 vector was 
electroporated  to  allow  entry  of  PD-L2  recombinant  pShuttle  vector.  Prior  to  homologous 
recombination, PD-L2 recombinant adenoviral constructs were sequenced. (B) Using Basic 
Local Alignment Search Tool the PDL2-FL and PDL2-SOL sequences were aligned with all 
highly similar sequence on the NCBI database of human origin.  
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5.3.2 AdV transduction of human islets does not affect their viability 
 
Isolated human islets were transduced with purified AdV particles with a range of viral titres 
from 103 to 3x103 MOI, based on the assumption that each islet cluster has approximately 1000 
cells. Islets were transduced with AdV for 3-4h in serum free conditions. EGFP was expressed 
by all islet clusters transduced with either the AdV-PDL2-FL construct or AdV Vector blank 
(AdV-VB) 24h post infection (figure 5.3.2 (A). AdV-VB transduced islets were considerably 
brighter under fluorescence compared to the AdV-PDL2-FL. Figure 5.3.2 (B) depicts FACS 
analysis data, which summarises the calculated viabilities of islets cells 48h post transduction. 
Transduction of islets at the highest tested MOI did not affect the viability of islets cells when 
compared to the untreated islets. Accordingly 3x103 was chosen as an optimal dose for islet 
transduction, to achieve maximal transduction efficiency.   
 
 
5.3.3 Transduction of human islets with AdV does not affect their function 
 
Human islets were analysed for function 48h post transduction at the optimal MOI of 3x103, by 
treating transduced islets with low and high concentrations of glucose in the static insulin 
release assay. Supernatants were analysed by ELISA for insulin concentration. The stimulation 
index was calculated as per appendix E. As shown in figure 5.3.3 the ability of transduced islets 
to  produce  insulin  in  response  to  high  glucose  is  not  affected  by  the  transduction  with 
adenovirus, as the stimulation index was not significantly different from the untreated group 
























Figure  5.3.2:  Human  islets  were  successfully  transduced  with  AdV  vectors  without 
significantly affecting viability.  (A) Human islets were transduced with varying MOI ranging 
from 102  -  3x103 and assessed by fluorescent microscopy after 48h (B) Transduced islets 
were harvested 48h post transfection and disaggregated with accutase and stained with PI to 
distinguish live cells from necrotic islet cells. Red dash line defines the viability of untreated 



















Figure 5.3.3: AdV transduction of human islets does not affect their function to produce 
insulin  in  response  to  a  high  glucose  environment.  Human  islets  were  transduced  at 
optimal MOI (3x103) and harvested 48h post transfection and used in a static insulin release 
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5.3.4 Islets transduced with AdV-PDL2-FL induces surface PD-L2 expression for 
at least 7days 
 
Human islets were dissociated 48h post transduction and analysed by FACS analysis.  AdV-
PDL2-FL induced PD-L2 protein surface expression in 17-19% of islet cells (Figure 5.3.4A), 
which was significantly higher than the expression seen in untreated and AdV-VB transduced 
islets  (p<0.03)  (Figure  5.3.4A).  Immunohistological  analysis  of  transduced  islets  (Figure 
5.3.4B),  showed  that  AdV-PDL2-FL  transduced  islets  co-expressed  insulin  and  PD-L2.  To 
determine the time course of expression of PD-L2 by transduced islets, PD-L2 protein content 
was examined by western blot 3, 5, and 7 days post initial transduction. AdV-VB was used as a 
transduction control. As shown in figure 5.3.4C, PD-L2 protein expression was seen at all time 
































Figure  5.3.4A:  AdV-PDL2-FL  transducted  human  islets  specifically  upregulate  the 
expression of transmembrane PD-L2. (A) Human islets were transduced at optimal MOI 
(3x103) and harvested 48h post transfection and disaggregated and stained with mAb mouse 
anti-human PD-L2. This primary mAb was detected using anti-mouse IgG-PE. (B) Percentage 
of cells expressing PD-L2 combined from 4 independent experiments. Mean ± SD *=p<0.05, 
NS= No Significance.  
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Figure 5.3.4B: AdV-PDL2-FL transducted human islets co-express insulin and PD-L2. 
Islets were transduced at optimal MOI (3x103) and harvested 48h post transfection. Islets were 
transferred on to slides and stained with insulin (RED) and PDL2 (GREEN).  200x objective.  



















Figure  5.3.4C:  AdV-PDL2-FL  transducted  human  islets  sustain  expression  of 
transmembrane PD-L2 up to 7 days post transfection in vitro. Optimally transduced islets 
(MOI 3x103) were harvested 3, 5 and 7 days post transduction. Protein lysates were assessed 
by western blot and visualised using chemiluminescence.   
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5.3.5 PD-L2 proteins expressed by human islets are able to bind PD-1 and induce 
signalling 
The function of the transgenic PD-L2 protein was tested to eliminate any problems associated 
with protein misfolding post transcription. Firstly, PDL2-FL expressed by HEK-293 cells was 
tested by flow cytometry for its ability to bind to a recombinant PD-1Fc protein. PD-L2-FL 
protein induced by AdV-PD-L2 in HEK-293 effectively bound to its receptor PD-1 (Figure 5.3.5), 
with high efficiency, untransduced and AdV-VB transduced controls did not express PD-L2 and 
thus did not bind to PD-1Fc (See APPENDIX H).  To test the efficiency of both PD-L2 isoforms 
to induce signalling after binding, a murine T-cell hybridoma cell line, engineered to express the 
human PD-1 extra-cellular portion fused with murine CD28 was used (kindly supplied by Prof. 
Simon Davis and Dr Sara Morgan - The Weatherall Institute of Molecular Medicine, Oxford, 
UK) Accordingly binding of PD-1 promotes signalling and produces murine IL-2 as a response. 
Transduced islets were co-cultured with PD-1/CD28 T cell hybridoma and supernatants were 
collected  for  IL-2  analysis  by  ELISA.    Figure  5.3.5B  demonstrates  that  signalling  was 
specifically induced by both PD-L2 isoforms. Full length PD-L2 induced signalling by 20 fold 
compared to untreated or AdV-VB transduced islets. However this was significantly less than 
soluble  PD-L2,  which  induced  signalling  by  1000  fold.  Blocking  PD-L2  function  with  a 
neutralising  mAb  inhibited  the  ability  of  soluble  PD-L2  to  bind  and  signal  through  PD-1, 



































Figure 5.3.5A: PD-L2 molecules induced by AdV-PDL2 are able to physically bind to PD-1 fc 
recombinant protein. Optimally transduced HEK-293 were harvested 24h post transduction and 
were tested for their ability to bind to recombinant PD-1fc by flow cytometry. Representative of 












































Figure  5.3.5B:  PD-L2  molecules  expressed  by  AdV-PDL2  transduced  islets  specifically 
promote PD-1 signalling. Optimally transduced human islets (MOI 3x103) were co-cultured with 
murine T cell hybridoma expressing hPD-1/mCD28 chimera for 3 days. Supernatants were 
collected  and  concentration  of  IL-2  was  used  as  a  measure  of  PD-1  signalling.  IL-2 
concentration was determined by ELISA.  Neutralizing antibody targeting PD-L2 was used to 
determine the specificity of PD-1 signalling. Mean ± SD of triplicates of sample, **=p<0.01, 
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5.4 DISCUSSION 
 
Disruption to the PD-1 pathway in mouse model, results in the spontaneous development of 
autoimmune diseases such as lupus-like proliferative arthritis, glomerulonephritis, autoimmune 
dilated cardiomyopathy and diabetes [174, 175, 371]. These studies demonstrate that PD-1 
plays a key role in the induction and maintenance of tolerance, providing inhibitory signals that 
regulate both the central and peripheral tolerance.  PD-L2 was a logical candidate molecule to 
investigate in the context of islet allo-immunity, given its strong affinity for PD-1 and evidence in 
human studies, which suggest PD-L2 is the potent ligand out of the two [184, 195].  This 
chapter aimed to investigate the induction of PD-L2 in human islets, which naturally do not 
express this inhibitory ligand. It was hypothesized that the expression of PD-L2 by human islet 
may promote PD-1 signaling, which may affect the proliferation of allo- and also auto-reactive 
T-cells which express the PD-1 receptor.    
 
In order to investigate this hypothesis recombinant  AdV constructs were generated, which 
either  expressed  the  soluble  or  full  transmembrane  isoform  of  PD-L2.  Bioinformatic  tools 
confirmed that the sequence used to generate the vectors, were homologous to the native 
sequence of human PD-L2. Proper protein folding was evidenced by the ability of PD-L2-FL to 
bind  to  PD-1  Fc  recombinant  proteins  despite  some  discrepancy  in  some  bases  in  the 
sequencing analysis (<2%). This discrepancy may be related to the fact that only forward and 
reverse  primers  were  used  to  determine  the  sequence  of  the  inserted  PD-L2  isotypes. 
Accordingly the efficiency of the sequencing itself may have not been optimal resulting in this 
small difference in bases. It would have therefore been beneficial to do the sequencing with 
internal primers to increase the efficiency of the sequencing. However given the ability of the 
produced molecules to bind to PD-1 and detectable with relevant anti-bodies, it demonstrated 
that the protein was folding properly and functional.   The transduction of human islets with   183 
either AdV-PDL2-FL or with the control vector (AdV-VB) did not demonstrate deleterious effects 
on the viability or functional characteristics of the islets.  Similarly, other studies have also 
shown efficacy of using AdV as a gene therapy vector for islet transplantation [118, 120, 121, 
372, 373]. However AdV vectors are limited by their poor capacity to transduce the inner mass 
of islets [363]. For this reason the expression of AdV induced PD-L2 expression was limited to 
only 17-19% of islet cells. Despite this low transduction efficiency of islets, immunoflorescence 
microscopy demonstrated that the AdV-PDL2-FL vector was also able to transduce beta-cells. 
This provided further evidence that AdV transduction of human beta-cells does not affect their 
ability to express insulin. A primary part of maintaining islet graft function is associated with the 
survival of beta-cells. T-cells in particular play a crucial part in beta-cell destruction both in allo-
immune and auto-immune processes. In the context of alloimmunity, TCR signaling by donor 
and recipient APC promotes T-cell activation (as discussed in chapter 1 section 1.3) and the 
externalization of the PD-1 molecule [169, 170], alloreactive T-cells infiltrate the graft to carry 
out their cytolytic functions to mediate islet mass destruction.  PD-L2 expression may therefore 
directly protect beta-cells from the cytolytic function of T-cells, as the PD-L2 will bind to PD-1 
receptor on these activated T-cells, to prevent their cytolytic activity. Similarly, the underlying 
problem of auto-reactive T-cells may also be managed in this manner as all activated T-cells 
express  the  PD-1  receptor.  Moreover,  the  PD-1  pathway  is  naturally  involved  in  the 
homeostasis of peripherial tolerance and the interruption of this pathway is believed to play an 
important  role  in  the  mediation  of  diabetes.  Thus  expression  of  PD-L2  may  help  in  re-
establishing this homeostasis, which is interrupted in T1D patients.  
 
Functionally,  PD-L2  expressed  by  transduced  human  islets  was  able  to  bind  to  the  PD-1 
receptor. More importantly both isoforms of PD-L2 were able to induce PD-1 signaling. Soluble 
PD-L2 was able to induce signaling via PD-1 by a surprisingly 1000 fold when compared to the   184 
transmembrane  isoform.  This interesting  fact,  to  the  best  of  our knowledge  has  not  been 
previously shown in the literature, although the relative expression of both isoforms was not 
determined in this study. Until now the inhibitory function of human PD-L2 has commonly been 
investigated using soluble PD-L2Ig [195, 201, 374]. Rodent studies in which PD-L2 is blocked 
or knocked out, have failed to demonstrate a potent inhibitory function of PD-L2, which may be 
related to species differences. However it may also be a reflection of the restricted expression 
of PD-L2 as a transmembrane molecule. Thus low bioavailability of PD-L2 to the PD-1 receptor 
reduces its potential to efficiently induce signaling. This is supported by evidence, which has 
shown that the concentration of PD-1 molecules at the immunological synapses is determined 
by the affinity and availability of its ligand, in particular PD-L2 more so than PD-L1 is important 
in recruiting PD-1 [375].  In addition, gene splice variants of PD-L2 in humans do exists which 
suggests that humans may naturally produce soluble PD-L2 [376]. In light of the data presented 
in this chapter, investigations into the function and bioavailability of naturally occurring human 
soluble  PD-L2,  warrants  further  investigation.  Furthermore  the  ability  of  soluble  PD-L2  to 
potently  activate  PD-1  signaling  is  of  special  relevance  to  islet  cell  protection  against 
immunological  attack,  as  soluble  PD-L2  may  also  protect  those  islet  cells  which  remain 
untransduced, an obvious advantage over the use of the transmembrane isoform.   However, 
there is evidence to suggest that AdV vectors can trigger an innate immune response through 
the induction of type 1 interferons [377, 378].  
 
The direct administration of AdV in vivo has been of concern, with studies demonstrating that 
patients may suffer from complications [379, 380].  Other studies have shown that the local 
delivery of low and intermediate doses of AdV vectors in humans are well tolerated up to the 
dose  of  1011  virus  particles  [381].  However  the  immunogenicity  of  AdV  particles  is  not 
significant in the context of this study, because the strategy of gene transfer involves ex vivo   185 
modification  of  islets.  Hence  islets  are  transfected  in  in  vitro  and  would  subsequently  be 
washed to remove virus particles prior to transplantation.  In the setting of islet transplantation, 
the advantages of using AdV as a gene therapy vector outweigh the reported disadvantages. In 
particular,  they  accommodate  large  or  multiple  transgene  expression,  they  are  replication 
deficient, non-oncogenic and transduce both dividing and non dividing cells.  AdV vectors 
provide  high  short-term  transient  expression  of  genes  and  high  viral  titers  can  be  easily 
generated. Furthermore, a recent study using CTLA-4Ig AdV mediated expression in mouse 
islets,  demonstrated  that  local  immunosuppression  can  be  achieved  with  soluble  secreted 
factors,  without  disturbing  other  immune  responses  [382].  The  use  of  non-viral  vectors  to 
induce transgenic expression in islets have also been used, but with poor success mainly due 
to the toxicity of transduction reagents, methods and inefficiency [383].  
 
In conclusion, in this chapter the immunomodulatory molecule PD-L2 was successfully cloned 
into  an  AdV  vector  to  encode  either  a  soluble  or  full  length  transmembrane  isoform. 
Transduced human islets maintained stable in vitro function. The potent capacity of soluble PD-
L2  to  induce  PD-1  signaling  in  comparison  to  its  transmembrane  counterpart  was  clearly 
highlighted in this chapter. Overall the secretion of soluble PDL2 by islets has the potential to 
protect  the  islet  allograft  from  activated  allo  and  auto  reactive  T-cells,  given  its  signaling 
capacity and warrants further investigation in a chimeric NOD-SCID islet transplant model.   
Studies investigating the inhibitory role of human PD-L2 thus far have been limited. Only one 
study  in  the  past  year  has  looked  that  the  role  of  human  PD-L2  in  the  context  of 
xenotransplantation, which demonstrated promising results in its role to negatively regulate 
human T-cell responses [204]. In light of this study and the data presented in this chapter 
human PD-L2 in the setting of allo- and auto- immunity warrants further investigation, as it may 
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Islet transplantation is a developing therapy for  patients affected by T1D, which has been 
limited by problems associated with hypoxia, poor revascularisation and allograft rejection. 
Immunosuppressive agents used to prevent allograft rejection are associated with severe side 
effects including islet toxicity, increased susceptibility of recipient to the potential development 
of  malignancies,  opportunistic  infections  and  cardio-vascular  problems.  Currently,  islet 
transplantation is only available to patients with poor blood glucose control that experience 
severe episodes of hypo-glycaemia unawareness. In order for islet transplantation to be used 
widely as a potentially curative treatment for T1D there is a need to develop novel therapies to 
treat allograft rejection without the use of immunosuppressive agents. Dendritic cells (DC) play 
an  important  role  in  promoting  allograft  rejection,  especially those  derived  from  the  donor 
tissue. However, under certain conditions DC can be modulated to promote acceptance of an 
allograft and induce tolerance. Thus, this thesis has explored strategies to promote immature 
hyporesponsiveness by manipulating monocyte-derived DC function.     
   
In chapter 3, the immunomodulatory effects of IFN-γ on human monocyte-derived DC were 
investigated. IFN-γ, a cytokine known for its pro-inflammatory role in allograft rejection, also 
has a paradoxical role in supporting allograft tolerance. Using a standard 7-day in vitro DC 
propagation protocol it was demonstrated that IFN-γ exerts its immunomodulatory function on 
monocytes early during DC differentiation (IFNγ-DCD0), resulting in an immature DC (iDC) 
phenotype with reduced expression of maturation marker CD83 and gene expression of NF-κB 
transcription factor RelB. IFNγ-DCD0 induced a state of T-cell hyporesponsiveness in MLR, 
which was independent of the generation of total Foxp3+ T-cells. The T-cell assay used to 
determine the promotion of Foxp3 Tregs, limited this chapter to demonstrate conclusively the 
difference in the promotion of Foxp3+ Tregs between UT-DC and IFNγ-DCD0.  Accordingly the 
use of total Foxp3+ population is not suitable in the context of these in vitro assays. As there   188 
are  inherent  problems  associated  with  human  activated  T-cell  effectors  that  are  known to 
express Foxp3 [271]. It is therefore necessary to use other markers such as CD25, Foxp3HI 
and CD127 low, which better reflect the presence of suppressive Tregs.  Therefore in hindsight 
the  reduced  capacity  of  IFNγ-DCD0  to  promote  Foxp3  Tregs,  may  have  reflected  poor 
stimulatory capacity of these cells to activate T-cells. IFN-γ treatment, on the other hand, at day 
5 (IFNγ-DCD5) did not modulate the stimulatory capacity of DC compared to untreated DC. 
Accordingly this chapter highlighted that the effect of IFN-γ to act as either a „pro-inflammatory‟ 
or  „anti-inflammatory‟  cytokine,  is  dependent  on  the  timing  of  IFN-γ  exposure  during  DC 
maturation or differentiation respectively. Thus IFN-γ is only effective in producing maturation 
arrested DC, when administered during DC differentiation. This effect however is not exclusive 
to IFN-γ as IL-10 has also been reported to mediate its DC modulatory effects early during DC 
differentiation,  having  minimal  effects  on  already  differentiated  DC.  More  importantly  this 
chapter demonstrated that these IFN-γ modulated cells are of DC lineage, which has not been 
previously  demonstrated  by  other  groups.  Overall  chapter  3  demonstrated  that  the  early 
application of IFN-γ during DC differentiation produced maturation arrested DC, which could 
potentially  promote  tolerogenic  immune  responses.  In  chapter  4  this  concept  was  further 
explored by using a rapid / fast DC protocol, making the use the IFN-γ modulated DC more 
relevant to translational DC Therapy.  
 
In chapter 4 a FAST-DC protocol was used to generate IFNγ-DC in 48h, which featured similar 
iDC phenotype seen in chapter 3.  The mechanism used by IFN-γ to modulate DC was also 
further examined. It was demonstrated at the molecular level that IFN-γ treatment reduced the 
phosphorylation  of  IL-4  activated  STAT-6,  which  in  turn  affected  the  downstream  gene 
expression of Interferon regulatory factor 4 (IRF4). Rapidly generated IFNγ-DC were shown to 
be terminally differentiated and poor stimulators of allogeneic T-cells causing significant T-cell   189 
hyporesponsiveness and promoting a higher frequency of CD4+CD25+ Foxp3HI T-regulatory 
cells. This however was significantly different to observations in chapter 3, where IFNγ-DCD0 
failed to promote a larger Treg population compared to UT-DC. It is believed that the difference 
in response is directly related to the different strategies used to define the Treg population in 
each chapter. As briefly discussed above not all T-cells expressing Foxp3 are suppressive in 
function, it has been previously reported that in humans CD4+CD25+Foxp3HI T-cell population 
is a better indicator of the suppressive function of human Tregs [271]. Therefore based on 
these findings the strategy of identifying suppressive Foxp3 population was modified in chapter 
4, which may then reflect the difference in the Treg results between chapters. However the 
suppressive activity of the Tregs generated by IFNγ-DC was confirmed in suppression assays. 
This then warranted further investigation of IFNγ-DC in an in vivo of islet transplantation. 
 
A surrogate chimeric NOD-SCID model of islet transplantation was then developed in chapter 
4. This model was different to that of previously published models of islet transplantation, as it 
involved the use of donor-derived DC, hence donor peripheral blood was required by this 
model, which considerably limited the potential of this model. As only South Australian donors 
could be used and only a few DC could be generated each time, thus limiting the ratio of 
DC:PBMNC used to reconstitute the transplanted NOD-SCID mice. Accordingly, the model 
achieved poor levels of human cell engraftment, which affected its ability to promote overt 
allograft rejection, as evidenced by hyperglycaemia. Poor cell engraftment may be attributable 
to  the  use  of  IP  route of administration  and  the  strain  of  NOD-SCID mice.  It  is therefore 
recommended as discussed in chapter 4 that a NOD-SCID lL2rynull mouse be used in future, as 
it has superior human cell engraftment  capability and approximately 20 times less human 
PBMNC  are  required  to  mediate  a  robust  allograft  rejection.  This  would  make  the  model 
developed in this chapter far more feasible, as less DC would be need to be propagated from   190 
donor blood monocytes.  Accordingly, due to the limitations encountered the potential of IFNγ-
DC to be tolerogenic in vivo still remains elusive, although the c-peptide levels in IFNγ-DC 
treatment were promising (Figure 4.3.5B). Further investigations into the genes modulated by 
IFN-γ  in  DC  is  required,  an  extensive  assessment  by  micro  gene  array  of  IFNγ-DC  is 
necessary, as IFN-γ is known to affect the expression of over 200 known genes. This will help 
to further characterise the mechanism used by IFN-γ to modulate DC function. In addition, it of 
interest to establish whether this phenomenon of controlling DC function mediated by IFN-γ 
occurs naturally in vivo as a homeostatic mechanism of controlling immune responses.  Never 
the less this strategy of generating donor-derived tolerogenic DC in just 2 days is both novel 
and clinically applicable, allowing the in vivo targeting of the direct pathway of recognition to 
promote allograft tolerance in humans a possible reality.  
 
In chapter 5, human islets were genetically modified with programmed cell death ligand 2 (PD-
L2), as an alternative approach to protecting the allograft from the recipient‟s immune system. 
PD-L2  is  a  ligand  for  programmed  death  1  (PD-1),  an  inhibitory  molecule  that  limits  the 
expansion  of  allo-  and  auto-reactive  T-cells.  Islets  do  not  express  PD-L2,  thus  it  was 
hypothesised that the induced expression of PD-L2 would confer protection to islets. In this 
chapter, two recombinant adenovirus constructs were generated  - one encoding a soluble 
isoform and the other expressing a full transmembrane molecule. It was demonstrated that AdV 
transduction did not affect the viability or insulin producing capacity of islets. Induced PD-L2 
was  able  to  bind  and  induce  signalling  through  PD-1.  However  soluble  PD-L2  was  more 
efficient at inducing signalling by 1000 fold, than the transmembrane isoform, a phenomenon 
which has not been previously described before in humans. These results are promising and 
warrant  further  investigation  in  a  chimeric  model  of  islet  transplantation,  to  determine  the 
protective effects of PD-L2 in a transplantation setting. The expression of soluble PD-L2 by   191 
transplanted human islets could potentially also inhibit the underlying cytolytic activity of auto-
reactive T-cells present in T1D patients. The ability to target both the problem of alloimmunity 
and autoimmunity with one inhibitory molecule makes PD-L2 all the more attractive as gene 
therapy treatment for T1D.  
 
Experiments to investigate the islet protective properties of PD-L2 in vivo were largely limited in 
this study by the availability of human islet tissue. This could be overcome by the use of a 
transgenic line of NOD-SCID mice, which express human HLA-A2.1.  It has been demonstrated 
that NOD-SCID-HLA-A2 positive islets transplanted into diabetic NOD-RagnullPrfInull mice, are 
readily rejected by HLA-A2.1-negative human PBMNC, which is comparable to the rejection of 
transplanted human islets in NOD-SCID mice [309]. Thus NOD-SCID-HLA-A2 positive islets 
could potentially be transduced with AdV-PDL2 and used in vivo to further investigate the 
immunoregulatory role of human PD-L2 to protect islet survival and function. In addition this 
model  would  also  address  the  inherent  variability  observed  between  donor  preparations 
following  islet  isolation.      Alternatively,  human  PD-L2  could  also  be  characterised  in  a 
xenogeneic pig islet transplant model. Where human PD-L2 transgenic pig islets could be 
transplanted into NOD-SCID lL2rynull and reconstituted with human PBMNC. The potential for 
human PD-L2 to promote human tolerogenic responses in a xenogeneic setting has been 
previously demonstrated, through the expression of human PD-L2 by pig APC. These finding 
further highlight the potential of human PD-L2 to protect pig islets in a xenogeneic model and 
warrants further investigation. The ability to use pig islets for the treatment of T1D, could serve 
as a great benefit as it could potentially overcome the shortage of organ donation and make 
this treatment more widely available.  
 
   192 
 
Overall this thesis has contributed new knowledge in firstly the field of DC therapy. It  has 
demonstrated that early application of IFN-γ during DC differentiation is crucial in altering the 
allo-fate of DC - producing hypo-responsive T-cells (Chapter 3). This has clinical applicability 
with  the  modification  of  the  FAST-DC  protocol,  which  allowed  the  propagation  of  IFN-γ 
tolerogenic  DC  in  48  hours  (Chapter  4),  making  tolerogenic  DC  therapy  more  clinically 
applicable to deceased donor transplantation. Secondly this thesis has demonstrated soluble 
PD-L2 expression by human islet may have potential to protect against both allo- and auto- 
reactive T-cell mediated immune responses. In addition, the ability of soluble PD-L2 to act 
more potently then the transmembrane isoform to induce PD-1 signalling is an observation 
which has not been previously documented in the literature before.  
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APPENDIX A- Table of primer sequences and conditions 
 
Gene  Forward primer  Reverse Primer  Cycling 
Conditions 
RelB   5’TTT  TAA  CAA  CCT  GGG 
CAT  CC   
5’  CGC  AGC  TCT  GAT 
GTG TTT GT 
25s @ 95°C 
25s@55°C; 
25s@72°C  
for 50 cycles 
  IL-12   5’ TTT GGA GAT GCT GGG 
CAG TAC A 
5’GAT GAT GTC CCT GAT 
GAA GAA GC 
25s @ 95°C; 
25s@ 60°C; 
25s@72°C  
for 50 cycles 
IDO   5’GGC  AAA  GGT  CAT  GGA 
GAT GT, 
5’ CTG CAG TAT CCA TCA 
CGA AA, 
25s @ 95°C; 
25s@ 55°C; 
25s@72°C  
for 50 cycles 
HLA-G   5’AAG GCC CAC GCA CAG 
ACT GAC AGA ATG AAC 
AGG TCG  CAG  CCA  ATC 
ATC CA 
25s @ 94°C; 
25s@ 55°C; 
25s@72°C  
for 50 cycles 
IRF4  5‘AGT  CCT  GAG  CGA  AAA 
CAG GA 
5’AAA  GCC  AAG  AGG 
TGC GAG TA 




GAPDH   5‘ATC  ACT  GCC  ACC  CAG 
AAG ACT 
5’CAT GCC AGT GAG CTT 
CCC GTT 






5’CGG  AAT  TCA  TGA  TCT 
TCC TCC TGC TA 
5’CGG  GAT  CCG  ATA 




Note: final  




5’CGG  AAT  TCA  TGA  TCT 
TCC TCC TGC TA 
5’CGG GAT CCG ATG AAA 




Note: final  

























































Varying IFN-γ concentration at time 0 of DC propagation 











































Dose (mg/kg)  mice n=  % Diabetic  Mortality 
170  5  40%  0% 
180  12  66%  8% 




Note doses 190-210 were grouped together because they cause high degree of morbidity 
and mortality and were considered as highly toxic. 180mg/kg was chosen over 170 as it 
improved  the  rate  of  diabetes  induction  by  approximately  30%,  with  low  degree  of 




































The above diagram illustrates how signalling of human PD-1 is measured by murine IL-2 
ELISA. In brief, when PD-L2 binds to the human PD-1 which forms the extracellular 
portion of the chimeric protein, which is fused to murine CD28. Thus signalling of PD-1 
induces the production of murine IL-2 as the hPD-1/mCD28 chimeric protein is 





                                          NOTE:   
   This diagram is included on page 220 of the print copy  



























































              Rojas D, Krishnan R. IFN-gamma generates maturation-arrested dendritic cells that 
induce T cell hyporesponsiveness independent of Foxp3(+) T-regulatory cell 














































APPENDIX G – Copy of publication of review  
Available Online 
Hughes A, Jessup C, Drogemuller C, Mohanasundaram D, Milner C, Rojas D, Russ GR, 
Coates PT. Gene therapy to improve pancreatic islet transplantation for Type 1 diabetes 



































































Both Untreated and AdV-VB  transduced HEK-293 controls do not express 
PD-L2 and thus do not bind to PD-1Fc. 